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Abstract 
 
In Africa, information on dengue burden in Africa is limited. Dengue diagnostics 
is also a key challenge in defining the true burden. Among the various diagnostic 
options, rapid diagnostic test (RDT) is a convenient and prompt tool for dengue 
diagnosis, especially in resource-limited environments. To assess current knowledge 
on the use of RDTs for dengue with respect to their economic impact, a systematic 
review was conducted of published data. Overall, data were limited to demonstrate an 
economic impact of dengue RDTs and the available two studies reached different 
conclusions: one concluded that one particular RDT would be a cost-effective tool in 
endemic setting, and the other, based on a modeling, showed that a dengue RDT 
would not be advantageous in terms of cost and effectiveness compared to current 
practice of antibiotics prescription for undifferentiated fever. 
This thesis presents patterns of dengue epidemiology and outbreak based on 
passive fever surveillance studies in Mombasa, Kenya, and Ouagadougou, Burkina 
Faso. To estimate the proportion and understand clinical patterns of dengue-positive 
cases among non-malarial febrile patients, we conducted passive health facility-based 
fever surveillance studies in Ouagadougou, Burkina Faso and Mombasa, Kenya. In 
Mombasa, of 482 non-malarial febrile patients, 223 (46%) were identified as dengue–
confirmed and 92 (19%) as dengue-probable. The surveillance covered the beginning 
of a dengue outbreak in April-May 2017, during which 67% of enrolled patients were 
dengue-confirmed.  In Ouagadougou, of 2929 non-malarial febrile patients, 540 (18%) 
were identified as dengue–confirmed and 571 (19%) as dengue-probable. During the 
study period, a dengue outbreak occurred in September-November 2016, during 
which 46% of enrolled patients were dengue-confirmed.  
To understand DENV transmission in the community, 4 repeated serosurveys 
were conducted among the same individuals at 6 month intervals in Ouagadougou. 
Seroprevalence at enrollment was 66%. The binomial regression based on IgG 
positivity by age, assuming constant force of infection (FoI) over calendar time, 
resulted in the FOI of 6% per year.  
In summary, in both Burkina Faso and Kenya, there is considerable 
transmission of DENV, in terms of proportion of DENV confirmed infections among 
iii 
 
non-malarial febrile patients in the healthcare facilities as well as seroprevalence and 
FoI in the community. These burden estimates can facilitate evidence-based decision 
making on interventions for dengue prevention and control, including a dengue 
vaccine. However, given the currently available information on dengue burden in Africa 
and the status of dengue vaccine development, including the only licensed vaccine 
with restrictions in public health use, consideration of dengue vaccine introduction may 
be premature for Africa and more data would be necessary to build evidence base on 
dengue in African settings. 
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1 Introduction 
 
Dengue fever is a mosquito-borne flavivirus infection caused by four related 
but antigenically distinct dengue viruses (DENVs, serotypes 1–4), and is a major and 
rapidly increasing global public health problem (1). The clinical illness ranges from 
self-limited mild febrile illness to classic dengue fever (DF) to the more severe form 
of illness, dengue hemorrhagic fever (DHF).  Recent studies have estimated an 
annual incidence of 50–100 million symptomatic infections globally, with 50,000 DHF 
cases requiring hospitalization and approximately 20,000 deaths (2-6). The case 
fatality is known to be about 2.5%, but reported to be as high as 10% (7, 8). Dengue 
is now endemic in more than 120 countries with over half the world’s population at 
risk of infection (9). Dengue disproportionately affects countries in the tropics and 
subtropics, many of which have limited health care resources  (10).  
Dengue virus is transmitted by Aedes mosquitoes. Despite mosquito control 
efforts, over the last few decades, diseases transmitted by Aedes mosquitoes have 
spread rapidly in tropical and subtropical parts of the world, including in Africa (11, 
12). Some of the factors that have driven epidemics of Aedes-transmitted viruses are: 
population growth, climate change, urbanization, globalization and geographic 
expansion of mosquitoes (13).  
The rapid spread of DENV transmission worldwide and its associated 
morbidities underscore the need for effective control and prevention measures. It is 
expected that dengue vaccines will significantly reduce burden of dengue, and there 
are continued efforts to develop ones that are safe, efficacious, and cost effective. 
There were some recent key developments in the dengue vaccine field, such as: 
licensure of Dengvaxia®  by Sanofi Pasteur in many dengue endemic countries, but 
its use is limited by the complexities in the performance and safety of Dengvaxia® ; 
progress made by other dengue vaccine manufacturers, including TDV by Takeda 
and TV003 by Butantan in Phase III clinical trials. With these ongoing dengue 
preventive and control efforts, in 2013 there was the analysis of GAVI’s vaccine 
investment strategy (VIS), in which dengue, one of the vaccine-preventable diseases 
under consideration, was not selected after review of the available data. The GAVI 
VIS acknowledged that the incidence has grown dramatically worldwide without 
effective treatments and vector control. However, due to unknown vaccine efficacy 
and the uncertainties of the disease burden, especially in Africa, dengue was not 
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selected in the vaccine policy. In the follow-up GAVI VIS in 2018, dengue was not 
considered.  
 
1.1 Global Distribution of Dengue  
 
There have been attempts to assess the global burden of dengue. Dengue 
transmission is well documented and the risk is known to be high in the Americas 
and Asia (2). Based on existing records on dengue occurrence globally, global 
distribution of dengue risk was assessed using modeling and cartographic 
approaches (2). The estimated number of dengue infections per year was 390 million 
(95% credible interval: 284–528), with 96 million (67–136) being apparent with any 
level of disease severity (2). This number of total infections is more than three times 
higher than the estimates of the World Health Organization (WHO) (2).  Among the 
apparent cases, the majority were from Asia [67 (95% credible interval: 47–94) 
million infections] and the Americas regions [13 (95% credible interval: 9–18) million 
infections] (2). The number of apparent infections from Africa was noteworthy 
[16 (95% credible interval: 11–23) million infections], being similar to that of the 
Americas, indicating a significantly larger burden than previously documented (2). In 
terms of inapparent infections, the pattern is similar. Of 294 (95% credible interval: 
217–392) million infections, the highest burden is found in Asia [204 (95% credible 
interval: 151–273) million infections] (2). It is followed by Africa [48 (95% credible 
interval: 34–65) million infections], which showed to be, again, similar to what was 
found for the Americas region [41 (95% credible interval: 31–53) million infections] 
(2).  
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Figure 1. Global map of countries showing predicted risk of dengue and reports of 
dengue cases.  
Source: Bhatt S. Gething PW, Brady OJ, et al. The global distribution and burden of 
dengue. Nature. 2013; 496:504–507. (2)  
Accessed: 14 May 2019. 
 
1.2 Dengue in Africa – Literature review 
 
In light of the progress and updates made in the field, the gap in terms of 
reliable data from Africa became more evident, with the dengue burden there being 
largely unknown (2). It is now timely to have population-based data generated from 
selected sites in Africa to facilitate better understanding of the disease and its 
significant impact in these lower-income, possibly GAVI-eligible, countries and 
evidence-based decision-making for control and preventive interventions.   
With an objective to explore what is available in the literature on dengue in 
Africa, a search of published data was performed using “((Dengue[Title]) AND 
(Africa[MeSH Terms]))” as a search term in PubMed (www.pubmed.org). In this 
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search, literature published up to May 2019 was covered. The search generated 224 
articles and title screening was performed on all 224 articles. Breakdown of articles 
based on the main topic based on title screening is provided in Table 1. 
 
Table 1. Articles on dengue in Africa, reviewed for title-screening  
 
From 224 articles, there were 15 articles based on systematic and literature 
reviews. Abstract review of these articles was done and they were reviews: on 
vectors (n=2); dengue in general, such as epidemiology and pathogenesis (n=4); 
dengue in the context of other co-circulating pathogens, such as yellow fever (n=2) 
and chikungunya viruses (n=1); and dengue mortality, as editorial (n=1). Five articles 
covered outcomes of systematic reviews or included findings from literature. One 
was by Amarasinghe et al. on overview of evidence on presence of dengue in Africa 
(14), described in greater details in section 1.2.1 below; and another with similar 
description of dengue in Africa was by Were (15). Another was based on data from 
Tanzania, reporting the estimated seroprevalance of past dengue infection to be up 
to 51% in health facility-based survey and 11% in a community-based study (16). 
The third one was a systematic review with a focus on Middle East and North Africa 
Main topic of the articles in title screening (n=224) No. of articles 
Vector, vector interventions 32 
Cost of illness  1 
Editorial  23 
Systematic or literature review 15     
Data generation  82 
Outbreak investigation  4 
Case reports  6 
Military, travellers or imported/exported cases 33 
Virus strains, phylogenetic analysis 14 
Immune response 5 
Laboratory assays and development of diagnostics 5 
Risk mapping using vector or environmental parameters 2 
Study protocol 1 
Undetermined language 1 
6 
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region and exploring the potential for outbreaks of multiple Aedes-transmitted 
diseases (17). The fourth was a report from expert conference on Dengue in Africa in 
2013 summarizing the existing evidence on literature and key action points to 
advance knowledge of the epidemiology of dengue in Africa (18). This is further 
described in detail in section 1.3. These review papers reached a common 
conclusion of insufficient data supporting Aedes or DENV presence in countries in 
Africa and highlighted the need for better DENV surveillance for control measures.  
Also, abstract review was done on 86 articles, which reported on outbreak 
(n=4) and data generation (n=82). All 86 articles were selected for abstract review. 
Abstract review resulted in exclusion of 20 articles that reported on virus and 
phylogenetic analysis (n=9); review (n=2); case report (n=1); travellers and exported 
cases (n=2); immune response (n=1); and outbreak alerts only (n=2). In addition, 
abstract review also excluded 3 articles with study results without denominator 
(population) and/or cases confirmed by lab results. If the studies were conducted on 
special groups (i.e. measles positive patients, blood donors, and pregnant women, 
etc.), these were not excluded.  
There were 66 articles, which reported study results with dengue case 
confirmation using laboratory tests. Breakdown of articles based on the country of 
data reporting and year of publication is provided in Table 2. 
 
Table 2. Articles on results of studies conducted in Africa, categorized by country 
and year of publication 
Region Country No. of 
articles 
Year of publication [no. published in the 
year, if more than 1] 
East 
Africa 
(n= 36) 
Sudan 12 2018(19), 2015 [3](20-22), 2014 [2](23, 24), 
2012[2](25, 26), 2011(27), 2010(28), 2006(29), 
1986(30)  
Kenya 9 2018(31)*, 2017[3](32, 33), 2016 [2](34, 35), 
2015[2](36, 37)*, 2011(38), 1982 (39) 
Tanzania 8 2018(40), 2016[3](41-43)*, 2014 [2](44, 45), 
2012[2](46, 47) 
Ethiopia 2 2018 [2](48, 49) 
Republic of 2 2016 (50)*, 1996 (51)* 
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Djibouti 
Reunion Is. 1 2011 (52) 
Somalia 1 1989 (53) 
Zambia 1 2014(54)  
West 
Africa 
(n= 14) 
Burkina 
Faso 
4 2018(55)*, 2017(56), 2016(57), 1985(58)*  
Nigeria 3 2017(59), 2016(60) , 1977 (61) 
Senegal 2 2014(62)*, 1986 (63) 
Sierra Leone 2 2017(64), 2016 (65) 
Côte 
d'Ivoire, 
1 2015(66) 
Ghana 1 2015(67) 
Mali 1 2011(68) 
Central 
Africa 
(n= 9) 
Gabon 5 2016(69), 2013(70), 2012(71), 2011(72), 2009 
(73)* 
Cameroon 3 2018[2](74, 75), 2014(76)  
Democratic 
Republic of 
the Congo 
1 2018(77) 
Southern 
Africa 
(n= 7)  
Mozambique 4 2018[2](78, 79)*, 2017(80) , 2016(81)*  
Angola 2 2015(82)*, 2013(83)*  
South Africa 1 1987(84) 
*based on outbreak investigation or cases identified during a dengue outbreak 
 
 These 66 articles all contained some defined population with laboratory-based 
detection of dengue cases. In the abstract review, it was found that 14 articles were 
based on cases identified in the outbreak or routine outbreak investigation.  
Of these 66 articles, 57 were published in the recent decade, in 2009 or after. 
More than half of the articles were published based on studies conducted in East 
Africa, in particularly there were 29 publications that were based on studies 
conducted in Sudan, Kenya and Tanzania. In West Africa, the majority of the articles 
were published based on studies conducted in Burkina Faso and Nigeria, but most of 
the articles were published after 2016. In Central Africa, the majority of the articles 
8 
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were published based on studies conducted in Gabon and all of the studies were 
published after 2009. More detailed reviews by country will be provided below.  
The review showed scarcity of data on dengue in Africa. They were mostly 
focused in some selected countries, such as Sudan, Kenya, Tanzania, etc. Also, with 
more heightened awareness and repeated outbreaks, it was in the more recent 
years that these studies became available as published articles. In terms of the 
currently available information based on this literature review, there was a 
consensus, in the literature, a considerable occurrence of dengue infections to occur 
in Africa, but with limited data to support it, especially due to the lack of reports with 
robust diagnostic confirmation. Available evidence underscores the need for 
improved surveillance and accurate assessment of epidemiology of dengue in Africa 
to document the largely hidden burden of dengue in Africa.  
 
1.2.1 Dengue and Aedes mosquito presence 
Two mosquito species, Aedes aegypti and Aedes albopictus are the vectors 
for some of the common arboviruses, including DENV. Both are widely distributed in 
the African continent (85-87). Presence of Aedes has been documented as early as 
1823 in Africa (86, 88). Transmission of different Aedes-transmitted diseases 
continues between known epidemics. However, except for well-known and 
historically important pathogens like the yellow fever virus, reports of cases of the 
other Aedes-transmitted viral diseases are limited to a few countries in Africa. It is 
mainly based on a few sporadic outbreaks and individual case reports, often among 
travelers (14, 89, 90).    
Previously, dengue was not recognized as an important etiology of non-
malarial febrile episodes in Africa, but this is being revised in the light of recent 
repeated outbreaks (91-93). However, most of the data are from studies are often 
not representative or population-based, being limited by their retrospective design 
using existing samples or outbreak investigations (14, 92, 94).  
The first isolation of dengue virus in Africa was in Nigeria in the 1960’s (86, 
95). In 2011, Amarasinghe et al. conducted a review of published literature, country 
reports, and WHO library database (14) covering 1960–2010. With this, two review 
papers described dengue cases to have been reported in 34 African countries with 
some documentation of reported dengue cases and Aedes aegypti presence (14, 15) 
9 
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(Table 3). Of the 34 countries, 22 have reported local disease transmission with the 
majority of (n=20) cases reported with laboratory-confirmation and the remaining two 
based on only clinically-confirmed cases (14). The remaining 12 were included 
based not on endemicity, but on cases among travelers returning from Africa (14). 
Also, there have been 20 outbreaks in 15 countries, mostly in East Africa, reported 
between 1960 and 2010 (14). Some of the countries with frequent reports of 
epidemics were Zanzibar (1823, 1870), Burkina Faso (1925), Egypt (1887, 1927), 
South Africa (1926–1927), and Senegal (1927–1928) (14). However, the authors 
pointed out that not all have been lab-confirmed. In addition to those 34, there were 
13 countries with evidence on only the presence of Aedes mosquitoes, and 5 with no 
evidence of dengue cases or Aedes.  
   
 
Table 3. Countries in Africa showing level of transmission of DENV* (14)  
 
Level of transmission Countries 
Locally acquired 
(n=7) 
Cape Verde, Egypt, Eritrea, Mauritius, Réunion 
Seychelles, Sudan 
Locally and travel acquired 
(n=15) 
 
Angola, Burkina Faso, Cameroon, Comoros, 
Republic of Djibouti, Côte d’Ivoire, Ghana, Kenya, 
Madagascar, Mozambique, Nigeria, Senegal, 
Somalia, South Africa, Zanzibar 
Travel/expatriate acquired 
(n=12) 
 
Benin, The Democratic Republic of Congo, Ethiopia, 
Equatorial Guinea, Gabon, Mali, Namibia, Rwanda, 
Tanzania, Togo, Uganda, Zambia 
Dengue has not been 
reported but that have Ae. 
aegypti mosquitoes (n=13) 
Mauritania, The Gambia, Guinea-Bissau, Guinea, 
Sierra Leone, Liberia, Niger, Chad, Central African 
Republic, Republic of the Congo, Malawi, 
Zimbabwe, and Botswana 
Data not available for 
dengue and Aedes 
mosquitoes (n=5) 
Western Sahara, Morocco, Algeria, Tunisia, and 
Libya 
* table modified by author based on data in the specified source  
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1.2.2 Available data on dengue in Africa 
There have been some reports of cases and epidemics of dengue in Africa. 
However, data on incidence and seroprevalence are rare and limited to some 
countries. A study in Nigeria estimated the prevalence of flavivirus infections among 
1,816 children and adults in urban and rural areas during the early 1970s using 
virus-specific hemagglutination inhibition and neutralization testing and the 
prevalence was 38% for DENV-1 infection and 45% for DENV-2 infection (61). Also, 
other previous studies in Nigeria reported dengue IgM antibody prevalence of 30% in 
febrile children in Ilorin, 17.2% in Ogbomoso, and 23.4% in 2014 in Ibadan (60, 96, 
97). By NS1 antigen, 35% prevalence was found in Ibadan (96).  
In Burkina Faso, 683 samples from pregnant women and blood donors were 
tested using IgG ELISA, and the authors estimated the prevalence to be 26.3% in 
rural settings and 36.5% in urban settings (98). While these estimates are much 
lower when compared against those from Asia and the Americas, it should be noted 
that there is a small number of studies and often the studies were not population-
based, with limited generalizability.  
In terms of serotypes, all four have been isolated in Africa, with DENV2 being 
the most prevalent serotype in epidemics (14). Table 4 lists the countries in Africa by 
serotype and the year of reported epidemic (14). Burkina Faso reported all four 
serotypes of DENV at different time points, Senegal 3 serotypes, and several other 
countries reported 2.  
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Table 4 Dengue epidemics in Africa by the circulating serotype*(14)  
Serotype Countries Year 
DENV1  Burkina Faso, Comoros, Ivory Coast, 
Kenya, Madagascar, Nigeria, South 
Africa, Sudan.  
1927, 1964, 1968, 1979, 
1984, 1984, 1992, 1993, 
1998, 2006, 2007, 2013  
DENV2  Burkina Faso, Comoros, Republic of 
Djibouti, Gabon, Ghana, Ivory Coast, 
Kenya, Mali, Reunion (France), 
Senegal, Seychelles, Somalia, Sudan.  
1977, 1978, 1979, 1982, 
1983, 1984, 1985, 1986, 
1987, 1990, 1991, 1992, 
1993, 1999, 2002, 2005, 
2008  
DENV3  Burkina Faso, Cameroon, Cape Verde, 
Ivory Coast, Mozambique, Senegal.  
1984, 1985, 1992, 1993, 
2006, 2007, 2008, 2009, 
2013  
DENV4  Burkina Faso, Senegal.  1980, 1985, 2013  
* generated by author using data from the specified source  
 
 
1.2.3 Modelling of dengue transmission in Africa 
In 2014, Messina et al. generated a series of global maps to show the extent 
of global spread of lab-confirmed dengue cases from 1943 to 2013 for each DENV 
serotype, and the expansion of dengue hyperendemicity (86). The authors used data 
sources to identify “occurrence” defined as the sub-national distribution of reported 
confirmed human infections with each DENV type (86). The authors identified 1000 
to 1956 occurrence points of geographical location of the cases, variable by serotype, 
excluding those with lack of evidence on testing (86). These maps showing the 
reporting history of each DENV type and the cumulative number of DENV types for 
the periods 1943–1959, 1960–1969, 1970–1979, 1980–1989, 1990–1999, and 
2000–2013, suggested a rapid growth in the reported DENV types (86). While this is 
more evident for the Asia-Pacific, the Americas, and the Indian subcontinent regions, 
more reported cases are becoming available recently for the Africa region, showing 
countries in West and East Africa with three or more DENV types reported (86). With 
such geographical expansion in the presence of one or more DENV types, it should 
be also noted that there is also potential increase in co-circulation of all four viruses, 
indicating possible hyperendemicity of DENV transmission (86).  
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As part of the Global Burden of Disease study in 2013, Stanaway et al. 
modelled mortality using the Cause of Death Ensemble Modelling tool and incidence 
from officially reported cases, with adjustment for under-reporting using published 
estimates of expansion factors (99). Using 1780 country-years of mortality data from 
130 countries, 1636 country-years of dengue case reports from 76 countries, and 
expansion factor estimates for 14 countries, various estimates indicating the burden 
due to dengue were generated (99). Also, using expansion factors estimated for 14 
countries to account for under-reporting, the authors reported exponentially 
increasing number of apparent cases globally, from 8.3 million in 1990 to 58.4 million 
in 2013 (99). The authors reported incidence using mixed-effects negative binomial 
models, and found the highest age-standardized incidence rates in southeast Asia, 
with an annual average of 34∙3 [95% uncertainty interval (UI): 12∙7–75∙0] cases per 
1000 people in the region (99). It was 18.2 (95% UI: 7.7-37.4) for Caribbean and 9.7 
(95% UI: 4.2-19.6) cases per 1000 people for Tropical Latin America regions in 2013 
(99). What is noteworthy was that it was 10.7 (95% UI: 4.6-21.6) cases per 1000 
people for Western sub-Saharan, 5.0 (95% UI: 1.9-11.0) for Central sub-Saharan, 
and 3.0 (95% UI: 1.0-7.2) for Eastern sub-Saharan Africa.  
In addition, the authors modeled dengue mortality using the Global Burden of 
Disease Cause of Death database, which contains data for 240 causes of death, and 
reported that, again, the highest age-standardized mortality rates were found in 
southeast Asia, with an annual average of 8.5 (95% UI: 3.9–10.7) cases per million 
people in the region (99). Similar to patterns found for incidence, mortality rate for 
Tropical Latin America regions at 1.4 (95% UI: 0.2-1.7) and this was comparable to 
Western sub-Saharan at 0.8 (95% UI: 0.6-1.1) and Central sub-Saharan regions at 
0.6 (95% UI: 0.4-0.9) (99). Number of deaths also increased from 1990 to 2013, from 
8657 to 9110, but the difference was not as dramatic as number of cases of 
apparent dengue. Overall, this study documented increased transmission of DENV in 
2013, in all regions, compared to 1990, and these estimates by region, again, show 
that DENV transmission in Africa is at a similar level, in terms of equal numbers of 
infections (both apparent and inapparent) as in Latin America (2), where 
hyperendemicity of DENV is well-documented (99). 
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1.3 Challenges leading to under-recognition of dengue in Africa  
The presence of Aedes mosquitoes and human DENV infection have been 
confirmed in Africa (14, 86). Also, there are modelling estimates predicting the 
intensity of transmission and level of disease burden. However, there is still limited 
data generated on dengue in Africa, on magnitude of DENV transmission, extent of 
its spread, serotype-specific information, with lack of adequate surveillance systems 
and research efforts (14, 86). 
There are several challenges that resulted in such data scarcity. African 
countries commonly have many competing public health problems. The frequently 
non-specific clinical presentation of dengue makes it difficult to distinguish from other 
causes of febrile illness (2, 15). Also, possible issues of under-reporting and 
treatment-seeking behavior different from other regions may also contribute to the 
challenges faced in Africa (2). 
This is further complicated by complexities of diagnostics with cross-reactivity 
across flaviviruses and not widely available diagnostic assays and laboratory 
capacity (18). Common tests for dengue diagnosis include serologic, virus isolation, 
molecular, and virus antigen detection as well as combination of these methods, 
variable in terms of test accuracy (i.e. sensitivity and/or specificity), extent to which 
technical expertise and infrastructure are required, etc. (100-102). There are rapid 
diagnostic tests (RDTs), with advantages of quick turnaround time and user-
friendliness, but the sensitivity and specificity may be compromised. Nonetheless, in 
Africa where laboratory diagnostic resources are limited, tests that are require 
technical resources, including equipment and set-up, and costly would not be 
adoptable and RDTs can be useful tools for dengue diagnosis (103).  
 
1.3.1 Laboratory diagnosis of dengue 
Limited diagnostic capacity for dengue contributes to the problem of a largely 
unknown dengue burden in Africa. In addition to the problem of various causes of 
acute febrile illness (AFI) with similar symptoms limiting accurate assessment of 
dengue burden, there are challenges due to the extent of availability of tests and 
inherent reliability of existing tests. Dengue diagnostics is complex with multiple 
considerations interplaying. The main concern is cross-reactivity across flaviviruses 
and that there are often multiple co-circulating flaviviruses in areas of dengue 
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endemicity (100, 101). Results of dengue serologic tests are hampered by cross-
reactivity as these serologic tests detect antibodies of other flaviviruses, such as 
Japanese encephalitis, St. Louis encephalitis, West Nile, yellow fever, and Zika (100, 
101). However, often dengue-endemic areas also have other flaviviruses circulating. 
In order to accurately determine the cause of infection, it may be necessary to 
perform additional analyses, but there is no known test that can perfectly distinguish 
specific flaviviruses (100).  
There are various testing options for dengue diagnosis: serology, molecular 
methods, and virus antigen detection as well as combination of these methods (100-
102). Among serologic tests, there is IgM Antibody Capture Enzyme-Linked 
Immunosorbent Assay (MAC-ELISA), which captures dengue virus-specific IgM 
antibodies, and IgM levels remain positive for 3-5 days after symptom onset and may 
remain up to 12 weeks following infection (101, 104). Often, a second sample should 
be obtained after day 7 of symptoms for interpretation of results to distinguish 
between recent, presumptive infection from current, infection (104). As with IgM, 
there is IgG ELISA test, which captures dengue virus-specific IgG antibodies. The 
difference is that IgG remains detectable after several months, and possibly life-long 
(101). Especially due to secondary dengue infection (previous infection with another 
serotype of a dengue virus, or infection or vaccination against another flavivirus), 
antibody titres may remain detectable and react against many flaviviruses (101). 
Then, even in the acute phase, IgG level can be detected and, with this feature of 
IgG, IgG and IgM levels, calculated as IgM/IgG antibody ratios, can distinguish 
primary and secondary dengue infections (101). Benefit of IgM and IgG ELISA is that 
these are available as laboratory-developed tests and commercial diagnostic kits 
(104). 
Due to cross-reaction with other flaviviruses, serologic test results may require 
further analyses by plaque reduction neutralization testing (PRNT) for confirmation 
(104).  PRNT is a more precise test that can determine cause of infection by 
detecting specific neutralizing antibodies (104). Hence, it can distinguish specific 
flaviviruses and DENV serotypes. However, it is known to be labor intensive and 
expensive, thus not widely available (104). And, a single PRNT is limited to 
determine the timing of infection (104).  
Molecular methods detect dengue virus RNA in the first 1-7 days in the course 
of illness (105). Commonly used is RT-PCR assay. This can distinguish the four 
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dengue virus serotypes and is available, in forms of multiplex or trioplex (dengue 
with chikungunya and Zika viruses) (105). A positive result from PCR indicates 
confirmed dengue infection, but a negative PCR result does not mean non-dengue 
(105). As a method to detect DENV antigen, there are NS1 tests that detect the non-
structural protein NS1 of dengue virus commonly in serum (106). NS1 can be 
detected in the acute phase of illness up to 7 days since onset of symptoms (106).  A 
positive NS1 test is indicative of a dengue infection but it does not provide serotype 
information (106). Also, a negative NS1 test result does not mean non-dengue (106). 
Conveniently, dengue NS1 tests are available as commercial diagnostic kits. 
Among this wide range of diagnostic options, different tests are used at 
different times, depending on the illness progression (time of sample collection), 
purpose of diagnosis  (point-of-care vs. surveillance), and availability of resources 
(laboratory facilities and expertise available, i.e. at national and regional reference 
laboratory-levels vs. lower-level clinical setting) (101). There are more reliable 
methods, such as molecular (PCR) assays, RNA detection, and PRNTs, but they are 
more labour-intensive and costly, requiring some infrastructure including technical 
expertise (101). In this context, RDTs can be useful tools for point-of-care diagnosis, 
especially in resource-limited settings (103).  
Given limited diagnostic capacity and laboratory facilities in the region, one 
way to address this challenge might be using dengue RDTs. In the expert 
conference held in Accra, Ghana, in February 2013 on Dengue in Africa, key 
questions regarding the expansion of dengue in Africa were addressed (18). 
Consistent with the points addressed in the introduction, key areas were identified to 
be in need for further advancement of our understanding of the epidemiology of 
dengue in Africa. In light of the need for representative data to be collected across 
Africa to understand the true burden of dengue, better collaboration among 
established networks was encouraged along with dengue diagnostic tools to be 
made more widely available in the healthcare setting in Africa to produce such data 
(18). It is so that policy recommendations could be developed based on such data 
generated for necessary actions to provide dengue vector control and health 
services (18).  
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1.3.1.1 Rapid diagnostic tests for dengue 
According to the ASSURED criteria defined by WHO for evaluation of POC 
devices for resource-limited settings, diagnostic tests would be ideal if they are: 
(1)  Affordable; (2) Sensitive; (3) Specific; (4) User-friendly (simple to use with 
minimal training); (5) Rapid (for prompt treatment) and Robust (no refrigerated 
storage); (6) Equipment-free; (7) Delivered to those who need it (107). There are 
several rapid tests available with reasonable sensitivity and specificity. While these 
are not considered the standard reference and their usefulness is not yet proven in 
clinical settings, they are known to be convenient and prompt option to support 
clinical diagnosis (108, 109). The conference on dengue in Africa held in Ghana 
concluded that it is necessary to make such tests available at sentinel sites and 
health facilities to support accurate diagnosis (18). 
There is a number of different commercially available rapid tests, based on 
the detection of dengue virus non-structural protein 1 (NS1) antigen, IgM, IgG, and 
IgA antibodies (101, 103). While the RDTs have advantages, such as more rapid 
turnaround time and user-friendliness in field settings for point-of-care diagnosis, 
these tests have variable sensitivity and specificity (101). Not all commercial rapid 
tests are validated by reference laboratories and rapid test results for diagnosis 
should be interpreted with caution (101). Also, to improve accuracy of RDTs, it has 
been suggested that RDTs could be used in combination with others, for example 
the combined test with NS1 antigen and IgM antibody (110, 111). Nonetheless, in 
resource-limited countries where there might be limited infrastructure and expertise, 
major benefits of using RDTs would be that they are available as user-friendly point-
of-care kits, with no other equipment or training needed. Also, these countries with 
no surveillance system established to monitor incidence of dengue, use of the 
dengue RDTs could be helpful for case detection to predict outbreak, and to allow 
individual dengue cases to be identified in the early phase of illness, hence 
facilitating better case management of dengue illness and possibly reducing the 
duration of illness, leading to lower cost-of-illness due to dengue (112, 113). 
Given the overall convenience and benefit of using RDTs, a systematic review 
was performed on published data to explore the economic impact of using RDTs, the 
cost-aspect of the benefit and impact when using dengue RDTs for dengue case 
detection (chapter 2). The hypothesis behind this review was that there may be 
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economic impact due to prompt detection of dengue in the early phase of illness 
using RDTs and economic impact is defined to be broad: both from the point of view 
of cost-effectiveness and from the perspective of financial impact of RDT in patients, 
i.e. early diagnosis possibly leading to cost-saving in patients. Evidence in the 
current literature on this was explored in more detail in chapter 2 of the thesis. 
 
1.3.1.2 Secondary versus primary infections  
Different testing options need to be applied considering the progress of illness. 
For example, molecular tests, such as PCR, are used within 7 days after onset of 
symptoms as well as NS1 antigen detection (100). However, serologic tests can be 
used after 7 days since onset of symptoms (100). Other considerations for the 
choice of diagnostic method include the set-up of laboratory facilities and technical 
expertise available, costs, and the time of sample collection.  
Test results also depend on whether it is primary versus secondary infection. 
It is important to differentiate the two in order to apply proper case management, 
given that secondary dengue infection, a known risk factor for dengue haemorrhagic 
fever (DHF) and dengue shock syndrome (DSS), can cause more severe disease 
than the primary infection (7, 114). In general, once a person is infected with DENV, 
the virus is found in serum or plasma for about 2-7 days and this coincides with the 
duration of fever (101, 115). And then, anti-dengue antibodies will appear days later 
and stay detectable with different patterns of immune response for primary and 
secondary infections. For primary, dengue as well as flavivirus-naïve, infections, 
there will be detectable IgM levels for 80% by day 5 of illness and this will stay 
detectable for 2 weeks after onset of symptoms, but will not stay detectable after 3 
months or so (101, 115). In case of primary infections, anti-dengue IgG appears 
afterwards.  
In secondary infection, antibody titres rise rapidly and IgG level can be 
detected at high levels from the initial phase of illness (115). It has been documented 
that it can last about 10 months to as long as life time (115). Also, in secondary 
infections, IgG shows cross reaction across different flaviviruses (115). What is 
different from primary infection is the lower IgM level in secondary infections. Due to 
these differences, to distinguish primary and secondary dengue infections, one 
common way to identify is to use IgM and IgG indices for calculation of IgG/IgM ratio 
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(114-116). Different cut-off values have been studied and a study reported that the 
IgG/IgM ratio of ≥ 1.10 had a sensitivity of 100%, specificity of 97.4%, and accuracy 
of 67.5% in differentiating secondary from primary dengue (114). Also, use of the 
ratio to discriminate primary from secondary dengue was shown to perform better 
later in the course of illness (116)  
 
1.3.2 Surveillance systems 
Moreover, many dengue endemic countries in Asia and Latin America have 
mandatory reporting of dengue cases to public health authorities or national 
surveillance systems to monitor incidence patterns (117). However, coupled with 
limitation in diagnostic resources, most African countries lack such mechanisms, and 
only sporadic outbreaks and individual case reports have been documented (117). 
Burkina Faso is one of the few countries with an established national routine 
surveillance of potential epidemic diseases, which has included dengue in the 
notification system since 2016. This is in addition to investigations during outbreak 
periods, conducted by the Ministry of Health of Burkina Faso, based on few health 
centers (118). Especially during the outbreak in 2017 in Burkina Faso, a laboratory-
based arbovirus sentinel surveillance was implemented during fall 2017, which was 
built on existing routine surveillance with enhancement of sample testing, 
improvements in case reporting as well as data management (119).  
There may be surveillance studies launched in response to these epidemics, 
but such activities would not remain in place during the non-epidemic seasons. Also, 
several disease burden studies assessing the causes of febrile illnesses were 
conducted in the past years in Africa. Yet, most studies solely identified the causes 
without comprehensive evaluation of clinical and epidemiologic patterns of infections 
with lab-confirmation of respective pathogens. Actual results from the field, whether 
from research study or local surveillance systems, provide better inputs for more 
accurate modeling outcomes on transmission and dynamics of DENV in the region.  
 
1.4 Gaps in knowledge 
A considerable level of dengue transmission may be occurring in Africa and, 
in selected few countries, there are more data becoming available on this recurring 
problem. However, with limited diagnostic capacity and surveillance systems, the 
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lack of data underscores the need for robust evidence based on population-based 
studies equipped with laboratory confirmation to support the extent of transmission 
and burden of dengue in the region. Due to the uncertainties of the disease burden 
in Africa and complexities associated with dengue vaccines (introduction of the only 
licensed one as well as development of the other candidates), it may be premature 
to consider vaccine introduction as an intervention in Africa. However, population-
based data generated from local studies will serve as important factors to be 
considered later, once a safe and cost-effective vaccine becomes available, for 
evidence-based policy decisions for control and prevention strategies, including 
introduction of vaccines.  
 
1.5 Study background and objectives 
Given the gap in the literature and to address the knowledge gap on the 
magnitude of the dengue problem and generate improved data on dengue 
epidemiology, passive facility-based fever surveillance studies were conducted 
among residents of Ouagadougou in Burkina Faso, and Mombasa in Kenya (120), 
funded by a 4-year grant to Dengue Vaccine Initiative (DVI) from the Bill and Melinda 
Gates Foundation in 2013. As part of the field operation of DVI, I was in charge of 
the studies in Burkina Faso and Kenya, the PhD program covers the work for which I 
led the grant writing to study design, project execution, and closing (more on the role 
of the candidate in the current project in section # 1.10).  
In both sites, partial or full outbreaks were captured during the study period 
and this allowed our data generated to: 1) assess the epidemiology of DF; and 2) 
compare dengue-positive cases to non-dengue cases and assess differences in 
clinical features of dengue during the outbreak and non-outbreak periods. Outpatient 
dengue accounts for the greatest burden of disease, both epidemiologically and 
economically; however, there continues to be a lack of data on dengue among non-
hospitalized cases (121, 122). The surveillance studies cover both hospitalized and 
outpatient department. Also, due to difference in the clinical and epidemiological 
patterns of dengue between adults and children, the age range for the surveillance 
studies covered 1 to 55 years of age (123, 124).  
In addition to the surveillance studies looking at symptomatic dengue fever 
episodes, to assess baseline population-based seroprevalence and calculate 
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subsequent rates of dengue infection by IgG seroconversion, repeated serosurveys 
were conducted among residents of Ouagadougou, Burkina Faso. In the same 
catchment area as the facility-based surveillance, 4 serosurveys, at intervals of 
about 6 months, were conducted in 3000 randomly selected residents between 1 
and 55 years of age. The last interval covered the 2016 outbreak and sero-
conversion rates were compared across demographic and clinical characteristics, 
and in the interval covering the outbreak versus those with no outbreak reported. 
To date, there had not been data generated from Africa, assessing the burden 
due to dengue fever episodes that sought healthcare and also estimating the 
ongoing rate of infection, measured by sero-conversions, in the community residents 
that do not seek care, from the same catchment area population. The data 
generated will not only provide the most updated estimates of the disease burden 
currently available but also will be used to make informed policy to facilitate 
decisions on adoption of various measures for dengue prevention and control.  
 
1.6 Study sites 
Study sites were selected, in part, based on their likelihood of supporting 
DENV transmission. To select sites, we considered dengue outbreaks and case 
reports in the literature, available seroprevalence studies, as well as country-specific 
dengue risk maps of the probability of DENV transmission and the level of evidence 
of dengue presence, reporting the consensus estimates based on modeling of 
probability of dengue presence in Africa (9, 86).  
In addition to referring to limited, but existing, data available from surveillance 
and research studies, site selection in 2013 was supported by modeling outcomes. 
One in particular, the published data on dengue incidence as well as vectors, and 
other supplementary data sources were applied to build country-specific models to 
assess the level of evidence consensus indicative of the probability of dengue 
presence and a range of evidence was reported (9, 86, 125). The authors generated 
country-specific dengue risk maps and burden estimates for all GAVI-eligible 
countries based on determined consensus on presence or absence of dengue and 
mapping of the country-specific probability of dengue occurrence (9, 86). According 
to the authors, Burkina Faso was reported to have evidence consensus of 88% in 
prediction of dengue presence (9, 86, 125). This high level of consensus of evidence 
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for dengue presence in Burkina Faso could be supported by the reported outbreak in 
2006 in Ouagadougou and 36.5% sero-positivity found in 2004 in the urban part of 
the country (9, 98). Kenya reported evidence consensus of 83% in prediction of 
dengue presence (9, 86, 125). This high level of consensus of evidence for dengue 
presence in Kenya could also be supported by the reported outbreaks reported in 
1982 and 2011 with 14% sero-positivity in adults in 2004 (9, 126, 127). The 
consensus level estimates for Burkina Faso and Kenya are indicative of “complete 
consensus” (if higher than 79%)(125).  
Another factor for consideration in site selection is adequate research 
infrastructure to implement the studies was taken into account. Finally, inclusion of 
different regions of Africa was also a factor in site selection. Thus, Ouagadougou, 
Burkina Faso, and Mombasa, Kenya were selected to measure the burden of 
dengue in selected sites from West and East Africa. 
 
1.6.1 Dengue in Burkina Faso 
PubMed (www.pubmed.org) was used to search for existing evidence on 
dengue in Burkina Faso. No other database was considered, but outbreak reports on 
WHO website or local MoH websites were reviewed. The search term combination 
used was; “(Dengue[MeSH Terms]) AND (Burkina Faso[MeSH Terms])”. This search 
generated 13 articles. All but 1 were published 2006 or later. Abstract review was 
done on all the articles and basic details of the obtained articles are summarized in 
Table 5. 
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Table 5. Articles on dengue in Burkina Faso 
Topic 
(No. of 
articles) 
Authors 
(ref.) 
Year Aim Methods 
Vector 
control 
(1) 
Ouedra
ogo et 
al.(128)  
2018 To evaluate the effectiveness of a community-based 
intervention for dengue vector control in 
Ouagadougou. 
Effectiveness 
study on a vector 
control 
intervention  
Cost of 
illness 
(1) 
Lee et 
al.(12)  
2019 To capture the entire cost incurred during the period 
of dengue illness in Burkina Faso, Kenya, and 
Cambodia and to understand how the economic 
burden of dengue is distributed between private and 
non-private payers. 
Cost-of-illness 
survey on dengue 
RDT-positive 
patients within a 
fever surveillance 
Review/
editorial 
(2) 
Sanou 
et 
al.(119)  
2018 To describe the successful implementation of 
laboratory-based arbovirus sentinel surveillance 
during a dengue outbreak during fall 2017, as an 
effort to build capacity to better understand the 
burden of disease caused by arboviruses in Burkina 
Faso. 
Description of the 
implementation,  
surveillance 
methods, and 
associated 
costs of enhanced 
surveillance as an 
outbreak response 
Ridde et 
al.(118) 
2014 To describe the need for rapid deployment of 
research and interventions on dengue fever in 
Burkina Faso, given the conventional focus being on 
malaria. 
Review on the 
need  for more 
research and 
public health 
interventions for 
dengue    
Data 
generati
on (4) 
Diallo et 
al. (56) 
2017 To study epidemiology, diagnostic and outcomes of 
dengue patients hospitalized for fever and painful 
syndrome with a positive test to the dengue non-
structural antigen 1, based on a retrospective study 
covering a period from January 2013 to December 
2014 in a private clinic in Ouagadougou. 
A retrospective 
study using data 
from patients who 
sought care at a 
private clinic  
Fournet 
et al. 
(129) 
2016 To evaluate flavivirus presence in Ouagadougou and 
the link between anti-flavivirus antibody 
seroprevalence and urbanization modes. 
A population-
based cross-
sectional survey 
conducted and 
among children 
Ridde et 
al. (57) 
2016 To describe epidemiology and vector ecology based 
on an exploratory cross-sectional survey of febrile 
A prospective 
cross-sectional 
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Of the 13 articles, 5 presented results from field studies and detailed results of 
outbreak investigation (55-57, 98, 129). Full text review was done on articles on 
outbreak investigation and on locally generated data. And the main results extracted 
from these studies are summarized below.  
The first outbreak of dengue in Burkina Faso occurred in 1925 (14). In 1982, 
DENV2 was reported in humans and mosquitoes after an outbreak in Ouagadougou 
patients performed from December 2013 to January 
2014 at six primary healthcare centers in 
Ouagadougou, as well as collection of data on 
potential Aedes breeding sites and larvae.  
survey based on 
patients identified 
at primary 
healthcare centers  
Collenb
erg et 
al. (98) 
2006 To assess seroprevalence of  six different human 
pathogenic viruses: human immunodeficiency virus 
(HIV); hepatitis B virus (HBV); hepatitis C virus 
(HCV); human T-cell leukemia virus (HTLV); human 
herpesvirus type 8 (HHV-8);and dengue virus, based  
on a seroprevalence study among pregnant women 
and blood donors from rural (Nouna) and urban 
(Ouagadougou) parts of Burkina Faso. 
A seroprevalence 
study among 
pregnant women 
and blood donors  
Outbrea
k 
investig
ation (1) 
Tarnagd
a et. al. 
(55)  
2018 To report on 1,327 probable cases of dengue in 
Burkina Faso in 2016. 
Outbreak 
investigation 
conducted among 
suspected dengue 
cases using a 
RDT 
Case 
reports, 
includin
g 
traveller
s’ or 
importe
d cases 
(3) 
 
Mamou
dou et 
al. (130)  
2016 To report three cases of hemorrhagic dengue 
observed at the Infectious Diseases Department CHU 
Yalgado Ouédraogo, Ouagadougou, and describe its 
epidemiological and clinical characteristics. 
A case report of 3 
DHF patients  
Hashim
oto et al. 
(131) 
2017 To present a case of dengue fever imported from 
Burkina Faso to Japan, with results from phylogenetic 
analysis.  
A case report of 
an imported DF 
patient to Japan 
Eldin et 
al. (132) 
2016 To report on two cases of dengue fever in travellers 
returning from Burkina Faso to France. 
A case report of 
two French 
travellers 
Virus 
strains 
(1) 
Gonzale
z (133) 
1985 To present viral identification and isolation of strains 
virus isolations, describe the observed syndrome and 
discuss the epidemiological patterns of the outbreak 
in the rainy season of 1982 in Ouagadougou. 
A prospective 
study of dengue-
like patients  
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(134, 135). There were declared outbreaks in 2013, 2016, and 2017 (118, 136-138). 
In 2016, between August and November, there were 1061 dengue RDT positive 
cases identified from all districts of Ouagadougou and 15 deaths reported (55, 137). 
The outbreak in September 2017 proved to be even larger, with 9029 suspected 
dengue cases, 5773 dengue RDT-positive cases, and 18 deaths throughout the 
country (138).  
In terms of proportion of acute dengue, Ridde et al. conducted a cross-
sectional survey among non-malarial febrile patients at 6 primary healthcare centers 
from December 2013 to January 2014 in Ouagadougou (57). Of the 379 subjects, 
8.7 % (33/379) had positive RDTs for dengue and almost 40% were either probable- 
or confirmed- dengue (57). In terms of seroprevalence, Collenberg et al. reported, 
based on a study based on testing 683 samples from pregnant women and blood 
donors using IgG ELISA, that the estimated prevalence was 26.3% in rural settings 
and 36.5% in urban settings (98). This was similar to what Fournet et al. reported 
based on a seroprevalence study (129). The authors reported the prevalence of past 
flavivirus infections among the enrolled children (n = 685) to be 22.7%, indicating 
active transmission of flaviviruses without distinguish across flaviviruses (129) 
These repeated epidemics and seroprevalence estimates suggest a 
considerable dengue burden in Burkina Faso. Nonetheless, there are not much data 
on comprehensive evaluation to understand patterns of dengue epidemiology (57). 
Also, Burkina Faso, like other countries in Africa, has other competing public health 
problems, and several of them have similar presenting symptoms, and the 
availability dengue diagnostic assays is limited (15, 118). 
Most African countries lack national surveillance systems to monitor dengue 
incidence. However, Burkina Faso is one of the few countries with an established 
national routine surveillance of potential epidemic diseases, which has included 
dengue in the notification system since 2016. In outbreak periods, the Ministry of 
Health of Burkina Faso conducts investigations, based on few health centers (118).  
1.6.2 Dengue in Kenya 
Similarly, PubMed was used to search for existing evidence on dengue in 
Kenya. The search term combination used was; “(Dengue[MeSH Terms]) AND 
(Kenya[MeSH Terms])”. The search generated 23 articles. Compared to Burkina 
Faso, there were more articles on Kenya from 1980’s and there were more articles 
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based on data generated from local studies. There were 2 letters published in Lancet 
by Johnson et al. in 1982 (139) and 1990 (140). Excluding these letters, abstract 
review was done on the remaining 21 articles and basic details of the obtained 
articles are summarized in Table 6. 
Table 6. Articles on dengue in Kenya 
Topic 
(No. of 
articles) 
Author
s (ref.) 
Year Aim Methods 
Vector –
related 
(8) 
Chepk
orir et 
al.(141
)  
2018 To reports on the Aedes mosquito species 
occurrence, diversity, and blood feeding patterns, 
as means of measuring the risk of transmission of 
YF and DEN viruses in Kacheliba sub-county, 
West Pokot County 
Entomological 
surveillance 
Nyase
mbe et 
al 
(142) 
2018 To assess selectivity in plant feeding using a 
DNA-based approach targeting trnH-psbA and 
matK genes and identify host plants of field-
collected Afro-tropical mosquito vectors of 
dengue, Rift Valley fever and malaria  
biochemical 
and molecular 
analyses of 
mosquito 
samples 
Agha 
et al. 
(143) 
2017 To survey water-holding containers for mosquito 
immature (larvae/pupae) indoors and outdoors 
from selected houses during the long rains, short 
rains and dry seasons (100 houses/season) in 
each County from October 2014-June 2016, and 
we compared DEN and YF risk in Kilifi County 
(DEN-outbreak-prone), and Kisumu and Nairobi 
Counties (no documented DEN outbreaks) 
Household-
based 
entomological 
survey  
Ngugi 
et al. 
(144) 
2017 To characterize breeding habitats and establish 
container productivity profiles of Ae. aegypti for a 
period of 24 months (June 2014 to May 2016)in 
rural and urban sites in western and coastal 
Kenya 
Household-
based 
entomological 
survey 
Lutomi
ah et 
al. 
(145) 
2016 To conduct an entomologic investigation and 
establish the mosquito species, and densities, 
causing the outbreak 
Entomologic 
surveillance 
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Owino 
et al. 
(146) 
2015 To describe the development and use of synthetic 
human odor baits for improved sampling of adult 
Ae. aegypti, in two dengue and chikungunya 
fevers endemic areas in Kenya; Kilifi and Busia 
counties 
biochemical 
and molecular 
analyses of 
human 
volunteers and 
mosquito 
samples 
Attawa
y et al. 
(147) 
2014 To identify highest and lowest areas of dengue 
risk within Kenya using a geospatial analysis, 
using the bioclimatic variables and elevation and 
mosquito habitat in environmental susceptibility 
analysis and geographical information systems 
Dengue risk 
mapping based 
on bioclimatic 
and 
entomological 
variables 
Midega 
et al. 
(148) 
2006 to identify the types of domestic container that are 
most productive for Aedes aegypti (L.) pupae 
Assessment of  
pupal/demogra
phic-survey 
methodology 
Cost of 
illness 
(1) 
Lee et 
al.(12)  
2019 to capture the entire cost incurred during the 
period of dengue illness in  Burkina Faso, Kenya, 
and Cambodia and to understand how the 
economic burden of dengue is distributed 
between private and non-private payers 
Cost-of-illness 
survey  
Data 
generati
on (8) 
Konon
goi et 
al. 
(149) 
2018 To report on entomologic investigations and 
laboratory confirmed chikungunya cases in 
northeastern Kenya using the patient blood 
samples received at the Kenya Medical Research 
Institute viral hemorrhagic fever laboratory and 
the immunoglobulin M enzyme linked 
immunosorbent assay (IgM ELISA) was used to 
test for the presence of IgM antibodies against 
chikungunya and dengue 
entomologic 
investigations 
and laboratory 
testing of 
existing 
patients 
samples  
Ngoi et 
al. (34) 
2016 To tested plasma samples obtained in a cross-
sectional study from febrile adult patients aged 
18-35 years seeking at seven health facilities in 
coastal Kenya in 2014-2015and evaluated for AHI 
and malaria as well as dengue and chikungunya 
A cross-
sectional study 
nested within a 
facility-based 
acute HIV 
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viruses infection study  
conducted 
among febrile 
adult  
Vu et 
al. (32) 
2017 To study a cluster of dengue virus infections in 
children in Kenya during July 2014-June 2015 
A prospective 
cohort of 
children 
Vu et 
al. (33) 
2017 To measure neutralizing antibody against DENV 
and, to evaluate assay specificity, WNV in serum 
samples that tested positive for serum anti-DENV 
IgG by enzyme-linked immunosorbent assay 
A prospective 
seroprevalence 
survey 
Konon
goi et 
al.(35) 
2016 To detect the presence of IgM antibodies against 
dengue, yellow fever, West Nile and Zika using 
868 samples from febrile patients were received 
from hospitals in Nairobi, northern and coastal 
Kenya from September 2011 to December 2014 
Hospital-based 
fever 
surveillance 
Ochien
g et al. 
(36) 
2015 to test for the presence of IgG antibodies to 
dengue virus (DENV), chikungunya virus (CHIKV) 
and Rift Valley fever virus (RVFV) using 1,091 
HIV-negative blood specimens from the 2007 
Kenya AIDS Indicator Survey  
Retrospective 
testing of using 
HIV-negative 
blood 
specimens 
from a national 
population-
based survey 
on AIDS 
Ellis et 
al. (37) 
2015 To investigate several individuals with dengue-like 
illnesses and negative malaria blood smears were 
identified in Mombasa, Kenya in February 2013, 
and to estimate the magnitude of local 
transmission including a serologic survey to 
determine incident dengue virus (DENV) 
infections 
Household-
based 
serosurvey 
Blayloc
k et al. 
(38) 
2011 To describes the seroincidence and 
seroprevalence of dengue infection in western 
Kenya based on testing for antibodies to dengue 
virus using an IgG indirect ELISA using banked 
Dengue 
seroprevalence 
survey 
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sera obtained from 354 healthy, afebrile children 
ages 12-47 months from Kisumu District, Kenya 
Virus 
isolation 
(1) 
Johnso
n et al. 
(150) 
1982 To describe the first virologically confirmed DENV 
2 in Kenya using 7 strains of virus identified in 
1982 from outpatients attending hospital on the 
Northern coast of Kenya 
serological 
study 
Outbrea
k 
investiga
tion (1) 
Obony
o et al 
(31) 
2018 To investigate a suspected dengue outbreak in 
Mandera town from September to October 2011 
Outbreak 
investigation  
Case 
reports, 
including 
Imported 
cases 
(1) 
Martyn
-
Simmo
ns 
et al. 
(151) 
2007 To report a case of widespread skin eruption in a 
UK women returning from a visit to Kenya 
Case report of 
1 UK traveler 
Diagnost
ic-
related 
(1) 
Wason
ga et 
al. 
(152) 
2015 to develop and evaluate an in-house IgM-capture 
enzyme linked immunosorbent assay (ELISA) for 
the detection of chikungunya virus infections and 
test performance among clinically suspected 
dengue patient samples from Eastern Kenya, 
collected in 2013 
Validation of an 
in-house ELISA 
 
Of the 21 articles, 9 presented results from field studies and detailed results of 
outbreak investigation. Full text review was done on articles on outbreak 
investigation and on locally generated data. And the main results extracted from 
these studies are summarized below.  
In Kenya, compared to other African countries, there is more evidence 
available for the presence of dengue, with several documented outbreaks in different 
locations. The most recent outbreak reported was in Mombasa in May 2017 (153). In 
2011, an outbreak was confirmed in Mandera, North Eastern region, and, in 2013, 
another in Mombasa continuing into 2014 (31, 37). In addition to outbreak 
investigations, a study based on 868 samples from febrile patients in multiple 
locations in Kenya from 2011 to 2014 reported 40% (345/868) of the samples to be 
dengue-positive by either IgM ELISA or RT-PCR (35).  
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A cohort study among 1258 children 1-17 years of age conducted in 2014-
2015 reported that among 1104 samples tested, 7.4% were positive for DENV RNA 
and all 4 serotypes were found (32). Also, a cross-sectional study among febrile 
adult patients aged 18-35 years tested for acute HIV infection (AHI) and malaria 
were used to evaluate presence of dengue and chikungunya virus infections (34). 
Authors found that 8.8% were positive for DENV infection, indicating a substantial 
level of DENV infections in coastal Kenya(34). 
In terms of seroprevalence, dengue was found to be the most common viral 
pathogen in retrospectively tested blood specimens from HIV-negative survey 
samples from the 2007 Kenya AIDS Indicator Survey, with 12.5% having dengue IgG 
(36). Similarly, a household survey in Mombasa reported that 13% of individuals had 
serological evidence of either past or current DENV infection, by IgM anti-DENV 
ELISA (37). When 830 anti-DENV IgG positive samples from children ≤ 10 years of 
age were tested with neutralization assay, 23% had neutralizing antibody to DENV, 
indicating DENV transmission in the region in the past decade (33). In 1982, when 
DENV2 was first isolated, prevalence of DENV2 antibody was measured in Malindi 
and it was found to be as high as 52% among outpatients (38). However, additional 
studies found this to have dropped to 1% seroprevalence of DENV 2 antibody 
among asymptomatic individuals, suggesting that DENV was not endemic (38). Also, 
a study testing antibodies to dengue virus using an IgG indirect ELISA among 354 
afebrile children ages 12-47 months in Kisumu also reported a seroprevalence of 1.1% 
and sero-incidence of 8.5 seroconversions per 10000 persons per year (38). 
While such information suggests notable dengue transmission in Kenya, what 
has been reported is variable, without much data on comprehensive evaluation on 
dengue epidemiology (36, 37). Often, published studies were based on retrospective 
testing of collected samples that are not well representative of the general population. 
Additionally, Kenya, like other African countries, has many competing public health 
problems with similar symptoms, and suffer from limited diagnostic capacity (15).  
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Table 7. Characteristics of the sites chosen for dengue burden studies in Africa  
 East West 
 Kenya Burkina Faso 
GDP per capita 
(2017 Est.)(154)  
1,594.8 (current 
USD) 
642 (current USD) 
Population(155) 48,466,927 19,173,322 
% Urban pop. (156)  25% 29% 
% pop. below poverty line 
(World Bank) 
45.9% (2005) 46.7% (2009) 
National surveillance 
system for dengue 
No No* 
Outbreak (14)  1982, 2011, 2013 1984, 2013, 2016, 2017 
Annual incidence of DENV 
infection 
8.5/1000(38, 157) - 
Reported seroprevalence 1.1-52% (38) 26.3 - 36.5% (98) 
*not available at the time of site selection, but system was established during the outbreak in 
2016, during the study period 
 
   
1.7 Aim, objectives and structure  
1.7.1 Aim 
The principal aim of the thesis is to measure the burden of dengue among 
non-malarial febrile patients seeking care at selected health facilities in Mombasa, 
Kenya, and Ouagadougou, Burkina Faso. Also, the thesis aims to assess 
seroprevalence and age-specific rates of infection measured by seroconversion of 
dengue IgG among randomly selected residents of Ouagadougou. Such data 
generated could facilitate evidence-based decision making on dengue prevention 
and control interventions in the region. 
 
1.7.2 Objectives 
 In order to measure the burden of dengue fever and determine 
seroprevalence and rates of infection of DENV, several approaches were pursued. 
The specific objectives of the thesis include: 
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1) Description of different dengue diagnostic tests and benefits of using dengue 
RDTs, based on review of currently available literature, in the context of cost-
effectiveness of dengue RDTs 
2) Estimation of the proportion of dengue among non-malarial febrile patients in 
Mombasa, Kenya 
a. Assessment of performance of clinical diagnosis of suspected dengue 
b. Description of epidemiologic characteristics of DF patients vs. non-DF 
patients during and before the outbreak period  
3) Estimation of the proportion of DF among non-malarial febrile patients in 
Ouagadougou, Burkina Faso 
a. Description of epidemiologic characteristics of DF patients vs. non-DF 
patients during and outside the 2016 outbreak  
4) Estimation of the seroprevalence of dengue and age-specific force of 
infection, measured by IgG ELISA, in repeated serosurveys conducted in 
Ouagadougou, Burkina Faso; and measure the effects, in terms of 
seroconversion rate ratios, of potential demographic and clinical risk factors.   
 
 To address the gaps in knowledge on dengue in Africa, the surveillance 
studies and serosurveys conducted in Burkina Faso and Kenya provide information 
on epidemiologic patterns and clinical characteristics of dengue-positive cases 
among non-malarial febrile episodes, and, in Burkina Faso, prevalence as well as 
age-specific rate of infection of DENV measured by seroconversion. As a major 
global public health problem, efforts have been made to develop effective tools to 
prevent and control against dengue, such as vector control and vaccines. In absence 
of population-based reliable data on dengue in Africa, an accurate, up to date 
description of the burden of dengue, evaluated through health facility-based fever 
surveillance studies and community-based serosurveys, will facilitate informed 
decision-making on implementation of control and preventive measures for dengue. 
 
1.7.3 Structure and contribution of research papers 
Continuing on from this introduction (chapter 1) where the background of the 
study is laid out, there is a brief description of dengue diagnostic options, focusing on 
dengue RDTs, as rapid tests might be a feasible diagnostic option in resource-limited 
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settings. In the context of benefits of using dengue RDTs, there is a literature review 
paper assessing existing evidence on cost aspect of the benefit of using dengue 
RDTs (chapter 2, paper 1) assessing economic impact of dengue RDTs where tests 
may lead to avoiding unnecessary treatments if found to be dengue positive on RDT. 
Then, the overall study design and methods are described in a study protocol paper 
(chapter 3, paper 2). It is followed by two papers, one examining the characteristics 
and epidemiology of Dengue in Mombasa (chapter 4, paper 3) and another in 
Ouagadougou (chapter 5, paper 4), in the health facility settings. These two papers 
report the proportions of dengue among non-malarial febrile patients in two sites and 
describe epidemiologic and clinical characteristics of dengue versus non-dengue 
patients during and before the outbreak period (in early 2017 in Mombasa and late 
2016 in Ouagadougou). The fifth paper of the thesis investigates the burden and 
characteristics of dengue by measuring seroprevalence and force of infection, as 
well as ratios of rate of dengue IgG seroconversions, in Ouagadougou in greater 
detail (chapter 6, paper 5). Discussion and conclusions are found in paper 6 (chapter 
7). 
 
1.7.3.1 Paper 1 (Chapter 2) 
Paper 1 in chapter 2, entitled “A systematic review of the economic impact of rapid 
diagnostic tests for dengue”, was published in BMC Health Services Research in 
2017 (158). With description of different testing options for dengue diagnosis and 
RDTs as a useful diagnostic option in resource-limited environments as in Africa, 
benefits of use of RDTs are described by this work based on the systematic review 
of published data on the use of RDTs for dengue with respect to their economic 
impact. 
 
1.7.3.2 Paper 2 (Chapter 3) 
Chapter 3 is a protocol paper (Paper 2) which was published as “Evaluating dengue 
burden in Africa in passive fever surveillance and seroprevalence studies: protocol of 
field studies of the Dengue Vaccine Initiative” in BMJ Open in 2018 (120). This paper 
described the design and methods of the studies in Africa, composed of the passive 
fever surveillance and serosurveys in 3 sites of the Dengue Vaccine Initiative, 
including Mombasa, Kenya, and Ouagadougou, Burkina Faso. While Gabon, as a 3rd 
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site of the DVI study was included in this paper, the thesis focuses only on studies 
conducted in Burkina Faso and Kenya.  
. 
1.7.3.3 Paper 3 (Chapter 4) 
Paper 3 in Chapter 4 was submitted and under review as “Clinical and epidemiologic 
characteristics associated with dengue fever before and during the 2017 outbreak in 
Mombasa, Kenya” in the PLoS Neglected Tropical Diseases in 2019. This work 
describes the epidemiologic and clinical characteristics of dengue before and during 
the outbreak in Mombasa, which started in April 2017, and compares performance of 
clinical diagnosis of suspected dengue during and before the outbreak.  
 
1.7.3.4 Paper 4 (Chapter 5) 
Paper 4 in Chapter 5 was submitted and under review as “Clinical and epidemiologic 
characteristics associated with dengue identified in the health facility-based 
surveillance before and during outbreak in 2016 in Ouagadougou, Burkina Faso” in 
the Journal of Infectious Diseases in 2019. This work is the first to describe the 
epidemiologic and clinical characteristics of dengue during and outside the large 
outbreak in Ouagadougou, which took place between September and November 
2016 
. 
1.7.3.5 Paper 5 (Chapter 6) 
Paper 5 has been written in preparation for publication and is titled “Dengue virus 
seroprevalence and force of infection in Ouagadougou, Burkina Faso”. This work 
details results from the repeated serosurveys conducted in Ouagadougou and 
describes seroprevalence by age and other characteristics. In addition, 
seroconversion rates are measured between the repeat surveys, including those 
periods containing the outbreak or not, and rate ratios for demographic and clinical 
characteristics are estimated. 
 
1.8 Ethical approval 
Approvals for the studies covered in this PhD were given by the Research 
Ethics Committee of the London School of Hygiene & Tropical Medicine (Reference 
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number: 17096, dated 1 May 2019, for the study in Burkina Faso; Reference number: 
10457, dated 18 February 2016, for the study in Kenya), as well as by the local IRBs 
and ethical committees. Details are provided in each chapter. 
 
1.9 Funding 
The thesis was based on part-time PhD program, supported by self-funding. 
The studies described in this thesis were supported by a grant to Dengue Vaccine 
Initiative awarded by the Bill and Melinda Gates Foundation (OPP 1053432).  
 
1.10 Role of the candidate in the current project and prior work 
 
1.10.1 Work prior to PhD 
I joined the International Vaccine Institute (IVI) in September 2009 as an 
epidemiologist in the dengue program in IVI, known as the Pediatric Dengue Vaccine 
Initiative (PDVI). PDVI was terminated in 2010 and Dengue Vaccine Initiative (DVI) 
was formed in a consortium format in 2011, funded by the Bill and Melinda Gates 
Foundation (OPP 1016669) for 4 years from 2011-2015. This grant supported 
activities of DVI program, including field studies, until 2015. In DVI, I was responsible 
for the field studies, including the passive health facility-based fever surveillance, 
cost-of-illness survey, repeated community-based serological survey, and healthcare 
utilization survey. With the aim of generating solid, high-quality data on 
comprehensive burden of the dengue disease among children and adults in a 
defined geographical area, in 2011, I designed and oversaw execution of the same 
package of studies, initially, in potential early adopter countries of dengue vaccines: 
Thailand, Colombia, and Vietnam.  
In late 2012 and early 2013, based on the continued interaction with the donor, 
DVI program decided to have the same package of field studies expanded to 
countries of low economic setting, likely GAVI-eligible countries. When this plan was 
in discussion, it was prior to GAVI VIS and the aim was to generate data to convince 
that dengue should be included in the GAVI VIS. In addition to being responsible for 
the field operation of DVI, by 2013, I was the acting program leader for dengue within 
IVI, and led the grant writing process for the upcoming phase of the DVI consortium, 
known as DVI II, including the expansion of field studies. 
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With the expansion, the proposal included to conduct the study package in 
West, Central, and East Africa (Burkina Faso, Gabon, and Kenya, respectively), with 
Cambodia as an additional country in SE Asia. The grant was confirmed in mid-2013 
(OPP 1053432) and study preparation, including designing of the studies and 
protocol writing, began immediately after the award confirmation. The studies in 
additional four sites were launched in 2014.  
 
1.10.2 Current project in the PhD thesis 
Being in charge of the field work of DVI, I was responsible for the overall 
execution of epidemiological studies during the project period, from protocol drafting, 
obtaining IRB approvals, data review/analysis, and presentations of the data. In all 
the sites, the standardized study design and methods were applied to conduct field 
studies. All the studies were based on minimal modification, to fit local context, 
based on the original DVI protocol I developed for the field site in Thailand in 2011. 
Using the work for which I led the grant writing and fundraising processes to support 
my own research initiatives, I decided to start the PhD study in LSHTM as a part-
time student (enrollment in November 2014).  
Therefore, for the studies included in this thesis, in addition to obtaining funds 
to support them, I was responsible for finding the right partners, finalizing of the 
study scope, study design, protocol preparation, obtaining IRB approvals, launch, 
monitoring of data collection, project execution, data analysis, and write-up of results. 
I was not the main on-site staff handling day-to-day study operation, but there were 
weekly monitoring of data transfer and fortnightly calls for study update with the 
study teams for each site. I travelled to the field sites regularly for data collection 
monitoring and control of data quality, in close collaboration with a designated data 
manager and the site PI. After discussion with the local collaborators, I requested to 
use the data from Kenya and Burkina Faso to analyse and draft manuscripts toward 
the PhD. These resulted in drafts of manuscripts of study findings included in the 
thesis (chapters 3, 4, 5, and 6).  
While I have not performed any laboratory work, I developed laboratory testing 
plans, including selection of samples to undergo further laboratory analyses, and 
oversaw sample inventory (i.e. to maximize the use of the existing sample volumes). 
Data collection in Burkina Faso ended in 1Q of 2017 and lab testing in both Burkina 
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Faso and in IVI, after samples were brought to Korea, continued until mid-2018. Data 
collection in Kenya ended in 2Q of 2016 and lab testing in both Burkina Faso and in 
IVI, after samples were brought to Korea, continued until mid-2017.  
The PhD study enabled me to maximize the epidemiological insights from the 
data, in particular with respect to my specific interests which include characterizing 
the clinical profile of dengue to understand patterns of dengue among healthcare 
seeking individuals, and estimating force of infection to understand community-
based DENV transmission.  
 
1.11 Contributions by candidate and others  
Unless otherwise noted, I, Jacqueline K. Lim, have performed all analyses and 
written all manuscripts included in this thesis.  I shared responsibilities in setting up 
some of the included studies, as described below. I have independently performed 
all literature reviews and have written the introduction and discussion sections of the 
thesis. I have not performed any laboratory work.  Specific contributions to each 
chapter follow. 
 
Paper 1: A systematic review of the economic impact of rapid diagnostic tests for 
dengue 
I am first author, and worked with Gian Luca di Tanna on conceiving the design of 
the review. I conducted the review and generated the draft of the manuscript 
including all tables and figures. I, as the first author, led the process of manuscript 
preparation, revision, and submission. Gian Luca di Tanna co-designed the study 
and provided oversight of the review. Neal Alexander contributed to the design of the 
review and to the writing of the manuscript. 
 
Paper 2: Evaluating dengue burden in Africa in passive fever surveillance and 
seroprevalence studies: protocol of field studies of the Dengue Vaccine Initiative 
I am first author. I developed the grant proposal that was successful in obtaining 
funds for the studies described in this protocol paper. The protocols of the studies in 
Africa were based on minimal modification, to fit local context, based on the original 
DVI protocol I developed for the field site in Thailand in 2011. I wrote the complete 
first draft of this protocol manuscript, drawing on the study protocol. I, as the first 
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author, led the process of manuscript preparation, revision, and submission. The 
study PIs are authors (Sammy M Njenga, Selidji Todagbe Agnandji, Seydou Yaro). 
Those that were involved in protocol development and participated in study set-up 
and data collection on site are also authors (Mabel Carabali, Jung-Seok Lee, Kang-
Sung Lee, Suk Namkung, Sl-Ki Lim, Valery Ridde, Jose Fernandes, Bertrand Lell, 
Sultani Hadley Matendechero, Meral Esen, Esther Andia, Noah Oyembo, Ahmed 
Barro, and Emmanuel Bonnet). Neal Alexander, as my PhD supervisor, and In-Kyu 
Yoon, the Director of DVI, provided oversight and guidance on the overall study 
design, project execution, and specific methodologies, e.g. epidemiology, statistical, 
and virology and other laboratory methods.  
 
Paper 3: Clinical and epidemiologic characteristics associated with dengue fever 
before and during the 2017 outbreak in Mombasa, Kenya 
I am first author. I developed the grant proposal that was successful in obtaining 
funds for the study described in this paper. I led the study design and wrote the 
protocol.  I oversaw the ethical approval process, supported study set-up, monitored 
data collection, performed literature review, performed data cleaning, and conducted 
statistical analysis including generating SAS code for analysis and all the figures.  I 
wrote the first draft of the manuscript. I then, as the first author, led the process of 
manuscript revision, and submission. Sultani Hadley Matendechero and Sammy M. 
Njenga, as the study PI and co-investigator, were responsible for study set-up and 
execution at the facilities in Mombasa. Neal Alexander, In-Kyu Yoon, and Sammy M. 
Njenga provided oversight and guidance on the overall study design, project 
execution, and specific methodologies, e.g. epidemiology, statistical, and virology 
and other laboratory methods. Jung-Seok Lee, Kang Sung Lee, Suk Namkung, Sl-Ki 
Lim, Esther Andia, and Noah Oyembo provided support in setting up the study at the 
sites, in sample and data collection, and data management and analysis. Henry 
Kanyi, So Hee Bae, and Jae Seung Yang performed laboratory work. Neal 
Alexander and Tansy Edwards oversaw statistical analysis, and contributed to 
manuscript preparation. 
 
Paper 4: Clinical and epidemiologic characteristics associated with dengue identified 
in the passive health facility-based surveillance before and during outbreak in 2016 
in Ouagadougou, Burkina Faso 
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I am first author. I led the study design and co-developed the protocol with Dr. Mabel 
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RESEARCH ARTICLE Open Access
A systematic review of the economic
impact of rapid diagnostic tests for dengue
Jacqueline Kyungah Lim1,2*, Neal Alexander2 and Gian Luca Di Tanna3
Abstract
Background: Dengue fever is rapidly expanding geographically, with about half of the world’s population now at
risk. Among the various diagnostic options, rapid diagnostic tests (RDTs) are convenient and prompt, but limited in
terms of accuracy and availability.
Methods: A systematic review was conducted of published data on the use of RDTs for dengue with respect to their
economic impact. The search was conducted with combinations of key search terms, including “((Dengue[Title]) AND
cost/economic)” and “rapid diagnostic test/assay (or point-of-care)”. Articles with insufficient report on cost/economic
aspect of dengue RDTs, usually on comparison of different RDTs or assessment of novel rapid diagnostic tools, were
excluded. This review has been registered in the PROSPERO International prospective register of systematic reviews
(registry #: CRD42015017775).
Results: Eleven articles were found through advanced search on Pubmed. From Embase and Web of Science, two and
14 articles were obtained, respectively. After removal of duplicate items, title screening was done on 21 published
works and 12 titles, including 2 meeting abstracts, were selected for abstract review. For full-text review, by two
independent reviewers, 5 articles and 1 meeting abstract were selected. Among these, the abstract was referring to the
same study results as one of the articles. After full text review, two studies (two articles and one abstract) were found
to report on cost-wise or economic benefits of dengue RDTs and were selected for data extraction. One study found
satisfactory performance of IgM-based Panbio RDT, concluding that it would be cost-effective in endemic settings. The
second study was a modeling analysis and showed that a dengue RDT would not be advantageous in terms of cost
and effectiveness compared to current practice of antibiotics prescription for acute febrile illness.
Conclusions: Despite growing use of RDTs in research and clinical settings, there were limited data to demonstrate an
economic impact. The available two studies reached different conclusions on the cost-effectiveness of dengue RDTs,
although only one of the two studies reported outcomes from cost-effectiveness analysis of dengue and the other was
considering febrile illness more generally. Evidence of such an impact would require further quantitative economic
studies.
Keywords: Dengue, Dengue fever, Diagnostic, rapid diagnostic test (RDT), Cost-effectiveness
Background
Dengue fever, a mosquito-borne flavivirus infection caused
by four related but antigenically distinct dengue viruses
(DENVs, serotypes 1–4), is a major and rapidly increasing
public health problem. Its geographic range now includes
about half of the world’s population and continues to
expand, with epidemics that disrupt health care systems
[1–4]. Current WHO estimates are of about 50–100 million
annual infections globally, while Bhatt et al. recently
estimated 390 million infections annually with 96 million
disease episodes [5–7].
However, there are no other suitable disease prevention
methods: mosquito vector control is often ineffective [8,
9]. There is a vaccine, Sanofi Pasteur’s live attenuated
Dengvaxia®, recently registered in multiple countries in
Southeast Asia and Latin America and it shows to have
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variable efficacy [10–13]. At present, there are no drugs
for specific treatment and there is a need for accurate and
cheap dengue diagnostic tests to be widely used in clinical
settings [14–16]. Thus, many dengue endemic countries
in the tropics are still experiencing a rise in cases and in
deaths due to dengue [17–20].
Recently the WHO Strategic Advisory Group of Experts
(SAGE) on Immunization emphasized the need for estima-
tion of the true burden of dengue disease, including cost of
illness [6]. Data are available, but mostly focused in coun-
tries in Asia and Latin America, with well-documented
hyper-endemicity and a long history of dengue transmis-
sion, such as Thailand [21, 22], the Philippines [23], Brazil
[24, 25], Mexico [26], and Colombia [27]. Most of the avail-
able burden data are from studies of the epidemiology and
evidence based on economic studies is limited [28, 29].
Among the key limitations of economic studies of den-
gue are the challenges in its diagnosis. Often, cost-related
studies for dengue are based on clinical, rather than labora-
tory, confirmation [30]. Available methods include virus
isolation, serology, and molecular methods [31]. One test
routinely used by research laboratories for virus identifica-
tion is Reverse Transcriptase-Polymerase Chain Reaction
(RT-PCR) assay [32]. While this is a definite proof of infec-
tion and confirms the serotype, commercial kits that in-
clude serotyping are often expensive and would require
serum samples collected in early phase during the illness
[33]. Another commonly used method is immunoglobulin
type M (IgM) antibody capture enzyme-linked immuno-
sorbent assay (MAC-ELISA) [31]. With IgM staying
elevated for 2 to 3 months, interpretation could be challen-
ging given that elevated IgM could be due either to recent
past infection or to cross-reactivity with other flaviviruses
[33]. Any clinical management decision reached on the
basis of a single blood sample collected in the acute phase
is not conclusive. Levels of immunoglobulin type G (IgG)
stay elevated for months to years, so a positive result on
one of the available assays could indicate a past infection,
thus has limited implications for clinical management [31].
Moreover, it may cross-react across the Flavivirus group
(dengue virus, Japanese encephalitis virus, West Nile virus,
yellow fever virus, Zika virus, etc.) [34]. There are other as-
says such as Plaque Reduction Neutralization Test (PRNT)
which detect serotype-specific antibodies [35]. Compared
to others mentioned, these are time-consuming and
labour-intensive, thus expensive [36, 37].
Amongst different diagnostic tools, rapid diagnostic
tests (RDTs) are a convenient (easy to use) and prompt
option, despite their limitations in terms of accuracy [38].
While their availability could be limited, especially in
resource-limited settings, RDTs are commonly used for
dengue detection in many endemic countries [38]. There
could be a number of different commercially available
tests and they could be based on the detection of dengue
virus non-structural protein 1 (NS1) antigen, IgM, IgG, and
IgA antibodies [39]. Often, these tests have high specificity
(usually around 90%), but lower levels of sensitivity, ranging
from 10 to 99%, in detection of dengue and could be cross-
reactive with other flaviviruses [39–42]. However, the speed
of RDTs provides early diagnosis of dengue possibly leading
to timely case management. Given their limited accuracy,
these RDTs are not considered the standard reference and
their usefulness is not yet proven in clinical settings [15,
43]. However, some literature supports the use of such tests
in combination with others, for example the combined test
with NS1 antigen and IgM antibody [42, 44].
Especially in terms of economic studies, one major
benefit of using RDTs would be that they allow dengue
detection in the early phase of illness (at presentation),
hence facilitating capture of the entire spectrum of costs
incurred throughout illness. Previous studies reported
that early detection is effective in reducing the duration
of illness, possibly leading to lower cost-of-illness due to
dengue [45, 46]. In recognition of the need to balance
speed, accuracy, and availability to maximize utility
when using RDTs for dengue detection for the patients
in clinical settings, a systematic review was performed to
explore the economic impact of using RDTs for dengue.
The hypothesis behind this review was that there may be
economic impact due to prompt detection of dengue in
the early phase of illness using RDTs and economic im-
pact is defined to be broad: both from the point of view
of cost-effectiveness and from the perspective of finan-
cial impact of RDT in patients, i.e. early diagnosis pos-
sibly leading to cost-saving in patients.
Methods
In this review, literature published in English up to
September 2017 was covered. Scientific databases used for
the search were: Embase, IBSS, Medline (including
PubMed), and Web of Science. In order to take more cau-
tion and not miss articles that may imply on economic
benefit of RDTs, the literature search was conducted in a
comprehensive approach. In Pubmed, advance search was
performed with search terms “((Dengue[Title]) AND
cost)” OR “((Dengue[Title]) AND economic)” AND:
1. “rapid diagnostic test[MeSH Terms]”
2. “RDT[MeSH Terms]”
3. “rapid test[MeSH Terms]”
4. “rapid assay[MeSH Terms]”
5. “rapid diagnostic assay[MeSH Terms]”
6. “point-of-care [MeSH Terms]”
7. “POC[MeSH Terms]”
8. “point-of-care test[MeSH Terms]”
MeSH terms are assigned by indexers of the National
Library of Medicine [47]. While the search on Pubmed
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was performed with above search terms with “rapid diag-
nostic test” and “point-of-care test” were used as MeSH
terms, additional articles were identified through IBSS,
EMBASE, and Web of Science via general search using
keywords:
1. “dengue and rapid diagnostic test (or RDT) and cost”
2. “dengue and rapid diagnostic test (or RDT) and
economic”
3. “dengue and point-of-care (or POC) and cost”
4. “dengue and point-of-care (or POC) and economic”.
From Embase, Web of Science, and WHOLIS, outcomes
of general search included meeting abstracts in addition
to full articles. Preliminary screening needed to be done
for search outcomes through Embase and Web of Science,
as their general search led to journals, not articles, where
each key word may appear in different articles.
After such preliminary screening was done for search
outcomes through Embase and Web of Science, title
screening, abstract review, and full-text review were done.
The development of this literature review is shown in the
flow chart (Fig. 1). Rationales for excluding articles obtained
through this multiple searches using different sources were
described in Fig. 1. Exclusion criteria were not relevant
articles that:
– mainly report on cost associated with a new diagnostic
technology
– report on different technologies or performance of
the tests without addressing cost or economic aspect
of RDT use
– report on RDT-confirmed dengue case numbers in a
study with insufficient information on economic
impact
Also included for full-text review were those describing,
in addition to those with direct reporting of quantitative
costs, some qualitative economic benefit, i.e. mention of
cost-effectiveness of RDTs without any quantitative valu-
ation of it. This was done to prevent loss of any articles
containing cost-related implication, even if not quantita-
tively specified in the article. Data were then extracted
from the full texts of the selected articles. The data extrac-
tion table was developed following the Consolidated
Health Economic Evaluation Reporting Standards
(CHEERS) statement and the reporting Checklist [48].
Also, the reporting Checklist for Cost-effectiveness Ana-
lyses from Second Panel on Cost-Effectiveness in Health
and Medicine (Additional file 1: Table S1) [48, 49]. In
addition, the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) were followed [48,
50]. This review is registered in the PROSPERO inter-
national prospective register of systematic reviews, under
the title “Systematic review of health economic assess-
ments of dengue rapid diagnostic tests” (registry number:
CRD42015017775). Full text review was performed inde-
pendently by two individuals.
Results
As shown in Fig. 1, a more focused advanced search on
Pubmed resulted in 11 articles and, after preliminary
screening of the outcomes of general search on EMBASE
and Web of Science, there were 15 published works (2
articles from EMBASE and 14 titles from Web of Science
with one in overlap). After removal of duplicative articles,
21 titles from all three sources underwent screening. For
abstract review, 10 articles and 2 meeting abstracts were
considered relevant and among these 5 articles were
selected for full-text review and 1 meeting abstract was
retained and, as an abstract, skipped the full-text review
step.
On review of the full text of the articles, it was found that
only two studies reported quantitative or qualitative
economic impact of RDT use for dengue: one by Lubell et
al. and another by Mitra et al. The second study was
reported in an abstract and an article, the former being
published first [51, 52]. As the abstract was referring to the
same study results as the articles, they were merged in the
data extraction stage and were presented as one combined
piece of work. Some others found with “cost” or
“economic” as one of the key search terms and reached the
full-text review stage were proven to contain information
on the cost aspects of dengue RDTs. However, some were
found to report on the actual price of the test or cost of
production of a new assay as they assess performance of it.
The extracted data and findings from these two studies are
included in Additional file 1: Tables S1, 2a, and 2b [51–53].
The article (2016) and meeting abstract (2014) by
Mitra et al. report that Panbio RDT alone is highly sen-
sitive and cost effective for diagnosis of dengue infec-
tion in their comparative evaluation of performance
and cost-effectiveness of commercially available
immunochromatography-based RDT kits [51, 52]. This
study is not, in fact, a cost-effectiveness analysis and re-
ports a high sensitivity (97%) for Panbio RDT and a cost
of 13.6 USD (reported in the abstract in 2014, 6.90
USD in the article in 2016) which they refer to as being
cost-effective without clearly defining the basis of mea-
surements, i.e. denominator [51, 52]. They compared
four commercially available RDTs [Panbio Dengue Duo
cassette, Standard Diagnostics (SD) Bioline Dengue
Duo, J. Mitra Dengue Day-1 test and Reckon Dengue
IgG/IgM] against composite reference criteria (CRC),
and compared the cost of the tests. The authors con-
ducted this study among stored blood samples from
281 patients who sought care for acute febrile illness at
Christian Medical College (CMC) hospital in Vellore,
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India [52]. The CRC was locally developed by infectious
diseases expert, virologist, epidemiologist, reflecting
WHO guidelines and this was used to identify dengue
cases while lab-confirmed etiology of other cases of
fever was needed to identify non-dengue controls. The
authors measured sensitivity, specificity, and predictive
values of these commercial RDTs in dengue cases and
non-dengue controls. Based on IgM capture positivity
of the four selected RDT kits, Panbio test was found to
have the highest sensitivity, followed by SD Duo (97.7
and 64.3% respectively) [52]. However, specificity was
higher for the Reckon RDT and SD Duo at 99.3 and
96.6%, respectively, compared to Panbio at 87.8%.
Based on NS1 antigen capture assay, none were found
to show satisfactory results in terms of sensitivity, while
specificity was high, around 90% [52]. Therefore, even
though the cost of Panbio test was the highest at 6.90
USD (in 2016) compared to the rest three ranging
Fig. 1 Flow of the literature search in the systematic review
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between 3.29 to 4.27 USD, it was concluded that IgM
assay by Panbio would be the test of choice and a cost-
effective option for diagnosis of acute dengue infection
in endemic settings.
An economic evaluation based on cost-effectiveness
modeling by Lubell et al. (2016) reported that use of a den-
gue RDT is found to be not advantageous, more costly
and less effective, when compared to the common practice
of presumptive treatment with antibiotics prescription
[53]. The authors developed a model to measure the im-
pact and cost-effectiveness of testing for elevated C-
reactive protein (CRP), compared with RDTs for dengue
and scrub typhus in the management of undifferentiated
fever. They used data from 1083 outpatients between 5
and 49 years of age from three provincial hospitals in rural
Laos [53]. A decision tree model was developed to deter-
mine cost effectiveness of different testing approaches for
undifferentiated fever and measure the ability of dengue
and scrub typhus rapid tests, compared with testing for el-
evated CRP, to inform antibiotic treatment as currently
practiced in clinical settings. The authors assumed sensi-
tivity and specificity of a dengue RDT to be 95% and con-
ducted economic evaluation to calculate the median
incremental cost, the number of disability adjusted life
years (DALYs) averted, and incremental cost-effectiveness
ratios (ICER) for each strategy compared to the current
practice of antibiotics prescription. For this, the model
adopted assumptions in sensitivity and specificity of tests,
costs of tests, the cost of a course of antibiotic, duration of
all self-limiting viral infections and treated bacterial infec-
tion, as well as duration of bacterial infections that do not
receive an appropriate treatment, mortality rate, a mean
loss of life-years for a case of death, etc. Another import-
ant parameter in the model was incidence. The authors
used incidence estimates of different pathogens to calcu-
late proportion of patients who were given antibiotics for
bacterial infections and proportion of those given antibi-
otics for viral infections. Furthermore, variable level of in-
cidence between half to double of what was found in the
fever study was applied in the model to test robustness of
model outcomes. The model output reported that a den-
gue RDT is dominated by current practice, with a higher
cost (median incremental cost = $1.5, Crl: 0.5; 3.2) and
fewer numbers of DALYs averted (−0.006 DALYs, CrI:
−0.301; 0.089) on average.
Discussion
The hypothesis behind this review was that prompt detec-
tion of dengue in the early phase of illness using RDTs may
lead to economic benefit in terms of patients’ cost of illness.
The review was from both the point of view of cost effect-
iveness of RDT and the perspective of financial impact of
RDT. We found two studies with different conclusions
[51–53]. Two studies were heterogenous in terms of design
— cost-effectiveness modelling or comparative evaluation
of performance of RDTs. They both took place in
dengue-endemic locations, in India and in Laos, over
different time periods between 2008 and 2013 [51–53].
In both studies, the authors acknowledged limited
generalizability to other populations of febrile patients,
possibly due to specific epidemiological characteristics
of each study area [51–53]. Epidemiological profiles,
such as a varying level of sero-prevalence and likely
high proportion of secondary infections [42], and par-
ticular serotype profiles [54, 55] could affect perform-
ance of RDTs for detection of dengue.
In the comparative evaluation of performance of RDTs,
the authors concluded that Panbio RDT is cost-effective.
Performance of IgM assay by Panbio was the most satisfac-
tory in the diagnosis of acute dengue infection and the cost
of the test was acceptable. This was although the cost based
on the manufacturer’s quoted price in India for Panbio was
the highest at 6.90 USD compared to the rest three: SD,
Reckon and J. Mitra at US$ 4.27, 3.29 and 3.61, respect-
ively. The authors also explored different combinations.
When NS1 antigen capture positivity alone was considered,
all three tests (Panbio is IgM assay only) showed sensitivity
below 30% while specificity was satisfactory, higher than
90% for all three tests. Thus, the authors concluded the
NS1-based test to be unreliable. Also, the authors explored
changes in performance when combined tests were used.
Paired with Panbio RDT, other three RDTs only marginally
increased the sensitivity while combination of Reckon with
any of the three RDTs was found to increase specificity to
higher than 99%. However, such combined testing would
double the cost. Thus, the authors concluded that Panbio
IgM-based RDT alone would be a cost-effective and sensi-
tive option especially during the times of outbreak in
dengue-endemic settings [51].
The main limitation of the study is that the RDT per-
formance was not compared with other standard tests,
such as NS1 or IgM capture based ELISA or RT-PCR.
There are standard ways of laboratory-based confirm-
ation of dengue infection using various assays that are
available. While the authors indicate that using CRC as
case definition is commonly done, such an assessment of
RDT performance may not be most accurate. Also, as
acknowledged by the authors, the study results could
have been affected by cross-reactivity with other flavi-
viruses circulating in the study area [52]. Also, dengue
RDTs are commonly used especially in the areas of high
incidence of dengue [56]. However, when the study mea-
sured prevalence of dengue, the authors found 15.9 to
49.3% of IgG positivity among the samples in the study
and it was comparatively lower than prevalence of IgG
positivity previously measured by other studies. If preva-
lence of dengue or other flaviviruses is lower than what
was previously estimated, then performance of the RDTs
Lim et al. BMC Health Services Research  (2017) 17:850 Page 5 of 9
J Lim PhD Thesis 57
would have been different in cases of low-level transmis-
sion of dengue or other flaviviruses.
Based on an economic evaluation using cost-
effectiveness modeling, Lubell et al. showed that the a den-
gue RDT would provide little or no advantage in terms of
health outcomes among patients with AFI while resulting
in higher costs than current practice of antibiotics prescrip-
tion [53]. As well as a dengue RDT, they had also modeled
cost-effectiveness of a scrub typhus RDT and CRP test. For
these two, the model showed that there are advantages
over current practice of antibiotics prescription while cost
would increase. There may be limited generalizability of
the model outcomes, due to some of specific assumptions
used in the model for this particular study sample obtained
from Laos. For example, the years of life lost per death was
assumed to be 45 years, based on the median age of outpa-
tients and life expectancy in Laos. For the costs of tests, a
gamma distribution was applied with a mean of $1.5, which
may be lower than the current price of commonly used
RDTs. The study was conducted in an outpatient-sample
where dengue was confirmed in about slightly higher than
10% of the patients. While the study explored how the
model outcomes would change if the incidence of dengue
were to be variable between 50 and 200% of what was
found in the fever study in Laos and found out that still
CRP test would outperform both RDTs for dengue and
scrub typhus, the study does not report how higher inci-
dence of dengue will impact the median incremental cost
and median DALYs averted by using dengue RDTs.
Also, the authors acknowledged limitations due to diag-
nostic uncertainty where multiple pathogens are detected
for some patients whereas some others had no identifiable
pathogen as the cause of illness. Depending on misclassifi-
cation due to diagnostic limitations, there may be changes
in economic benefit of dengue RDTs. Another limitation
of the study was that the model does not consider societal
impact of such viral infections where use of dengue RDTs
may not be immediately cost-effective, but diagnosis based
on dengue RDTs may provide benefit by raising awareness
for signs of severe manifestation of illness or alerting
health authorities of outbreaks for preventive and control
measures, etc.
The authors, qualitatively, report that there would be
improvements to current practice of antibiotics prescrip-
tion whereby a dengue RDT would be used to prevent
antibiotics prescribed to patients with viral infections
[53]. Although not measured, there are long-term bene-
fits of vigilant antibiotics prescription where dengue
RDTs could be used for non-dengue confirmation to
prompt antibiotics prescription, leading to a higher
probability of bacterial infections receiving appropriate
treatment. If these societal impact and long-term indir-
ect benefits were considered in economic evaluation,
dengue RDTs may be associated with higher cost-
effectiveness than what was predicted in the current
model.
The main assumption behind the topic of this review
was the prompt detection of dengue in the early phase of
illness using RDTs leading to economic impact, with both
perspectives of cost-effectiveness and financial benefit.
There are RDTs that detect IgA, IgM or IgG antibodies, as
well as NS1 antigen [39]. Depending on the detection
methods, the utility of these RDTs may be quite different
and there can be variable performance characteristics.
Only the study by Mitra et al. used commercially available
RDTs for comparison, and Lubell et al. conducted a mod-
eling analysis using a hypothetical RDT for dengue with
95% sensitivity and specificity in the model assumption.
With limited evidence, such comparison among different
test methods (or kits) could not be made in this review
[42, 57]. Also, RDT performance could vary depending on
factors such as the type of infection (primary vs. secondary
infection), the time since onset of illness, and the serotype.
It was assumed that the decision to use RDTs and refer to
the test result for diagnosis and to guide clinical manage-
ment would be at discretion of clinicians. Although there
were no data reporting such findings, different RDTs’ vari-
able range of performance and accuracy could lead to mis-
classification in terms of dengue diagnosis. And this could
affect the test performance and lead to bias by under or
over-estimating the economic impact of early detection of
dengue. Limited by data availability and lack of assurance
on the direction of bias, these factors influencing perform-
ance were not considered in this literature review.
With 2.5 billion people at risk, efforts to develop vac-
cine and other preventive tools continue, but dengue re-
mains a substantial burden to the healthcare system and
society in the endemic countries. [7, 58]. The total an-
nual global cost of dengue illness was estimated at
US$8·9 billion and in a large country like Brazil, it is re-
ported that the estimated cost for dengue for the epi-
demic season in the societal perspective would reach as
high as US$ 1212 million after adjusting for under-
reporting [28, 58, 59]. In a study reviewing medical costs
associated with case management for dengue fever pa-
tients in Mexico, real costs for patients, reported to the
Secretariat of Health, were US$33 for outpatients, and
US$491 for inpatients [60]. How burdensome dengue
treatment costs would be to households was shown in a
study conducted in Cambodia where survey results were
compared in households with dengue positive and the
ones with dengue-negative children [61]. On average,
the total cost of lab-confirmed dengue was 31.5 USD
and the total cost per hospitalized dengue case was 40.1
USD [61]. To finance the cost of a febrile illness, 67% of
households incurred an average debt of 23.5 USD [61].
Compared to an average one-week expenditure on food
in Cambodia, about 9.5 US dollars per household, the
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costs of treatment for dengue, whether outpatient or
hospitalized, put enormous financial strain on the house-
hold [61].
Given this burden and financial strain placed by dengue
on the health system, as well as individuals and house-
holds, many of the articles reviewed acknowledge the need
for accurate and simple diagnostic assays for infection in
resource-limited settings in regions of high dengue en-
demicity. However, we have found only two studies with
different conclusions reached: one concluded that Panbio
RDT at 6.90 USD was cost-effective; the other concluded
that a dengue RDT is associated with negative DALYs
averted while resulting in higher costs than current prac-
tice of antibiotics prescription. The two studies differ in
design and findings cannot be directly compared. With no
additional studies that explicitly estimated the cost-
effectiveness of RDTs for dengue other than these two
studies, such assessments must await future studies for
more conclusive evidence. Likewise, any economic impact
of RDT use in clinical settings, for patients, to health sys-
tems, and for particular situations such as outbreaks, re-
mains to be assessed. Such work would guide appropriate
interventions to improve patient management in
resource-limited settings to reduce the burden of dengue.
Conclusions
Existing studies of dengue RDTs are largely epidemiological
and we found two studies which reported quantitative and
qualitative economic impact of their use. However, these
two studies reported different conclusions and there is a
need for new studies to specifically measure economic
impact of dengue RDTs. Such studies would yield greater
understanding of the benefit of RDTs for dengue and hence
could help reduce the costs incurred due to dengue illness.
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Protocol
AbstrACt
Introduction Dengue is an important and well-
documented public health problem in the Asia-Pacific and 
Latin American regions. However, in Africa, information 
on disease burden is limited to case reports and reports 
of sporadic outbreaks, thus hindering the implementation 
of public health actions for disease control. To gather 
evidence on the undocumented burden of dengue in Africa, 
epidemiological studies with standardised methods were 
launched in three locations in Africa.
Methods and analysis In 2014–2017, the Dengue 
Vaccine Initiative initiated field studies at three sites in 
Ouagadougou, Burkina Faso; Lambaréné, Gabon and 
Mombasa, Kenya to obtain comparable incidence data 
on dengue and assess its burden through standardised 
hospital-based surveillance and community-based 
serological methods. Multidisciplinary measurements of 
the burden of dengue were obtained through field studies 
that included passive facility-based fever surveillance, 
cost-of-illness surveys, serological surveys and healthcare 
utilisation surveys. All three sites conducted case detection 
using standardised procedures with uniform laboratory 
assays to diagnose dengue. Healthcare utilisation surveys 
were conducted to adjust population denominators in 
incidence calculations for differing healthcare seeking 
patterns. The fever surveillance data will allow calculation 
of age-specific incidence rates and comparison of 
symptomatic presentation between patients with dengue 
and non-dengue using multivariable logistic regression. 
Serological surveys assessed changes in immune status 
of cohorts of approximately 3000 randomly selected 
residents at each site at 6-month intervals. The age-
stratified serosurvey data will allow calculation of 
seroprevalence and force of infection of dengue. Cost-of-
illness evaluations were conducted among patients with 
acute dengue by Rapid Diagnostic Test.
Ethics and dissemination By standardising methods 
to evaluate dengue burden across several sites in Africa, 
these studies will generate evidence for dengue burden 
in Africa and data will be disseminated as publication in 
peer-review journals in 2018.
bACkground  
Dengue fever, a mosquito-borne flavivirus 
infection caused by four related but antigen-
ically distinct dengue viruses (DENVs, sero-
types 1–4), is a major and rapidly increasing 
global public health problem. Recent studies 
have estimated an annual incidence of 
50–100 million symptomatic infections glob-
ally.1 Dengue is a high burden disease that 
disproportionately affects countries in the 
tropics and subtropics, many of which have 
limited healthcare resources.2 Although one 
dengue vaccine has been recently licensed 
in several endemic countries, the vaccine has 
restricted age and epidemiological indica-
tions. Other prevention and control measures 
such as vector control are suboptimal as 
strengths and limitations of this study
 ► There have not been population-based studies 
conducted with a multidisciplinary approach (ie, 
surveillance, healthcare utilisation and serosurvey 
in one catchment area population). Data from the 
passive surveillance will be used to calculate annual 
incidences of dengue and data from the serosurvey 
will estimate the force of infection and prevalence.
 ► The studies were conducted in three locations 
in Africa, based on standardised methods and 
laboratory algorithm. Thus, comparison by site 
would be possible.
 ► This is not a cohort study. The passive facility-based 
surveillance may lead to underestimation of the 
burden of dengue fever by measuring incidence 
based on only those that sought care at our study 
facilities.
 ► There may be limited generalisability of our study 
results to other dengue-endemic parts of Africa.
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stand-alone interventions,3 4 and no drugs for treatment 
are currently available.
Like in Asia and the Americas, epidemics of dengue 
were reported from Africa in the late 19th and early 20th 
centuries.5 6 Specifically for Africa, there are records of 
multiple dengue case reports between 1964 and 1968 with 
DENV 2 in Nigeria.7 Data from several studies conducted 
in the 1960–1970s in Nigeria supported a substantially 
high level of immunity in adults as well as children.8 9 
In 2011, Amarasinghe et al conducted a comprehensive 
review of literature on dengue in Africa and described 
that dengue cases have been reported in 34 countries 
in Africa, with most of these countries also having Aedes 
mosquitoes.6 However, prior studies which suggested 
the presence of dengue in Africa were limited by their 
retrospective design or sample collection (blood donors 
or sample collected from surveys of other diseases), and 
often from travellers, with a small number of reported 
autochthonous cases, to demonstrate the true, popula-
tion-based, burden of dengue. Also, while many dengue 
endemic countries in Asia and Latin America have 
mandatory reporting of dengue cases to public health 
authorities and national surveillance systems in place 
to monitor incidence patterns,10 most African countries 
lack such established reporting mechanisms and only 
sporadic outbreaks and individual case reports have been 
documented. In addition, the frequently non-specific 
clinical presentation of dengue may be difficult to distin-
guish from the myriad other infectious diseases present 
in Africa, since dengue diagnostic assays are not widely 
available. Thus, the burden of dengue remains largely 
unknown in Africa.6 11 Without such dengue burden data, 
informed decision-making about prevention and control 
measures, including dengue vaccine introduction, in 
Africa are not possible.
Limited by surveillance capacity hindering continuous 
reporting in the region, there had not been frequent and 
systematic reporting of dengue in Africa. African ancestry 
is known to be protective against severe dengue and the 
candidate genes were recently identified in a Cuban 
patient.12 13 Bhatt et al’s modelling of the global dengue 
burden suggests high burden in Africa in terms of equal 
numbers of infections (both apparent and inapparent) as 
in Latin America.1 There are new findings about dengue 
in Africa, but there is still much unknown about the magni-
tude of the dengue problem in the continent. To improve 
estimates of population-based dengue disease burden in 
Africa and validate whether the undocumented burden 
of dengue is as high in Africa as in the Americas with 
empirical data, the Dengue Vaccine Initiative (DVI) initi-
ated field studies at three sites in West (Ouagadougou, 
Burkina Faso), West-Central (Lambaréné, Gabon) and 
East Africa (Mombasa, Kenya). In each of the three sites, 
a standardised package of study components, including 
passive facility-based fever surveillance, healthcare utilisa-
tion surveys, cost-of-illness surveys and serological surveys 
(figure 1), was initiated between December 2014 and 
March 2016.
MEthods
site selection
Study sites were selected, in part, based on their likeli-
hood of supporting DENV transmission. To select sites, 
we considered dengue outbreaks and cases reports in 
the literature, available seroprevalence studies as well as 
country-specific dengue risk maps of the probability of 
DENV transmission and the level of evidence of dengue 
presence, reporting the uncertainty of the consensus 
estimates of dengue in Africa.7 14 In addition, adequate 
research infrastructure to implement the studies was 
taken into account. Finally, inclusion of different regions 
of Africa was also a factor in site selection. Thus, Ouaga-
dougou, Burkina Faso; Lambaréné, Gabon and Mombasa, 
Kenya were selected, respectively, to measure the burden 
of dengue in selected sites from West, (West-) Central and 
East Africa.
In Burkina Faso, the first reported dengue outbreak 
occurred in Ouagadougou in 1982 due to DENV-2.6 
Serological prevalence of dengue antibodies among 
pregnant women and blood donors was found to be 
26.3% in a rural setting (Nouna village) and 36.5% in an 
urban setting (Ouagadougou) in 2006.15 More recently, 
an observational study conducted by Ridde et al among 
febrile patients consulting at selected study facilities 
in 2013–2014 showed 8.7% (33/379) to be positive by 
dengue rapid diagnostic test (RDT) and 15 of 60 samples 
tested by RT-PCR to be dengue-positive.16 With evidence 
for the presence of dengue, along with a strong health 
and demographic surveillance system (Ouaga-HDSS) 
which could be used to describe the demographic charac-
teristics of the catchment area, a field study was initiated 
in Ouagadougou, Burkina Faso in December 2014.
In Gabon, cases of dengue haemorrhagic fever 
(DHF) caused by up to three different DENV serotypes 
have been reported, and dengue seroprevalence has 
been found to be between 5% and 20%.17–19 Results 
of a recently published study demonstrated sero-
prevalence of 12.3% among toddlers approximately 
30 months of age in semirural Lambaréné between 
2007 and 2010.20 However, a different study in 2005–
2008 suggested minimal DENV transmission in rural 
areas of Gabon.21 This latter study examined anti-
bodies against dengue in individuals from randomly 
selected villages representing about 10% of all Gabo-
nese villages. Blood samples were tested by anti-DENV 
IgG and IgM capture ELISA and found to have only 
minimal IgG (0.5%) and IgM (0.5%) seroprevalence. 
Based on these low prevalences, the authors concluded 
that there was no active circulation of DENV in rural 
Gabon. However, the low seroprevalence may have 
been affected by low sensitivities of the tests used, 
leading to a high rate of false negative results and/
or selection bias in the blood sample pool among the 
selected villagers.22 Seroprevalence estimates in the 
2007/2010 study may have also been impacted by the 
possibility of false-positive results due to IgG cross-re-
activity among flaviviruses.21 Nevertheless, given the 
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possibility of DENV circulation in Gabon, a field 
study was initiated in Lambaréné in March 2015 in 
a community with a catchment population of about 
77 000 residents, using the clinical research infra-
structure of the Centre de Recherches Medicales de 
Lambaréné (CERMEL), benefiting from experienced 
research staff who conducted a large Phase 3 malaria 
vaccine trial.23 24
In Kenya, more evidence is available for the pres-
ence of dengue based on local data. Dengue was the 
most common viral pathogen in retrospectively tested 
blood specimens from HIV-negative survey samples 
from the 2007 Kenya AIDS Indicator Survey. Anti-
body testing for dengue as well as chikungunya and 
Rift Valley fever was performed by IgG ELISA using 
either commercial kits or CDC assays; 12.5% were 
found to be dengue-positive.25 Similarly, a household 
survey found 13% of individuals from 701 households 
in Mombasa had serological evidence of either past 
or current DENV infection.26 These data suggest 
that there is more dengue in Kenya than indicated 
by public health reporting, possibly due to misdi-
agnosis.25 26 A field study was initiated in Mombasa, 
Kenya in March 2016.
study participants
For the passive facility-based fever surveillance, individ-
uals who met the following criteria were eligible for study 
enrolment:
1. Age 1–55 years old.
2. Resident of the catchment area covered by healthcare 
facilities participating in the study, without plans to 
move out of the catchment area within 12 months.
3. Signed informed consent and assent for those aged 
between 7 (13 for Kenya) and 17 years.
4. Patients presenting with current fever (axillary tem-
perature ≥37.5°C) or history of fever for ≤7 days 
duration without localising signs (fever caused by a lo-
calised infection as well as fever with a known and con-
firmed aetiology other than dengue, such as malaria 
Figure 1 Description of the study components, including passive facility-based fever surveillance, healthcare utilisation 
surveys, cost-of-illness surveys and serological surveys. There are two arms in the study package, composed of four parts. In 
the health facility-based arm of the study package, there are passive facility-based fever surveillance and cost-of-illness survey 
embedded within the surveillance. In the community arm of the study, there are serological survey and healthcare utilisation 
survey.
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confirmed by malaria RDT, as listed in the patient 
identification standard operating procedure [SOP]).
For the serological survey, criteria 1–3 were applied. 
For the healthcare utilisation survey, household inter-
views were conducted among the heads or representatives 
of the household invited from each family participating 
in the serosurvey.
study area and population
Burkina Faso, located in West Africa, has a population of 
14 017 462. The country is mainly rural with about 29% 
of the population reported to be living in urban areas in 
2014. However, Burkina Faso is urbanising rapidly and is 
positioned as the country with the fourth fastest urbani-
sation in the last 25 years.27 28 The capital, Ouagadougou, 
has a population of 2 741 128. The majority of the popu-
lation live in urban settings. About 45% of the popula-
tion are under 15 years of age.29 The city is divided into 
12 districts and 52 sectors. Ouagadougou is the country’s 
largest city and the cultural and economic centre. The 
city is part of the Soudano-Sahelian area, with a rainfall 
of about 800 mm per year. The rainy season is from May 
to October, with a mean temperature of 28°C (82°F). 
The cold season runs from December to January, with a 
minimum average temperature of 16°C (61°F). During 
the hot season, which runs from March to May, the 
temperature can reach as high as 43°C (109°F).
The HDSS is in place in Ouagadougou. Ouaga-HDSS 
monitors a population of 81 717 residents; according 
to this surveillance system, the city population is very 
stable with a rate of migration of 4.1% and more than 
80% of the inhabitants with ownership of their houses 
[20]. A map of the city and the study area is shown in 
figure 2.
Gabon, located on the west coast of Central Africa, has 
an area of nearly 270 000 square kilometres (100 000 sq. 
mi) with a population estimated at 1.5 million. Its capital 
and largest city is Libreville. In 2014, it is reported that 
87% of the Gabonese population lived in urban areas.28 
The sixth largest city, Lambaréné, the capital of Moyen-
Ogooué province, is located 75 km south of the equator, 
with a population of 25 257 in 2009. The majority of 
Lambaréné residents live in semirural areas. About 42% 
of the Gabonese population is under 15 years of age.29 
Similarly, Lambaréné’s population is relatively young with 
about 50% under 20 years of age.
The health services of Gabon are mostly public, but 
there are some private institutions as well. With one of 
the best medical infrastructure in the region, almost 
90% of the population have access to healthcare services. 
Albert Schweitzer Hospital (ASH) is a private institution 
which served as a study site for the passive fever surveil-
lance study.30 31 The study area in Lambaréné is shown in 
figure 3.
Figure 2 Map of the study area in Ouagadougou, Burkina Faso.
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Kenya, located in East Africa, lies on the equator, 
covering 581 309 km2 (224 445 sq. mi), with a popula-
tion of approximately 45 million people in 2014.32 Kenya 
generally has a warm and humid tropical climate but is 
diverse, ranging from the cooler climate around the 
capital city, Nairobi, to a hot and dry climate inland as 
well as a desert-like climate in the north-eastern regions 
along the border with Somalia and Ethiopia.32 The 
capital, Nairobi, is a regional commercial hub. The main 
industries include agriculture, exporting tea and coffee 
as well as the service industry.
Kenya is divided into 47 semiautonomous counties. 
Mombasa is the country’s second largest city after Nairobi 
and is located on the east coast of the country.32 Admin-
istratively, Mombasa is the capital of Mombasa County, 
which was formerly called Coast Province. This overall 
Coast region covers over 80 000 km2 in the south-eastern 
part of Kenya, constituting about 15% of the country's 
land area, with a population of 3 325 307 residents.
The main economic driver of Mombasa is tourism 
and trading industry. Mombasa itself has a population 
of about 1.3 million with almost 50% of the population 
under 15 years of age.29 Increasingly, the population of 
the province lives in urban areas; at present about 45% 
live in Mombasa and other urban centres. The ‘long 
rains’ period begins around April and the ‘short rains’ 
period begins in October.32 Mean annual temperature 
ranges from 24°C to 27°C, but maximum temperature 
averages over 30°C between January and April.
Figure 4 shows the area of Mvita subcounty of Mombasa, 
which was the catchment area for the study in Kenya, with 
a catchment population of 74 735 residents. The map 
indicates the three facilities involved in the study.
sample size
Given the paucity of available age-specific dengue inci-
dence data in the study countries or nearby countries, it 
was difficult to obtain population-based incidence to make 
assumptions when calculating sample sizes. The required 
catchment population for the passive facility-based fever 
surveillance was roughly estimated based on the limited 
data available in the literature. Annual incidence esti-
mates were calculated based on available prevalence esti-
mates with the assumption that the outcome of interest 
has zero prevalence at age zero, and that force of infec-
tion is constant. It was assumed that prevalence estimates 
found for one particular age group would be adjusted as 
the annual incidence and used across all ages.
Wichmann et al calculated an expansion factor for 
children by comparing data from three cohort studies 
to national surveillance data in Southeast Asia.33 For 
children in Thailand, the age-specific expansion factors 
Figure 3 Map of the study area in Lambaréné, Gabon.
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calculated were 11.85 for <5 years, 8.76 for 5–9 years 
and 7.81 for 10–14 years.33 The results show that, even 
for Asia where better reporting and surveillance systems 
are available, there is a considerable degree of under-re-
porting. For Africa, there may be more dengue cases 
under-ascertained (not seeking care) and under-reported 
(not reported even if a patient with dengue seeks care, 
given that dengue is not one of the routinely notifiable 
diseases in Africa), but such information on the extent 
of underestimation of dengue was not available.34 35 Also, 
the incidence estimates used in our sample size calcula-
tions were not from population-based studies. While it 
would have been ideal to adjust the incidence further 
for likely underestimation, the annual incidence used 
in sample size calculations could not be adjusted for 
possible under-reporting due to the lack of data. The 
sample sizes were calculated with 95% confidence levels 
and a margin of error at a fixed significance level within 
25% of the true proportion of incidence. This gives rela-
tive precision of 75%, considering the gap in evidence 
for dengue incidence in the study areas. The final sample 
sizes were calculated by assuming 10%–20% (variable by 
site) non-response rate or loss to follow-up. The required 
catchment population size for the fever surveillance study 
in Burkina Faso was estimated to be 100 000, Gabon to be 
77 000 and Kenya to be 70 000. In these catchment popu-
lations, the number of enrolled subjects depends on the 
number of eligible patients who seek care at the study 
facilities. How many eligible febrile episodes would actu-
ally present at our study facilities was difficult to predict; 
but after assessment of the volume of febrile patients at 
the facilities, a realistic upper limit for enrolment for a 
study period of approximately 1.5 years was set at 3000 
subjects to offer enrolment to all consenting eligible 
patients.
For the serological survey, the sample size was calcu-
lated similarly using the prevalence proportion based 
on published literature. Seroprevalence of 0.304 for 
Burkina Faso,15 0.123 for Gabon,21 and 0.144 for Kenya36 
were used. With the same confidence levels and allowed 
margin of error and assuming 10%–30% (variable by site) 
non-response rate, the sample size was calculated to be 
3000 participants at each site. Again, with the scarcity of 
data from the selected countries, there were no other 
Figure 4 Map of the study area in Mombasa, Kenya.
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prevalence estimates reported or estimates from different 
age groups. As prevalence is expected to increase with age 
and higher prevalence would give a smaller sample size, 
our calculations are likely to be conservative.
study components
Fever surveillance—design and methods
To determine burden due to symptomatic dengue in 
each of the three sites in Burkina Faso, Gabon and 
Kenya, passive facility-based fever surveillance was imple-
mented in a well-defined catchment area population. 
In Burkina Faso, the surveillance study was initiated 
in December 2014 in five selected primary healthcare 
centres, locally called ‘Centre de Santé et de Promotion 
Sociale’, in the municipality of Ouagadougou, with a 
catchment population of 105 000 residents. This project 
was implemented in collaboration with Centre Muraz in 
Bobo-Dioulasso, EQUITE sante programme (a collabo-
rative programme between University of Montreal and 
Action-Gouvernance-Integration-Reinforcement, AGIR, 
based in Ouagadougou, funded by the Canadian Insti-
tute of Health Research) and DVI. In Gabon, the surveil-
lance study was initiated in the ASH serving a catchment 
population of 130 000 residents in the Moyen-Ogooué 
and surroundings within Lambaréné, in collaboration 
with CERMEL and Institute of Tropical Medicine in 
Tubingen, Germany. In Kenya, the surveillance study was 
implemented at Ganjoni dispensary, Tudor subcounty 
Hospital and Coast Provincial General Hospital, serving a 
catchment population of 70 000 residents in Mombasa, in 
collaboration with Kenya Medical Research Institute and 
Ministry of Health of Kenya.
As described in figure 5, both outpatients and inpa-
tients at the designated study facilities, who meet inclu-
sion criteria as mentioned earlier were tested for dengue, 
first with SD Dengue Duo RDT. Dengue confirmation 
was done by detection of dengue virus in serum samples 
using PCR as well as antidengue IgM and IgG antibodies 
in acute and convalescent serum by ELISA (SD Dengue 
IgM & IgG capture ELISA tests, Standard Diagnostics, 
Yongin-Si, Korea).10 37 Every consecutive patient meeting 
inclusion criteria was eligible for enrolment during the 
study period. Infants<1 year old were not included due 
to operational limitations, such as difficulty of infantile 
bleeding.
In Ouagadougou, Burkina Faso, the fever surveillance 
was initiated in December 2014 and continued until 
February 2017 (approximately 2 years). In Lambaréné, 
Gabon, the fever surveillance was initiated in April 
2015 and continued until January 2017 (approximately 
1.5 years). In Mombasa, Kenya, the fever surveillance 
was initiated in March 2016 and continued until May 
2017 (15 months).
Among subjects enrolled in the fever surveillance, 
those who were positive by dengue rapid diagnostic test 
were offered further enrolment in the cost-of-illness 
survey, consisting of interviews on the day of acute illness 
visit, day 10–14 from the first visit and day 28, if illness 
continues. The cost-of-illness survey questionnaire was 
designed to estimate the direct medical, direct non-med-
ical and indirect costs associated with dengue-positive 
patients identified at study facilities. This survey also 
estimates the cost of treating dengue at the facility level. 
Data were gathered by linking patients’ medical records 
concerning outpatient visits, inpatient visits and service 
consumption (eg, diagnostic tests, medication and other 
services provided to patients). The cost-of-illness portion 
of the study will be described separately.
Fever surveillance—laboratory testing
As shown in figure 6, in all three sites, acute samples 
were tested using a commercial RDT for dengue NS1 and 
IgM/IgG (Dengue Duo, Standard Diagnostics, Yongin-Si, 
Korea). Dengue Duo RDT was used on the day of acute 
illness visit at the site of patient presentation (day 1). The 
acute and convalescent samples were subsequently tested 
at a local laboratory using dengue IgM/IgG ELISA (SD 
Dengue IgM & IgG Capture ELISA, Standard Diagnostics, 
Yongin-Si, Korea). The serum was separated and stored in 
4 aliquots of about 500 µL for various laboratory tests, as 
indicated in consent documents.
After ELISA testing, samples were shipped to the 
International Vaccine Institute (IVI) in Korea. Samples 
with positive results by RDT or ELISA, as well as a small 
number of samples with negative results, undergo further 
testing by RT-PCR at the Clinical Immunology Labo-
ratory of IVI. Four DENV serotype-specific real-time 
RT-PCR assays are used for laboratory confirmation of 
dengue and serotyping.38 The DENV 1–4 RT-PCR assays 
are carried out in 25 µL reaction mixtures containing 
5 µL template RNA, TagMan Fast Virus 1-step mastermix 
(Applied Biosystems), 0.9 µM of each primer and 0.2 µM 
probe.38 Amplification and detection are performed in a 
StepOne Plus real-time PCR system, and the baseline and 
threshold are determined using the auto-baseline and 
threshold feature in StepOne Software V.2.2.2 (Applied 
Biosystems). Thermocycling parameters are as follows: 
reverse transcription at 50°C for 5 min, inactivation at 
95°C for 20 s, followed by 45 cycles of fluorescence detec-
tion at 95°C for 3 s and annealing at 60°C for 30 s.38 A 
specimen is considered positive if target amplification is 
recorded within 40 cycles.
Serological survey—design and methods
While the facility-based fever surveillance studies provide 
estimates of the burden of medically attended dengue 
disease, evaluation of all DENV infections in a popu-
lation—including subclinical and mildly symptomatic 
infections, which impact immune status—is needed 
to capture the overall impact of dengue. As part of the 
study package, population-based serological surveys 
were conducted in the same catchment population 
used for the fever surveillance. At each of the three sites 
in Africa, the serosurvey was conducted on a cohort of 
approximately 3000 randomly selected residents of urban 
and semiurban parts of Ouagadougou, Lambaréné and 
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Mombasa. Without individual-level census information 
on all residents of Lambaréné and Mombasa, with help 
of community/village health workers, randomisation 
was done based on neighbourhoods (or defined areas 
for which the health workers/volunteers are respon-
sible) as cluster units. As the community/village health 
workers are familiar with the villages and their residents, 
they are good entry points into the communities. With 
these health workers, the field team screened houses in 
the selected villages by knocking on doors of every 5–7 
houses, depending on the household density per neigh-
bourhood. Also, demographic information collected in 
previous research projects conducted in the same area 
was used as a guide, if available. In the case of the site 
in Ouagadougou, HDSS data were available and the 
EQUITE SANTE, a CIHR funded research programme of 
the University of Montreal, had set up a geographic infor-
mation system database of houses in the study area. Using 
these data, households of potential enrolees of the sero-
survey were preselected randomly and household visits 
were made in Ouagadougou. In the three sites, about 45% 
of the serosurvey samples were targeted to be collected 
from children 1 to 14 years of age, and 55% were targeted 
to be collected from adults between 15 and 55 years of 
Figure 5 Patient flow in the fever surveillance. Eligible febrile patients identified and enrolled as study subjects followed these 
steps to complete participation in the passive fever surveillance. * A small number of those samples that are negative on ELISA 
or NS1 are tested with PCR to exclude false negative results of the ELISA. CRF, case report form. 
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age to reflect the age distribution of the general popula-
tion of the area. Household-based enrolment was offered 
to the head of the household until the specific cap for the 
age-group was reached in Lambaréné and Mombasa.
Randomly selected subjects 1–55 years of age under-
went phlebotomy (5 mL for children and 7 mL for adults) 
twice—before the rainy season and after the rainy season, 
at approximately 6-month intervals. The sera were eval-
uated using IgG indirect ELISA at baseline and after 
6 months. The presence of dengue IgG antibodies at 
6-month intervals will be used to estimate the level of 
occurrence of inapparent DENV infection and to calcu-
late the rate of infection in the catchment population. 
Flow cytometry-based DENV neutralisation assays will be 
applied to a subset of samples to assess for presence of 
dengue neutralising antibodies and seroconversion over 
the 6-month interval. In addition to overall seroconver-
sion, age-specific seroconversion estimates in the catch-
ment population as well as the proportion of inapparent 
infections will be determined.
Serological survey—laboratory testing
From the samples collected in the serosurvey, about 
200 µL of serum were used and tested at a local labora-
tory using dengue IgG ELISA (Panbio Dengue IgG Indi-
rect ELISA, Alere North America, Florida, USA). After 
ELISA testing for dengue IgG at the local laboratories, 
samples were shipped to IVI. Given potential serological 
cross-reactivity among flaviviruses,39 flow cytometry-based 
neutralisation assays will be performed against selected 
flaviviruses to include yellow fever virus, West Nile virus, 
Zika virus and Japanese Encephalitis virus, in addition 
to DENV 1-4, at the Clinical Immunology Lab of IVI.40 41 
About 50 samples per bleed for four bleeds in Burkina 
Faso and two bleeds in Gabon and Kenya will be tested.
About 1000 µL of serum is allotted for this proce-
dure. The flow cytometry-based neutralisation assays 
are performed in duplicate in 96-well cell culture plates 
with flat-bottom wells, each containing DC-SIGN-ex-
pressing U937 cells.40 The amount of virus used in the 
assay infects between 7% and 15% of the cells. Human 
immune sera are serially diluted and the virus is prein-
cubated with the sera for 1 hour at 37°C.40 The cells are 
washed, the virus and serum mixture is added to the cells 
for 1 hour at 37°C and the cells are further incubated 
for 24–48 hours at 37°C in 5% CO2. The cells are fixed, 
permeabilised and stained with fluoresce-conjugated 
monoclonal antibody 4G2, which recognises the flavivirus 
E protein.42 FACScan flow cytometer (Becton Dickinson, 
San Diego, California, USA) is used to analyse the cells.40 
The serum dilution that neutralises 50% of the viruses is 
calculated by nonlinear, dose-response regression analysis 
with Prism 4.0 software (GraphPad Software, San Diego, 
California, USA).
In addition, a Luminex-based multiplex immunoassay 
will be performed on a randomly selected subsample 
to assess for IgG to different flaviviruses.43 About 200 
samples per bleed for four bleeds in Burkina Faso and 
two bleeds in Gabon will be tested. Detection of IgG 
against ZIKV and each of the four DENV serotypes will be 
performed on patient serum samples using an in-house 
microsphere-based multiplex immunoassay (arbo-MIA) 
at the Clinical Immunology Lab of IVI.44 45 The arbo-MIA 
is based on a mixture of microspheres covalently coupled 
with either DENV-1, DENV-2, DENV-3, DENV-4 or ZIKV 
Figure 6 Laboratory testing algorithm for dengue. Samples from subjects of the passive fever surveillance would follow these 
steps of the testing algorithm for confirmation of dengue. *Dengue Duo®test is performed on enrolled febrile patients to identify 
dengue cases for immediate follow-up of dengue-confirmed cases in the cost-of-illness survey. **Selected samples, including 
those that were found positive by IgM and NS1 on Dengue Duo®,as well as those positive by IgM and IgG capture ELISA, will 
be tested with RT-PCR. 
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recombinant antigens (E protein domain III) produced 
in Drosophila S2 expression system. Briefly, microsphere 
mixtures were sequentially incubated in the dark under 
constant shaking with a 1:400 dilution of patient serum 
samples, with 2 µg/mL antihuman IgG biotin-conjugated 
antibody (Jackson Immunoresearch, West Grove, Penn-
sylvania, USA) and with 2 µg/mL streptavidin-R-phyco-
erythrin conjugate (Life technologies). After the final 
incubation, the median fluorescence intensity (MFI) 
of each microsphere set is quantified using a BioPlex 
200 instrument (Bio-Rad Laboratories, Hercules, Cali-
fornia, USA). Samples are considered seropositive if the 
ratio of MFI values obtained for the viral antigen to the 
control antigen is superior to the defined cut-off. The 
cut-off of the MIA is determined for each viral antigen by 
receiving operating characteristic (ROC) curve analysis 
using well-characterised sera.
In Lambaréné, the enrolment bleed took place in 
November–December 2015, while the second blood 
collection occurred in May 2016. In Ouagadougou, 
the enrolment bleed took place in May–June 2015 with 
follow-up blood collections in December 2015, June 2016 
and January 2017. In Mombasa, the enrolment bleed 
took place in May 2016 with the second blood collection 
in November 2016–February 2017.
Healthcare utilisation survey
As the passive fever surveillance was conducted at study 
facilities, patients with potential dengue could be missed 
if they seek care elsewhere. To identify the proportion of 
fever and dengue cases potentially missed by the passive 
surveillance system due to patients living in the study 
area but seeking care outside of study facilities, a popu-
lation-based healthcare utilisation survey was conducted 
in 400 randomly selected households from the study 
catchment area to characterise the healthcare utilisation 
patterns of the households when they have (self-reported) 
febrile episodes among the family members. In addition 
to assessing health-seeking behaviours of the residents, 
preferences in terms of health-seeking behaviour and 
respective reasons for their preferences were investi-
gated. The questionnaire was administered to 400 heads 
of households. Among 3000 residents who participated 
in the serosurvey, there were about 600 households. 
From these households, 400 heads of households were 
randomly selected and offered enrolment in the health 
utilisation survey. Heads of households or a senior repre-
sentative within the household were asked questions on 
health seeking patterns of their family members.
study questionnaires
For the fever surveillance study, questionnaires were 
administered at the acute illness visit and the convalescent 
visit. The convalescent visit may take place at the health-
care facility (10–14 days later) or at the patient’s home 
(15–21 days after the acute visit), according to patient 
preference and availability. The questionnaires were 
completed by medical staff of the study facilities, including 
demographic and clinical information (eg, signs, symp-
toms, past medical history, treatments prescribed and 
diagnoses). The same staff also completed the follow-up 
questionnaire at the convalescent visit within 21 days 
from the acute visit. Study nurses completed surveillance 
enrolment log. Lab technicians completed the lab section 
(mostly dengue-related diagnostics) and the forms were 
compiled by the study coordinator on site.
For the serosurvey component, questionnaires were 
administered at the household by trained field team staff 
at each serosurvey visit. Study nurses completed the ques-
tionnaire after a brief physical and medical examination. 
At the follow-up visit(s) in about 6 months, the same staff 
made the household visits to complete the follow-up ques-
tionnaire. Enrolment log was maintained by the study 
coordinator on site.
Variables of the surveillance questionnaires
The variables collected are listed in table 1.
Planned statistical analysis
From the fever surveillance data, incidence of symptom-
atic dengue among patients that seek healthcare at the 
study facilities will be calculated. Age-specific incidence 
rates in all the children and adults will be determined by 
referring to the size and distribution of the general popu-
lation of the study area at the time of surveillance as the 
denominator in calculation of the incidence of symptom-
atic dengue cases. Each person residing in the study area 
is assumed to contribute 12 months of person time to the 
denominator. Although the study areas all report a low 
migration rate, the in-migration is assumed to balance the 
out-migration of the population during the study period. 
Age-specific incidence of symptomatic dengue will be 
calculated by using age-specific denominators and the 
number of symptomatic dengue cases in eligible individ-
uals as the numerator.
Using the data collected in the Healthcare Utilisation 
Survey, the proportion of febrile cases missed by the 
passive surveillance system will be determined. Then 
using the proportion, the numerator will be further 
adjusted in recognition of those missed fever cases from 
the study area, which could have been dengue. Also, 
comparison will be made between those that agreed to 
participate and those that declined participation among 
the eligible potential enrolees. The enrolment log, which 
records basic information obtained during the screening 
process of potential enrolees, will be reviewed. In addi-
tion to checking that our sample of febrile cases is repre-
sentative of febrile patients of the general population 
in the catchment area, refusal rates will be determined 
based on information in the log. Then, the refusal rates 
will be used to adjust the numerator.
SPSS software will be used for analysis of the fever surveil-
lance data. Multivariable logistic regression will be used to 
compare confirmed patients with dengue versus patients 
with non-dengue febrile in terms of symptomatic presen-
tation, based on signs and symptoms collected from all 
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patients with laboratory-confirmed dengue by serology and 
RT-PCR, adjusting for possible confounders, such as age, 
days since onset of fever, primary versus secondary infection, 
inpatient versus outpatient and so on. Differences in symp-
tomatic complex of dengue fever (DF) (and DHF, if data 
allows) by age and serotype will be also determined using 
multivariable logistic regression.
As outpatient disease accounts for the greater part of 
dengue disease burden, clinical profile of individuals with 
DENV infection will be characterised by the type of treat-
ment (hospitalised vs outpatients) as well as by severity 
of the disease (severe vs non-severe by the 2009 WHO 
criteria).46 Classification is determined after the course 
of illness is completed (typically during the convalescent 
visit). Symptomatic dengue is classified as outpatient or 
hospitalised. Progression of dengue is recorded as DF, 
DHF I, DHF II, DHF III or DHF IV, and clinical patterns 
will be compared by the severity grade.46 47 These will be 
compared with results obtained from other DVI studies in 
Latin America (Colombia) and Asia (Thailand, Vietnam 
and Cambodia). Overall, comparisons will be made across 
Burkina Faso, Gabon and Kenya.
Table 1 List of variables collected in the passive fever surveillance data collection form
Topic Description Items
Basic information Demographic and basic information about the 
patient and the treatment received
Type of treatment, where patient is enrolled (IPD vs OPD)
Date of fever onset, duration of fever
Current temperature
Tourniquet test results
Patient’s address (district and village-level)
Date of visit, date of birth, age and sex
Weight and height
General health 
condition
Current condition of the patient (self-report) and 
underlying diseases of the patient
How well the patient could handle daily activities
Pre-existing conditions
Signs and 
symptoms during 
this illness
A set of signs and symptoms that may be 
related to fever and dengue (dengue fever and 
dengue haemorrhagic fever) at both visits 1 and 
2
Rash, fatigue, headache, retro-orbital pain, neck/ear pain, 
sore throat, breathing difficulty, cough, expectoration, 
gastrointestinal signs (nausea/vomiting, diarrhoea, 
abdominal pain and so on), haemorrhagic signs (nose/
gum bleeding, ecchymosis, petechiae and so on), signs 
of shock (cyanosis, capillary refill), arthralgia, myalgia, 
loss of appetite, jaundice and so on
Medical history Previous dengue-related or other flavivirus 
infection as well as vaccination history (self-
report)
Previous dengue infection and related hospitalisation
Previous infection to other commonly circulating arboviral 
infection in the area (ie, Yellow fever vaccination history)
Laboratory 
findings
Records from the routine laboratory tests 
widely used in clinical fever/dengue patient 
management, as part of the hospital care 
procedure
Platelet count, haematocrit, haemoglobin, leucocytes, 
neutrophils, protein level, AST, ALT, urine test results and 
so on
Clinical diagnosis Clinician’s diagnosis with or without referring to 
the RDT
Diagnosis given by the physician based on clinical 
presentation after physical examination of the patient
Dengue testing 
results
Results from the dengue tests, mainly RDTs for 
dengue as well as other commonly circulating 
arbovirus in the area
Dates of blood draw
Test results of the RDT
IgM/IgG capture ELISA results
PCR results (if available)
Treatment Medicine(s) prescribed and the starting and end 
dates
Antibiotics, paracetamol, ibuprofen, aspirin and others 
that may be site-specifically prescribed
Outcome Outcome of this particular visit Hospitalised, returned home or referral
Hospitalisation Information collected only among hospitalised 
patients in the surveillance to record other 
severe signs and progression of illness
Admission and discharge diagnoses
Presence of haemorrhagic signs or shock syndrome
Hospital charges Expenses and hospital charges incurred by 
patient on the visit 1
Amount of the out of pocket payment by the patient or 
the family/or guardian
Breakdown of the hospital charges (laboratory, 
medication, admission-related charges)
Final outcome Outcome of the patient’s illness at the second 
visit
Final diagnosis given for the patient, outcome of illness
Completion of study participation (early termination and 
the reason and so on)
ALT, Alanine AminoTransferase; AST, Aspartate aminotransferase; IPD, Inpatient department; OPD, Outpatient department; RDT, Rapid 
Diagnostic Test. 
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With the age-stratified sera that reflect the age distribu-
tion of the general population of the country, the serolog-
ical survey sampling strategy ensures sufficient subjects to 
obtain precise age-specific estimates of seropositivity and 
seroconversion of the catchment area population. The 
seroconversion rate and change in the immune status will 
be determined by age group during the study period. The 
age-stratified serosurvey data will also allow calculation of 
the force of infection of dengue in the study population. 
After enrolment, there are subjects who drop out in the 
follow-up bleeds about 6 months later. Basic demographic 
information will be compared between those that completed 
participation and those with incomplete participation to 
check whether study subjects represent the catchment area 
population. Comparisons will be made among Burkina Faso, 
Gabon and Kenya.
Ethical considerations
To minimise inconvenience of the study to patients, clini-
cians and nurses were sensitised and trained regarding 
the study requirements and procedures in order for data 
collection to be integrated into routine patient care. The 
clinicians and nurses selected for the study receive coordi-
nated support from study field staff throughout the study 
process. Written informed consent and assent for partic-
ipants 7 (13 for Kenya)−17 years of age were obtained 
from patients by study staff. Study staff go through 
consent and assent documents for short summary of the 
disease, detailed description of study procedures and 
information on reimbursement. Patient data are docu-
mented in the study designated office; only the study staff 
have access to the data that are de-identified. Data are 
exclusively handled in the study office and stored safely in 
a protected database in the study office as well as on the 
DVI main server.
dIsCussIon
Dengue cases have been detected since the 1960s in 
Africa, and there has been continued presence of Aedes 
vectors in the continent.5 7 However, very few dengue 
studies have been conducted in Africa, and little evidence 
is based on population-based studies.6 Compared with the 
volume of evidence from SE Asia and the Americas, there 
is critical data scarcity on dengue in Africa. Suspicion of 
substantial dengue burden in Africa is based on limited 
reports of outbreaks and a handful of seroprevalence 
studies testing different viruses among samples that likely 
do not represent the general population. In the three 
countries selected for our field studies, somewhat more 
data are available, but are still very limited. In Burkina 
Faso, a recent observational study conducted in 2013 
reported that 8.7% of the febrile patients showed positive 
results on dengue RDT.16 In Gabon, one study suggested 
minimal DENV circulation in rural areas,21 while another 
study reported 12.3% seroprevalence, by IgG antibodies 
against dengue, among toddlers 30 months of age in 
semirural parts of Lambaréné.20 In Kenya, about 13% of 
the individuals in Mombasa have been reported to have 
evidence of past or current DENV infection by RT-PCR 
and IgM antidengue ELISA after the 2013 outbreak.26 
Despite the limited scope and generalisability of these 
studies, they suggest that there may be more dengue 
than previously appreciated due to underestimation and 
misdiagnosis.25 26
These studies suggest the presence of dengue and 
some level of underlying seroprevalence in the coun-
tries of our field studies. However, often these studies are 
limited by their retrospective design or sample collection 
(blood donors or sample collected from surveys of other 
diseases) to demonstrate the true, population-based, 
burden of dengue. We proposed to address this gap by 
population-based dengue surveillance and seropreva-
lence studies in West, (West-) Central and East Africa.
The present studies at three sites in Africa will provide 
important information on undocumented DENV circu-
lation in Africa. Such data will help to strengthen the 
evidence base for dengue burden in Africa. Better 
defined disease burden data based on our studies could 
be used to assess the relative need for dengue prevention 
and control measures, such as whether a dengue vaccine 
would be a cost-effective public health intervention for 
countries in Africa. Clinical findings from our studies 
could also be used as a guide for dengue case detection 
and case management.
The studies have some important limitations. We recog-
nise variability of dengue epidemiology over time and 
by region. Due to resource constraints, our studies are 
limited in terms of time frames and geographical extent. 
These constraints may limit the generalisability of our 
study results.
One potential source of bias in estimating the incidence 
of symptomatic dengue is under-ascertainment due to 
the community residents with relevant symptoms seeking 
care from other healthcare providers and facilities than 
the study facilities. As the study design remains passive 
surveillance, cases are ascertained only at our study facil-
ities. By estimating the proportion of febrile patients 
seeking care elsewhere as well as refusal rates among 
the potential enrolees that were screened for eligibility 
criteria, the degree of febrile patients missed by the study 
can be determined. Inverse probability weighting will be 
used to account for these potential subjects missed by 
the surveillance as adjustments in incidence calculation. 
Also, depending on the transmission volume of dengue 
or other cocirculating diseases with onset of fever, there 
may be patients that are diagnosed with other diseases 
and ruled out for dengue. Furthermore, with respect to 
dengue diagnostics for our serological surveys, there are 
other circulating flaviviruses in Africa leading to chal-
lenges in identifying antibodies to past dengue infec-
tions. While our testing plan assesses for some flaviviruses, 
others known to circulate in Africa, such as Banzi and 
Usutu viruses, are not part of the testing plan.48–50 Due to 
resource limitations, serological testing will be limited to 
yellow fever virus, West Nile virus, Zika virus and Japanese 
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Encephalitis virus as well as DENV 1–4. Therefore, in 
some cases, it may be difficult to determine prior expo-
sure to DENV versus other flaviviruses based on serolog-
ical data. This cross-reactivity may lead to overestimation 
of dengue force of infection.
In addition, the serosurvey and healthcare utilisation 
survey are conducted on a randomised subsample of the 
catchment area population and there may be limited 
generalisability of the data collected from these surveys. 
With unknown differences among those that agree to 
participate and those that do not agree, the data may not 
be representative of the general population of the study 
countries.
ConClusIon
The data collected from our studies will contribute to 
the assessment of the unknown dengue disease burden 
in Burkina Faso, Gabon and Kenya. These data can fill a 
gap in undocumented burden of dengue in the region 
and, collectively, may be used to infer dengue burden in 
other areas of Western, Central and Eastern Africa. Coun-
tries in Africa may not consider introduction of a dengue 
vaccine as a priority in the near future due to many other 
competing public health problems and limited resources. 
For cost-effective implementation of public health inter-
ventions, accurate data on dengue burden from epide-
miological studies would be needed for policy makers to 
make evidence-based decisions on control and prevention 
of dengue. Our studies will provide some much needed 
information based on population-based research to assess 
dengue burden in Africa.
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Chapter 4. Clinical and epidemiologic characteristics 
associated with dengue fever before and during the 2017 
outbreak in Mombasa, Kenya 
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Abstract 
Information on dengue burden in Africa is limited. To estimate the proportion of dengue-
positive cases among febrile patients, we conducted passive health facility-based fever 
surveillance in Mombasa, Kenya. The occurrence of an outbreak during the study 
enabled us to compare clinical indicators of dengue before and during the outbreak. 
Non-malarial febrile patients between 1 and 55 years of age, from Mvita sub-county, 
were enrolled at three health facilities. Acute and convalescent blood samples were 
collected within an interval of 10-21 days of fever onset. Acute samples were tested with 
Dengue Duo®  RDT and a selected subset with RT-PCR, and acute/convalescent 
samples with IgM/IgG ELISA.  
Among 482 non-malarial febrile patients enrolled, 295 (61.2%) were identified as 
dengue-positive based on laboratory results. The passive surveillance covered the 
beginning of a dengue outbreak in April-May 2017, during which 73.9% (122/165) of 
enrolled patients were dengue-positive. During non-outbreak period, 54.6% (173/317) 
were dengue-positive. When clinical diagnosis was compared against dengue positivity, 
the sensitivity (82.8%) was higher during the outbreak than the non-outbreak period 
(49.1%), but the specificity was lower (86.1% vs. 91.7%). Both positive predictive and 
negative predictive rates were higher during the outbreak than non-outbreak (PPV=94.4 
vs. 87.6% and NPV=63.8 vs 60.0%, respectively). In adjusted analyses, 
nausea/vomiting, during the outbreak, and arthralgia, headache, and loss of appetite, 
during non-outbreak period, were found to be associated with dengue-positivity.   
In our study, about half of the dengue cases were identified during the outbreak that 
occurred in the last two months of the 15-month surveillance period. Nonetheless, there 
was a substantial occurrence of dengue cases even in the non-outbreak period. Clinical 
features of dengue patients differed between the outbreak and non-outbreak period, 
and clinical diagnosis was less accurate in the latter. More data from additional 
prospective and longitudinal studies would help to further define patterns of dengue in 
Kenya for improved case detection. 
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Author summary: There are fewer studies on dengue in Africa, relative to the Asia-
Pacific and Latin American regions. To estimate the proportion of dengue among 
patients with fever, and to identify clinical features of dengue during outbreak and non-
outbreak periods, we studied 482 patients with non-malarial fever, aged 1-55 years, who 
attended three health facilities in Mombasa, Kenya. Cases were tested with a rapid test 
for dengue, and further tests were carried out on paired blood samples taken 10-21 
days apart. Even before the dramatic increase during the outbreak, there was a 
substantial number of dengue patients. Clinical diagnosis was more accurate, relative to 
dengue-positive cases, during the outbreak period. On average, dengue symptoms 
varied between the outbreak, and the non-outbreak periods. For example, 
nausea/vomiting were associated with dengue in the outbreak period, and joint pain, 
loss of appetite, and headache in the non-outbreak period. More data from additional 
studies would more clearly identify characteristics of dengue in Mombasa. 
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Introduction 
 
 Dengue fever (DF) is a mosquito-borne flavivirus infection caused by four 
related but antigenically distinct dengue viruses (DENVs, serotypes 1–4), and is a major 
and rapidly increasing global public health problem (1). Recent studies have estimated 
an annual incidence of 50–100 million symptomatic infections globally, with 50,000 
dengue hemorrhagic fever (DHF) cases requiring hospitalization and approximately 
20,000 deaths annually (2-6). Dengue disproportionately affects countries in the tropics 
and subtropics, many of which have limited health care resources (7).  
Aedes mosquitoes and dengue cases were documented as early as 1823 in 34 
countries in Africa, and Ae. aegypti and Ae. albopictus are widely distributed in the 
continent (8-11). The first isolation of dengue virus in Africa was in Nigeria in the 1960’s 
(10, 12). However, most reports have come from a small number of countries, and few 
prospective and population-based dengue studies have been conducted (11, 13, 14). 
Moreover, the ability of many previous studies to demonstrate the true, population-
based, burden of dengue was limited by their retrospective design or sample collection 
among special groups, such as blood donors. Also, while many dengue endemic 
countries in Asia and Latin America have mandatory reporting of dengue cases (15), 
most African countries lack such mechanisms, and only sporadic outbreaks and 
individual case reports have been documented.  
In Kenya, compared to other African countries, there is more evidence available 
for the presence of dengue, with several documented epidemics and outbreaks in 
different locations. The most recent outbreak reported was from Mombasa in May 2017 
(16). In 2011, an outbreak was confirmed in Mandera, North Eastern region, and, in 
2013, another in Mombasa continuing up to 2014 (17, 18). In addition to outbreak 
investigations, a study based on 868 samples from febrile patients identified from 
September 2011 to December 2014 in multiple locations in Kenya reported 40% 
(345/868) of the samples to be dengue-positive for dengue by either IgM Enzyme-linked 
immunosorbent assay (ELISA) or by RT-PCR (19). In terms of sero-prevalence, dengue 
was found to be the most common viral pathogen in retrospectively tested blood 
specimens from HIV-negative survey samples from the 2007 Kenya AIDS Indicator 
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Survey, with 12.5% having dengue IgG (20). Similarly, a household survey in Mombasa 
reported that 13% of individuals had serological evidence of either past or current DENV 
infection, by IgM anti-DENV ELISA. While such information suggests a notable dengue 
transmission in Kenya, its magnitude remains largely unknown (17, 20). Often, 
published studies were based on retrospective testing of collected samples that are not 
well representative of the general population. Additionally, Kenya, like other African 
countries, has many competing public health problems. The frequently non-specific 
clinical presentation of dengue makes it difficult to distinguish from other causes of 
febrile illness, especially since dengue diagnostic assays are not widely available (21).  
The Dengue Vaccine Initiative (DVI), in collaboration with the Kenya Medical 
Research Institute (KEMRI) and the Ministry of Health of Kenya, conducted passive 
facility-based fever surveillance in Mombasa, Kenya. The study served three objectives. 
First, to estimate the proportion of dengue cases and compare their clinical patterns to 
other non-malarial febrile patients. The occurrence of an outbreak during the study 
period allowed us to include the following two further objectives: to evaluate the 
performance of clinical diagnosis, in terms of sensitivity and specificity relative to status 
of dengue positivity, before and during the outbreak, and, finally, to identify signs and 
symptoms associated with dengue patients, before and during the outbreak.   
 
Methods 
 
Site selection  
 
Site selection was based on published literature on dengue transmission, and 
reports of outbreaks and cases, seroprevalence studies, dengue burden modelling and 
research infrastructure (10, 22, 23). Ganjoni health centre, Tudor sub-county Hospital, 
and Coast Provincial General Hospital (CPGH) in Mombasa, Kenya were selected in 
consultation with collaborators in Kenya Medical Research Institute (KEMRI) and 
Ministry of Health of Kenya, serving catchment population of 74,735 residents in 
Mombasa (Fig. 1) (22, 24, 25).  
In the 6-level system of healthcare service delivery in Kenya, Ganjoni health 
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centre is a Kenya Essential Package for Health (KEPH) level 2 health service provider, 
focusing on primary care and health promotion for the community. Tudor sub-county 
Hospital is KEPH level 4, district-level health centre with outpatient and observation 
care; and CPGH is KEPH level 5, the largest tertiary referral center in the entire coast 
region.  
 
Study area and population 
 
Coastal Kenya, in eastern Africa, has a warm and humid tropical climate (25). 
Mombasa, the country’s second largest city after Nairobi, has a population of about 1.3 
million, of whom almost 50% are under 15 years of age (6, 24). The “long rains” period 
begins around April and the “short rains” around October (25). This study took place 
between March 2016 and May 2017 (15 months) (Figure 1).  
 
 
Study design 
 
Passive fever surveillance 
  
Investigational methods used in this study have previously been described (22). 
To determine the burden of symptomatic dengue in Mombasa, among non-malaria 
febrile patients, passive facility-based surveillance was implemented in the three 
facilities, enrolling both outpatients and inpatients (22). First, patients who were febrile, 
or with a history of fever in the past 7 days, were tested for malaria using RDT (either 
CareStart™ Malaria or SD BIOLINE Malaria kit) as part of routine practice. Those 
eligible and agreeing to participate were referred to a study physician (Figure 2). Malaria 
RDT-negative patients were enrolled in the study and tested with dengue RDTs. An 
acute sample of blood was taken at first presentation with current or history of fever. 
Phlebotomists performed a blood draw of 7-10 ml with aseptic measures using 
disposable needles and syringes. The whole blood was used for the dengue RDT. After 
collection of blood samples, a study physician conducted interviews and physical 
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examinations and the surveillance case report forms were completed to capture 
symptom history, medical history, treatment and laboratory results (22).   
The patient was asked to return to the facility for the convalescent sample 
collection 10-14 days after the first visit. After the 14th day, if the patient had not 
returned, a house visit was made and the second blood sample was collected within 21 
days of the first visit.  
Confirmation of positive RDT was done by detection of IgM/IgG antibodies 
against dengue virus using ELISA (on all the samples) and dengue virus using PCR (on 
a selected subset) in serum samples as described below (15, 26).  
 
Study participants  
 
For the passive facility-based fever surveillance, individuals who met the following 
criteria were eligible for study enrollment: 
1. Age 1- 55 years; 
2. Resident of the catchment area covered by healthcare facilities participating in 
the study, without plans to move out within 12 months; 
3. Signed informed consent, and assent for those aged between 13 and 17 years; 
and 
4. Patients presenting with current fever (body temperature ≥ 37.5º C) or history of 
fever for ≤ 7 days duration without localizing signs (fever caused by a localized 
infection as well as fever with a known and confirmed etiology other than dengue, 
such as malaria confirmed by malaria RDT). 
 
 
Laboratory Testing Algorithm  
 
Acute samples were tested using a commercial RDT for dengue NS1 and 
IgM/IgG (Dengue Duo® , Standard Diagnostics, Yongin-Si, Korea) on the day of the first 
visit at the site of patient presentation (day 1). The acute and convalescent samples 
were subsequently tested in the KEMRI laboratory using dengue IgM/IgG ELISA (SD 
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Dengue IgM & IgG Capture ELISA® , Standard Diagnostics, Yongin-Si, Korea). The 
results from IgM/IgG ELISA and RDT were used for selecting samples that would go on 
to further testing. Those samples that met the following criteria underwent molecular 
analysis with RT-PCR (27): (i) NS1- or IgM-positive on the rapid test in acute phase; 
and/or (ii) sero-converted between acute and convalescence phase on IgM and IgG 
capture ELISA. RT-PCR was also performed on a limited number of randomly selected 
samples that were sero-positive at both acute and convalescent time points by IgM and 
IgG capture ELISA as well as those negative by RDT and IgM/IgG ELISA at all time 
points. In addition, convalescent samples were tested using chikungunya IgM ELISA kit 
(SD Chikungunya IgM ELISA® , Standard Diagnostics, Yongin-Si, Korea). The detailed 
laboratory testing procedure has been previously described (22). 
Laboratory confirmation for dengue infection was performed according to WHO 
diagnostic criteria (28). Sero-conversion of anti-dengue IgM and IgG between the acute 
and convalescent phases and/or virus detection (RT-PCR) in the acute serum specimen 
was considered to be confirmed dengue. A positive IgM serology in single serum and/or 
positive on NS1 or IgM of RDT in single acute serum were criteria of probable dengue 
infection (28). Confirmed and probable dengue infections were grouped to be dengue-
positive in this analysis. Samples with negative results on RT-PCR and sero-negative 
results on paired IgM and IgG ELISA results were classified as non-dengue. Also, a 
positive IgG serology in single serum, with negative results from all other tests, was 
classified as non-dengue.  
 
 
Statistical analysis 
 
There were three components in the analysis. 
 
1. Clinical characteristics of dengue-positive versus non-dengue cases 
A descriptive summary of characteristics is presented for dengue-positive versus 
non-dengue cases. Age was initially broken down to 8-level categorical variable for 
descriptive purposes. A body temperature ≥38.0°C, the 75th percentile of the body 
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temperature measured at the time of enrollment, was used to create a dichotomous 
variable indicating a higher body temperature at the patient’s first presentation. Clinical 
diagnosis at admission, prior to lab-confirmation, was grouped with suspected dengue, 
undifferentiated fever, and non-dengue.  
In the penultimate month of surveillance (April 2017) as we observed a steep rise 
in the dengue caseload, there was a public health alert issued by Mombasa County 
health officials over a dengue outbreak and it was declared an outbreak in May (29-32). 
The last two months of surveillance were analyzed as an outbreak period and the 
previous months as non-outbreak. Yellow fever vaccination history was dichotomized 
between those who reported having been vaccinated versus those who did not 
remember or reported no vaccination. Dichotomous variables were also created for 
various signs and symptoms (presence vs. absence). For nausea and vomiting, patients 
were asked whether they had nausea and/or vomiting during their illness. Categorical 
pair-wise comparisons were made across dengue status using χ2 or Fisher’s exact tests. 
Continuous variables were compared using Student’s t-test or ANOVA.  
 
2. Accuracy of the clinical diagnosis of suspected dengue 
Clinical diagnosis as categorized as suspected dengue based on clinician 
judgement or other than suspected dengue. Sensitivity, specificity, positive predictive 
value (PPV) and negative predictive value (NPV), relative to dengue-positive status, 
were reported with corresponding 95% CIs.   
 
3. Differences in dengue cases between outbreak and non-outbreak periods 
Finally, clinical indicators associated with dengue-positive cases were identified 
using multivariable logistic regression. The analysis was to assess how the clinical 
profile of dengue cases differed between those presenting during the outbreak versus 
non-outbreak periods.  
A final model was built for the outcome of dengue positivity (dengue-positive vs. 
non-dengue) for the outbreak and non-outbreak periods with the same a priori 
confounders of age, gender, treatment center, and fever duration. Age is a known 
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confounder for dengue and presentation as a primary or subsequent infection. It was 
categorized into three and then two levels due to data sparsity. Gender may be related 
to Aedes exposure and may mediate clinical presentation (33). Treatment center may 
be a proxy for otherwise any unexplained variation. Fever duration prior to the visit, 
reflecting disease progression, may affect level of viremia and clinical presentation (34, 
35).  
A backward stepwise process was used to select variables to be entered in the 
final multivariable model for the outbreak and non-outbreak periods, with a significance 
level of 0.2 for entry and 0.1 for retention. Other variables investigated were variables 
on clinical presentation, such as high body temperature at enrollment, various signs and 
symptoms. Clinical diagnosis of suspected dengue was considered too closely related 
to dengue positivity as well as some of the signs and symptoms, and was not included 
in the model. Due to data sparsity, some signs and symptoms from the descriptive and 
univariable analyses were not included in the model building. All analyses were 
performed using SAS®  version 9.4 (SAS Institute, Cary, North Carolina).  
 
Ethical considerations 
The study protocol obtained ethical approvals from the Institutional Review 
Boards (IRBs) of the International Vaccine Institute, the London School of Hygiene and 
Tropical Medicine, and the KEMRI Scientific and Ethical Review Unit.  
All adult subjects provided informed consent, and a parent or guardian of any 
child participant provided informed consent on the child’s behalf with assent from the 
child aged between 13 and 17 years. For all subjects, written consent was obtained.  
 
 
Results  
 
General and clinical characteristics of dengue cases 
Of 513 enrolled individuals, 31 had incomplete visit 1 (acute) lab data (i.e. RDT 
results available but no sample for ELISA or PCR, Figure 2). These patients were found 
to be non-differential to those that were in the analysis sample, in terms of age, gender, 
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status of being kept under observation, and days into illness at the time of enrollment. 
However, they were more likely (25/31) to be enrolled at CPGH, where the majority of 
our analysis sample was also enrolled. Of the remaining 482 patients, 223 (46%) had 
confirmed dengue infections based on paired ELISA and/or PCR, 72 (15%) were 
classified as dengue-probable, and 187 (39%) as non-dengue cases. Table 1 describes 
the demographic and clinical characteristics between dengue-positive and non-dengue 
cases and the breakdown by 3-level dengue-status (dengue-confirmed, probable, and 
non-dengue) is presented in supplementary tables. Of these dengue- positive cases, 69% 
(205/295) were based on PCR confirmation (Fig. 2). Also, 29% (48 of 166 paired 
samples tested) and 24% (39 of 160 paired samples tested) were lab-confirmed with 
dengue infection by seroconversion between acute and convalescent samples using 
IgM and IgG capture ELISA, respectively. There were 32 patients confirmed by both 
PCR and ELISA (of either IgM or IgG seroconversion) and 18 patients by 
seroconversion on ELISA alone.  
Only two of the 482 patients were required to be kept under observation <3 days 
and both were dengue-positive patients. Close to 80% of the dengue-positive patients 
were between 15 and 34 years-of-age (Table 1). Of the 482 patients, the average time 
between fever onset and presentation was 3.0 days, with no evidence that this differed 
between dengue-positive and non-dengue cases. However, the average entire duration 
of fever illness was significantly longer for dengue cases than non-dengue cases — 6.9 
versus 4.9 days — among 309 patients with data on endpoint of their fever illness 
duration.  
 
Table 1. Demographic and clinical characteristics between dengue-positive and non-
dengue cases among febrile enrollees of the health facility-based fever surveillance in 
Mombasa, Kenya in 2016-2017  
Characteristics N (%) p-value 
Dengue-
positive 
(n=295) 
Non-dengue 
(n=187) 
Total 
(n=482) 
Place of enrollment    0.645 
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 CPGH 139 (47.12) 94 (50.27) 233 (48.34)  
 Tudor 123 (41.69) 70 (37.43) 193 (40.04)  
 Ganjoni 33 (11.19) 23 (12.30) 56 (11.62)  
Mean age (SD) 23.35 (9.23) 23.14 (13.46) 23.27 (11.05) 0.839 
Age group (years)    <.001 
1-4 8 (2.71) 31 (16.58) 39 (8.09)  
5-9 10 (3.39) 6 (3.21) 16 (3.32)  
10-14 13 (4.41) 6 (3.21) 19 (3.94)  
15-19 45 (15.25) 21 (11.23) 66 (13.69)  
20-24 124 (42.03) 39 (20.86) 163 (33.82)  
25-34 61 (20.68) 44 (23.53) 105 (21.78)  
35-44 24 (8.14) 28 (14.97) 52 (10.79)  
45-55 10 (3.39) 12 (6.42) 22 (4.56)  
Female 117 (39.66) 90 (48.13) 207 (42.95) 0.067 
IPD/OPD 2 (0.68)/293 
(99.32) 
0/187 (100.0) 2 (0.41)/480 
(99.59) 
0.259 
Fever duration prior to visit 
(days, SD) 
2.96 (1.92) 2.84 (1.79) 2.91 (1.87) 0.513 
Fever duration, entire 
illness (days, SD)* 
6.88 (3.75) 4.91 (2.76) 6.17 (3.55) <.001 
Temperature at 
presentation (SD) 
37.85 (0.66) 37.71 (0.73) 37.80 (0.69) 0.024 
Temperature at presentati
on  
   0.014 
   Below 38.0°c 179 (60.68) 134 (71.66) 313 (64.94)  
   ≥ 38.0°c 116 (39.32) 53 (28.34) 169 (35.06)  
Prev. dengue infection** 3 (1.02) 3 (1.60) 6 (1.24) 0.323 
YF vaccination** 146 (49.49) 77 (41.18) 223 (46.27) 0.074 
Clinical diagnosis     
   Suspected dengue 186 (63.05) 18 (9.63) 204 (42.32) <.001 
   Undifferentiated fever 76 (25.76) 121 (64.71) 197 (40.87)  
   Non-dengue  33 (11.19) 48 (25.67) 81 (16.80)  
     URI 18 (54.55) 27 (56.25) 45 (55.56)  
     Malaria 1 (3.03) 3 (6.25) 4 (4.94)  
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     UTI 2 (6.06) 2 (4.17) 4 (4.94)  
     Diarrheal illness 1 (3.03) 1 (2.08) 2 (2.47)  
     Others 11 (33.33) 15 (31.25) 26 (32.10)  
Signs and symptoms** 
(presence) 
    
     Rash 34 (11.53) 10 (5.35) 44 (9.13) 0.022 
     Fatigue/weakness 269 (91.19) 156 (83.42) 425 (88.17) 0.010 
     Headache   282 (95.59) 155 (82.89) 437 (90.66) <.001 
Retro-orbital pain 166 (56.27) 69 (36.90) 235 (48.76) <.001 
     Neck pain 90 (30.51) 43 (22.99) 133 (27.59) 0.072 
     Ear pain 23 (7.80) 10 (5.35) 33 (6.85) 0.300 
     Breathing difficulty 1 (0.34) 5 (2.67) 6 (1.24) 0.035 
     Nasal congestion 15 (5.08) 26 (13.90) 41 (8.51) 0.001 
     Rhinorrhea 27 (9.15) 37 (19.79) 64 (13.28) 0.001 
     Sore Throat  17 (5.76) 22 (11.76) 39 (8.09) 0.019 
Cough 46 (15.59) 48 (25.67) 94 (19.50) 0.007 
     Sputum production   9 (3.05) 15 (8.02) 24 (4.98) 0.015 
     Nausea & vomiting 151 (51.19) 75 (40.11) 226 (46.89) 0.018 
     Diarrhea  31 (10.51) 25 (13.37) 56 (11.62) 0.340 
     Constipation 13 (4.41) 9 (4.81) 22 (4.56) 0.835 
     Abdominal pain 101 (34.24) 55 (29.41) 156 (32.37) 0.270 
     Nose bleeding 8 (2.71) 0 8 (1.66) 0.026 
     Gum bleeding 10 (3.39) 0 10 (2.07) 0.008 
     Flushed face 6 (2.03) 5 (2.67) 11 (2.28) 0.647 
     Loss of appetite 195 (66.10) 93 (49.73) 288 (59.75) <.001 
     Myalgia   221 (74.92) 114 (60.96) 335 (69.50) 0.001 
     Arthralgia   222 (75.25) 104 (55.61) 326 (67.63) <.001 
*only among those that reported the end of fever illness (n=309; 199 dengue and 110 
non-dengue patients) 
**based on self-report 
 
Of the 482 RDT results, 189 patients (39.2%) were positive for NS1 and/or IgM. 
In terms of clinical diagnosis, about 42% (204/482) of enrolled febrile patients had 
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clinically suspected dengue (Table 1). Among dengue-positive patients, 63% (186/295) 
were clinically suspected dengue, prior to lab-confirmation of dengue. Of the non-
dengue patients, the majority, 64.7 and 25.7% were diagnosed with undifferentiated 
fever and non-dengue, respectively.  
There were peaks of dengue incidence in April-June 2016 and April-May 2017 
(Figure 3), coinciding with the “long rains” season. Of 295 dengue cases, 173 were 
identified before (173/317), and 122 during the outbreak (122/165). DENV-2 was the 
predominant serotype during the 1 year period before the outbreak, with a lower level of 
DENV 1 throughout the study period (Figure 3). The outbreak was also largely DENV 2. 
In terms of symptoms, rash, fatigue, headache, retro-orbital pain, 
nausea/vomiting, nose bleeding, gum bleeding, loss of appetite, myalgia, and arthralgia 
were found more commonly among dengue-positive cases, compared to non-dengue. 
Breathing difficulty, nasal congestion, rhinorrhea, sore throat, cough, and sputum 
production were found more commonly among non-dengue cases, compared to 
dengue-positive cases.   
 
Accuracy of dengue case detection by clinical diagnosis with suspected dengue 
Among 482 patients, clinical diagnosis (suspected dengue vs. other than 
suspected dengue) was compared against dengue positivity (dengue-positive vs. non-
dengue cases). While clinical diagnosis of dengue and RDT positive result were found 
to be closely related in our data, clinical diagnosis was often made in the absence of 
knowledge of the dengue RDT result. Even though the rapid test results become 
available in 15-20 minutes, due to the patient flow and the volume of febrile patients as 
well as the level of physician availability, the results may or may not have been available 
at the time of diagnosis.  
Clinical diagnosis of dengue had quite high specificity (90%) while sensitivity 
was 63% (Table 2). During the outbreak, the sensitivity of clinical diagnosis was 
significantly higher (83% vs. 49%) than prior to it, but specificity was slightly lower (86% 
vs. 92%). Both PPV and NPV were higher during the outbreak.  
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Table 2. Sensitivity and positive predictive value of clinical diagnosis vs. lab confirmation of dengue among febrile patients 
in Kenya 
 Overall Outbreak Non-outbreak 
Clinical diagnosis (by 
the physician*) 
Total Clinical diagnosis (by 
the physician*) 
Total Clinical diagnosis (by 
the physician*) 
Total 
Suspected 
dengue 
Other 
than 
dengue 
Suspected 
dengue 
Other 
than 
dengue 
Suspected 
dengue 
Other than 
dengue 
Dengue 
positivity 
(defined 
in this 
study) 
Dengue-
positive 
(dengue 
confirmed & 
probable 
cases) 
186 109 295 101 21 122 85 88 173 
Non-
dengue 
18 169 187 6 37 43 12 132 144 
Total 204 278 482 107 58 165 97 220 317 
 Sensitivity = 63.05% (57.26 to 
68.57%) 
Specificity = 90.37 %% (85.21 to 
94.19%) 
PPV = 91.18% (86.85 to 94.18%)    
NPV = 60.79 % (57.01 to 64.45%) 
Sensitivity = 82.79% (74.90 to 
89.02%) 
Specificity = 86.05% (72.07 to 
94.70%) 
PPV = 94.39% (88.86 to 97.26%)    
NPV = 63.79% (53.97 to 72.59%) 
Sensitivity = 49.13% (41.47 to 
56.83%) 
Specificity = 91.67% (85.90 to 
95.62%) 
PPV = 87.63% (80.14 to 92.56%)    
NPV = 60.00% (56.24 to 63.64%) 
PPV, positive predictive value; NPV, negative predictive value 
* referring to the RDT test results was at the discretion of the attending physician and in some cases, RDT test was 
performed at the lab while the patient is being examined by the physician 
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Differences in dengue cases between outbreak and non-outbreak periods 
From univariable analyses during the outbreak (Table 3A), the variables found to be 
associated with increased odds of dengue positivity, compared to non-dengue, were 
fatigue/weakness and nausea/vomiting. During the non-outbreak period (Table 3B), gender, 
age, retro-orbital pain, myalgia, arthralgia, loss of appetite, and headache, were associated 
with increased odds of dengue compared to non-dengue. Rhinorrhea and nasal congestion 
were associated with decreased odds.  
 
Table 3A. Univariable analysis showing associations with dengue positivity during the 
period of outbreak in the health facility-based fever surveillance  
Characteristics During outbreak (n=165) 
Total 
N 
N (%) 
Dengue-
positive  
(n=122) 
N (%) Non- 
dengue 
(n=43) 
Univariable analysis 
Dengue-positive vs. no 
dengue  
OR  95% CI  p-
Value  
Gender      0.659 
   Male 93 70 (75.27) 23 (24.73) Ref -  
   Female 72 52 (72.22) 20 (27.78) 0.85 0.43-1.72  
Age (years)      0.123 
   1-19 38 28 (73.68) 10 (26.32) Ref -  
   20-24  77 62 (80.52) 15 (19.48) 1.48 0.59-3.69  
   25-55 50 32 (64.00) 18 (36.00) 0.64 0.25-1.60  
Treatment center      0.929 
   CPGH 56 41 (73.21) 15 (26.79) Ref -  
   Tudor 87 64 (73.56) 23 (26.44) 1.02 0.47-2.18  
   Ganjoni 22 17 (77.27) 5 (22.73) 1.24 0.39-3.97  
Fever duration prior to 
visit 
     0.449 
   1-2 days 71 54 (76.06) 17 (23.94) Ref -  
   3 days 49 33 (67.35) 16 (32.65) 0.65 0.29-1.46  
   4-7 days 45 35 (77.78) 10 (22.22) 1.10 0.45-2.68  
Temperature at presentat
ion  
     0.130 
   Below 38.0°c 70 56 (80.0) 14 (20.0) Ref -  
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   ≥ 38.0°c 95 66 (69.47) 29 (30.53) 1.76 0.85-3.65  
Presence of signs and 
symptoms (ref. absence)  
      
   Retro-orbital pain 109 84 (77.06) 25 (22.94) 1.59 0.78-3.26 0.204 
   Myalgia 127 97 (76.38) 30 (23.62) 1.68 0.77-3.69 0.195 
   Arthralgia 125 96 (76.80) 29 (23.20) 1.78 0.83-3.86 0.142 
   Fatigue/weakness* 148 113 (76.35) 35 (23.65) 2.87 1.03-8.00 0.044 
   Loss of appetite 126 97 (76.98) 29 (23.02) 1.87 0.86-4.07 0.112 
   Headache 162 120 (74.07) 42 (25.93) 1.43 0.13-16.16 0.773 
   Neck pain 50 40 (80.0) 10 (20.0) 1.61 0.72-3.59 0.245 
   Ear pain 11 9 (81.82) 2 (18.18) 1.63 0.34-7.87 0.541 
   Rhinorrhea 9 7 (77.78) 2 (22.22) 1.25 0.25-6.25 0.788 
   Nasal congestion 4 2 (50.0) 2 (50.0) 0.34 0.05-2.50 0.291 
   Cough 20 12 (60.0) 8 (40.0) 0.48 0.18-1.26 0.136 
   Nausea & vomiting* 86 71 (82.56) 15 (17.44) 2.56 1.26-5.36 0.001 
   Diarrhea  18 14 (77.78) 4 (22.22) 1.26 0.39-4.07 0.695 
   Abdominal pain 67 49 (73.13) 18 (26.87) 0.93 0.46-1.89 0.846 
   Sore Throat 10 6 (60.0) 4 (40.0) 0.50 0.14-1.88 0.308 
Statistical significance of the frequencies: *p-value<0.05 **p-value<.001 
 
 
 
Table 3B. Univariable analysis showing associations with dengue positivity during the 
period of non-outbreak (n=317) in the health facility-based fever surveillance 
Characteristics During non-outbreak (n=317) 
Total 
N 
N (%) 
Dengue-
positive 
(n=173) 
N (%) 
Non- 
dengue 
(n=144) 
Univariable analysis 
Dengue-positive vs. no dengue  
OR  95% CI  p-Value  
Gender*      0.048 
   Male 182 108 (59.34) 74 (40.66) Ref -  
   Female 135 65 (48.15) 70 (51.85) 0.64 0.41-1.00  
Age (years)**      <.001 
   1-19 102 48 (47.06) 54 (52.94) Ref -  
   20-24  86 62 (72.09) 24 (27.91) 2.91 1.58-5.35  
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   25-55 129 63 (48.84) 66 (51.16) 1.07 0.64-1.81  
Treatment center      0.649 
   CPGH 177 98 (55.37) 79 (44.63) Ref -  
   Tudor 106 59 (55.66) 47 (44.34) 1.01 0.62-1.64  
   Ganjoni 34 16 (47.06) 18 (52.94) 0.72 0.34-1.50  
Fever duration prior to 
visit 
     0.258 
   1-2 days 176 98 (55.68) 78 (44.32) Ref -  
   3 days 69 32 (46.38) 37 (53.62) 0.69 0.39-1.20  
   4-7 days 72 43 (59.72) 29 (40.28) 1.18 0.68-2.06  
Temperature at present
ation  
     0.147 
   Below 38.0°c 218 113 (51.83) 105 
(48.17) 
Ref -  
   ≥ 38.0°c 99 60 (60.61) 39 (39.39) 1.43 0.88-2.32  
Presence of signs and 
symptoms (ref. absence)  
      
   Retro-orbital pain* 126 82 (65.08) 44 (34.92) 2.05 1.29-3.26 0.002 
   Myalgia* 208 124 (59.62) 84 (40.38) 1.81 1.13-2.89 0.013 
   Arthralgia** 201 126 (62.69) 75 (37.31) 2.47 1.54-3.94 <.001 
   Fatigue/weakness 277 156 (56.32) 121 
(43.68) 
1.74 0.89-3.41 0.104 
   Loss of appetite* 162 98 (60.49) 64 (39.51) 1.63 1.05-2.55 0.031 
   Headache** 275 162 (58.91) 113 
(41.09) 
4.04 1.95-8.37 <.001 
   Neck pain 83 50 (60.24) 33 (39.76) 1.37 0.82-2.28 0.228 
   Ear pain 22 14 (63.64) 8 (36.36) 1.50 0.61-3.68 0.379 
   Rhinorrhea* 55 20 (36.36) 35 (63.64) 0.41 0.22-0.74 0.003 
   Nasal congestion* 37 13 (35.14) 24 (64.86) 0.41 0.20-0.83 0.014 
   Cough 74 34 (45.95) 40 (54.05) 0.64 0.38-1.07 0.090 
   Nausea & vomiting 140 80 (57.14) 60 (42.86) 1.20 0.77-1.88 0.414 
   Diarrhea  38 17 (44.74) 21 (55.26) 0.64 0.32-1.26 0.197 
   Abdominal pain 89 52 (58.43) 37 (41.57) 1.24 0.76-2.04 0.390 
   Sore Throat 29 11 (37.93) 18 (62.07) 0.48 0.22-1.04 0.063 
Statistical significance of the frequencies: *p-value<0.05 **p-value<.001 
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During the outbreak, the multivariable model building process selected 
nausea/vomiting. During the non-outbreak period, the process selected age, high body 
temperature, diarrhea, arthralgia, nasal congestion, loss of appetite, and headache. With 
age, gender, treatment center, and fever duration prior to visit as a prior adjustments and 
high body temperature identified to be significantly associated in the variable 
screening/selection process, the final model was run for the outbreak and non-outbreak 
periods, with significant signs and symptoms (nausea/vomiting, diarrhea, arthralgia, nasal 
congestion, loss of appetite, and headache). Table 4 shows that, during the outbreak period, 
dengue cases were associated with 2.6 times greater odds of presenting with 
nausea/vomiting, compared to non-dengue cases. Table 4 (on the right) shows that, during 
the non-outbreak period, dengue cases were 2.0 times more likely to present with arthralgia, 
3.1 times more likely to present with headache, and 1.9 times more likely to present with 
loss of appetite, compared to non-dengue cases.  
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Table 4. Multivariable associations with dengue positivity by outbreak status 
Characteristics Multivariate analysis 
During the outbreak* (n=165) 
Dengue-positive (n=122)  
ref. no dengue (n=43) 
During non-outbreak (n=317) 
Dengue-positive (n=173) 
ref. no dengue (n=144) 
aOR  95% CI  p-
Value 
aOR  95% CI  p-
Value 
Gender   0.378   0.221 
   Male    Ref -  
   Female 0.70 0.32-1.55  0.73 0.44 – 1.21  
Age (years)   0.319   0.009 
   1-19    Ref -  
   20-24  1.47 0.55-3.94  2.36 1.16-4.83  
   25-55 0.72 0.26-1.95  0.90 0.47-1.74  
Treatment center   0.978   0.161 
   CPGH    Ref -  
   Tudor 1.09 0.46-2.55  1.28 0.68-2.40  
   Ganjoni 1.13 0.30-4.24  0.53 0.22-1.26  
Temperature at presentation    0.212   0.066 
   Below 38.0°c    Ref -  
   ≥ 38.0°c 1.71 0.74-3.96  1.72 0.97-3.08  
Fever duration prior to visit   0.451   0.088 
   1-2 days    Ref -  
   3 days 0.57 0.23-1.43  0.52 0.27-0.98  
   4-7 days 0.94 0.35-2.50  1.05 0.56-1.98  
Presence of signs and symptoms 
(ref. absence)  
      
   Nausea/vomiting 2.55 1.11-5.87 0.028 1.21 0.71-2.07 0.474 
   Nasal congestion 0.22 0.03-1.82 0.160 0.52 0.23-1.18 0.117 
   Arthralgia 1.71 0.65-4.55 0.280 2.01 1.15-3.50 0.014 
   Headache 1.37 0.08-
23.96 
0.831 3.06 1.26-7.42 0.013 
   Loss of appetite 1.19 0.47-3.02 0.722 1.92 1.10-3.37 0.023 
   Diarrhea 1.28 0.35-4.69 0.710 0.47 0.22-1.02 0.057 
*in April-May of 2017; aOR = adjusted odds ratio 
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Discussion 
 
Overall, evidence on dengue in Africa is limited (11). For Kenya, most of the 
evidence on dengue from outbreak investigations and retrospective testing of existing 
serum banks from other studies (17, 18). Our data showed that dengue infection is an 
important cause of non-malarial febrile illness in patients seeking care at public health 
facilities in Mombasa. Approximately half the dengue cases of the 15-month study were 
identified in the last two months, which coincided with an outbreak. This allowed us to 
demonstrate differences in clinical and symptomatic patterns between the outbreak and 
non-outbreak periods. 
 
General and clinical characteristics of dengue cases 
 
A key finding of our study was that a substantial number of dengue-positive cases 
was identified, including a notable outbreak in Apr/May 2017, in Mombasa. Dengue cases 
were 2.4 times more common during the outbreak, than in non-outbreak period (O.R=2.36, 
95% C.I=1.56-3.57). Of 482 non-malarial febrile patients, 295 (61.2%) were identified to be 
dengue-positive. Of those patients enrolled before the outbreak, about half (173/317, 
54.6%), were identified to be dengue-positive, compared to more than two-thirds of those 
enrolled during the outbreak (122/165, 73.9%). This shows the magnitude of the dengue 
outbreak captured in the first two months, compared to the baseline caseload in non-
outbreak period. 
The high proportion of dengue-positive cases should be interpreted bearing in mind 
that malaria cases were excluded from the denominator. Also, it is expected that the 
proportion of cases would be increased during a dengue outbreak. In the current study, 
although it was only the first two months of the outbreak, the study happened to capture the 
start of a dengue outbreak in April 2017 (Fig. 3) (29, 31, 32). This could still have caused 
the proportion of dengue cases, over the duration of the whole study, to be higher than in 
non-epidemic years. Officially reported to WHO, this outbreak in Mombasa had more than 
half of the individuals (540/945) lab-confirmed with dengue in May and June 2017 (16).  
Among comparable previous studies, few reported levels of dengue as high as in 
the current study (18). In particular, a surveillance study conducted in seven Mombasa 
hospitals in 2013 found that, among 267 cases with suspected dengue, 58% were lab-
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confirmed with a current infection (17). In our data, of 204 dengue-suspected patients, 156 
(76%) were dengue-confirmed by either PCR and/or ELISA (suppl. Table 1). There may be 
differences in study settings, but these still indicate similarly high proportions of dengue 
cases. 
However, most other studies report different findings from ours. A study tested 500 
samples from febrile patients identified in CPGH from January 2014 to March 2015 using 
in-house indirect ELISA and Focus Reduction Neutralization tests (FRNT) (36). This study 
found DENV to account for 15% of all the fevers presenting, even without screening out 
malaria RDT-positive cases (36). A study conducted in Kilifi, about 70km along the coast 
from Mombasa, reported that about 10% of febrile adults that were not acute HIV infection 
and also RDT-negative for malaria were PCR-confirmed with dengue in 2014-2015 (37). 
Among the corresponding subgroup in our study, there were 173 (50.4%) dengue cases 
confirmed by either PCR and/or ELISA among 343 febrile patients between 18-35 years-of-
age. Even if we consider the differences in the study setting (location, outbreak in the study 
period) and methods (different diagnostic tests, i.e. dengue-confirmation using only PCR 
among HIV and malaria negative febrile patients in Kilifi and ELISA/FRNT among all febrile 
patients in Mombasa), the estimate of proportion of dengue was higher in our data.   
Those cases who were RDT-negative at baseline were less likely than RDT-positive 
cases to provide a convalescent sample, despite reminders and home visits. Thus, our 
analysis dataset included those without a convalescent sample in order to minimize likely 
upward bias it could have resulted in estimation of the proportion of dengue-positive cases.  
During the study period, there was a programmatic challenge to patient recruitment 
when there was a strike among medical officers. This lasted 71 days between September 
and November of 2016. Health facilities remained operational and there were clinical 
officers and other health facility staff on duty. The official absence of medical officers at 
health facilities could have influenced health-seeking behavior and our surveillance might 
otherwise have enrolled a larger volume of febrile patients. If so, our denominator of non-
malarial fever cases could have been bigger and the proportion of dengue, before the 
outbreak, could have been lower.  
There are limited data from Kenya and Africa on how dengue affects different age 
groups. Among those attending health facilities in the current study, dengue cases were 
more concentrated between 15 and 34 years-of-age, higher on average than in the 2011 
outbreak in Mandera in which 30% of dengue cases were below 10 years of age with 
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another 20% between 10 and 19 years (18). However, our findings may have been 
impacted by age-specific health-seeking behavior, with 70% of all enrollees being 
teenagers or young adults. 
In the context of other co-circulating pathogens, chikungunya was also suspected to 
be a possible co-circulating virus in the area. Retrospectively, we performed chikungunya 
testing to see if there could have been co-infections with dengue. On all the convalescent 
samples, we performed Chikungunya IgM ELISA tests and none was found positive. 
Furthermore, our study did not enroll malaria RDT positive patients in the patient screening 
process, even though some of them could have had co-infection with dengue. A study on 
the 2011 dengue outbreak in Mandera town, Kenya, reported 4 out of 30 lab-confirmed 
dengue cases to have malaria co-infection (18). However, overall, such concurrent infection 
is reported to be uncommon (38, 39).  
 
Accuracy of dengue case detection by clinical diagnosis with suspected dengue 
 
Overall, of 295 dengue-positive cases, 186 (63.1%) were clinically diagnosed with 
suspected dengue. Their clinical diagnosis of suspect dengue was made prior to lab-
confirmation of dengue and, often, in the absence of knowledge of the dengue RDT results. 
The sensitivity of clinical diagnosis, relative to dengue-positivity, was significantly higher 
during the outbreak compared to non-outbreak (83% vs. 49%), while specificity was similar 
(86% vs. 92%). In terms of PPV and NPV, clinical diagnosis performed better during the 
outbreak (PPV=94% and NPV=64%), compared to non-outbreak (PPV=88% and 
NPV=60%).  
Guidelines for case detection and management remained unchanged throughout the 
study period and, being part of the routine practice, was not influenced by the study 
procedure. Despite possibly limited applicability, for clinical judgement, the 1997 WHO 
dengue case classification criteria were used in the study facilities for diagnosis and 
management for suspected dengue (40). In addition to referring to the criteria, clinicians 
suspected dengue if the patient tested negative for malaria (by RDT or microscopy) or did 
not respond to antimalarial treatment. With increased dengue transmission and caseload 
during the outbreak, clinicians may be more alert to identify dengue cases during outbreak. 
One potential factor influencing performance of clinical diagnosis could have been a 
difference in duration of illness before presentation, although, in fact, this was similar in the 
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outbreak and non-outbreak periods (34, 35).  
 
Differences in dengue cases between outbreak and non-outbreak periods 
 
The main objective of the third component of this analysis was to assess how the 
clinical presentation of dengue-positive cases might differ between outbreak and non-
outbreak periods. The final model, with a priori confounders and controlled for high body 
temperature, showed that, during the outbreak period, dengue cases were more likely to 
present with nausea/vomiting. During the non-outbreak period, dengue-positive cases were 
more likely to present with arthralgia, headache, and loss of appetite, compared to non-
dengue cases.  
These differences in symptomatic presentation of dengue between the outbreak and 
non-outbreak periods were reported in other studies. A previous surveillance study of the 
2011 dengue outbreak in Mandera, Kenya, also reported high frequencies of vomiting, 
arthralgia, and headache among dengue cases, albeit with a small sample size of 30 
dengue cases (18). In various other study settings, these variables have been reported as 
being positively associated with dengue, some specifically in outbreak settings (41-43). 
Specifically for gastrointestinal symptoms, there had been previous studies, which indicated 
higher odds of nausea and vomiting among dengue cases compared against non-dengue 
cases (44-46).  
The 1997 case definition differentiates probable and confirmed DF, DHF, and 
dengue shock syndrome (DSS) (40). As in the 1997 case definition, nausea/vomiting, 
arthralgia, and headache were signs associated with dengue in the current study (40). The 
revised 2009 WHO case definitions classified the illness into dengue with and without 
warning signs, and severe dengue (40, 47). According to this revised scheme, warning 
signs, possibly leading to severe dengue, include abdominal pain, persistent vomiting 
and/or diarrhea, lethargy, clinical fluid accumulation, and mucosal bleeding (40, 47). Of 
these warning signs, we found only nausea/vomiting to be associated with dengue positivity. 
Also, there are some data suggesting association of gastrointestinal signs, such as 
nausea/vomiting, to hospitalized and more severe dengue (44, 48). Also, a meta-analysis 
on symptoms of severe dengue disease reported vomiting/nausea to be significant 
predictor for progression into severe dengue whereas headache showed protective effect 
against progression into severe dengue (49).  
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In the current study, most of the dengue-positive cases were mild. In the whole 
study, only two cases required hospitalization and both were dengue-positive. Both were 
clinically diagnosed with dengue, not DHF, and no complications were recorded. Of these 
two, one had a complete record of admission: no complication was reported, and they spent 
two days in hospital before discharge. While our study did not collect data on other 
indicators of dengue severity, nausea/vomiting being associated with dengue cases in the 
outbreak, but not before, may indicate likely severity of dengue illness during the outbreak 
(44, 48, 49).    
For the non-outbreak period, arthralgia, loss of appetite, and headache, were found 
to be associated with dengue-positivity, consistent with previous reports in epidemic and 
non-epidemic settings (42, 50, 51). This is also consistent with previous findings that these 
symptoms were more strongly associated with classical DF than with severe forms (45, 52), 
with the case profile of the current study being closer to the former.  
In our study, DENV-2 was the predominant serotype during both before and during 
the outbreak (Figure 3). A study of febrile patients in CPGH from January 2014 to March 
2015 also reported that DENV 2 was the predominant serotype, followed by DENV 3 and 
DENV 1(36). Outbreaks may coincide with a shift in dengue serotypes (53-55), but this was 
not observed in the current study. In Mombasa, between 2011 and 2014, the most frequent 
serotype was DENV 1 followed by DENV 3 (19). The outbreak recorded in Mombasa in 
2013 was also documented to be DENV 1 (56). Although in different regions, in a cohort of 
children in Western Kenya, in Kisumu and Chulaimbo, the serotypes identified among 
dengue cases in March and April 2016 was also DENV 1 (57). DENV2 may have partially 
replaced DENV1 prior to our study. However, lacking more detailed information on virus 
strain, it is difficult to determine whether there were virological differences between 
outbreak and non-outbreak periods. 
 
Limitations and strengths 
 
Dengue transmission can vary substantially over time and space. In endemic areas, 
dengue epidemics occur at between 3 and 5-year intervals (53). Hence, the generalizability 
of the current study is limited by its duration of 15 months and geographical restriction to 
one area of Mvita sub-county. Furthermore, one source of bias could be due to the study 
design, where cases were enrolled only at our study facilities and we missed those 
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community residents with relevant symptoms seeking care from other healthcare providers 
than the study facilities, including private clinics. This may further restrict the generalizability 
of the findings. 
Nonetheless, our study held several strengths not found in previous studies. By 
implementing the surveillance at three different KEPH levels of public health facilities, we 
were able to capture the wide spectrum of clinical manifestations of dengue. Unlike 
previous dengue studies in Kenya focusing mostly on outbreaks, this study captured the 
time before the outbreak as well as the first two months of the outbreak, with a large sample 
size and high dengue caseload, enabling an exploration of the differences between dengue 
and non-dengue cases (Fig. 3) (29, 31, 32).  
 
 
Conclusion 
 
Our data provide evidence for a high level of transmission of dengue in Mombasa 
and demonstrate the magnitude of the 2017 outbreak, compared to baseline during the 
non-outbreak period. The study findings also provide some insight into differences in clinical 
and epidemiological patterns of dengue cases between the outbreak and non-outbreak 
periods. Dengue detection by clinical diagnosis was more accurate during the outbreak 
than before it. More data from additional prospective and longitudinal studies would further 
define patterns of dengue in Kenya for improved case detection and monitoring of dengue 
outbreaks. 
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Figure 1. A map of the area of catchment population and study facilities.  
Notes: The map shows the approximate location of the three selected study facilities 
(Ganjoni health centre, Tudor sub-county Hospital, and Coast Provincial General Hospital), 
covering the catchment area population of residents of Mvita sub-county, Mombasa, Kenya.  
Source: Lim et. al (22).  
  
  
 
 
 
 
 
  
ELISA PCR 
439 patients with IgM and/or IgM ELISA 
results on single (n=157) or paired (n=282) 
samples 
 
 
74 patients had no ELISA results (missing 
on visit 2 samples) 
A subset* of 267 acute samples selected and 
tested with RT-PCR 
- 224 had ELISA results 
- 43 did not have any ELISA results 
 
There were 246 samples not tested with PCR 
- 215 had ELISA results 
- 31 did not have any ELISA results 
 
31 did not have sufficient data to 
determine dengue positivity 
Screened 584 patients with non-malarial fever (documented T > 37.5C) or 
history of fever < 7 days presented at the hospital 
The analysis is based on 482 patients  
(187 dengue-negative) 
Dengue confirmed in 223 patients  
 25 PCR positive and IgM/IgG seroconverted 
 6 PCR positive and IgM seroconverted 
 4 PCR positive and IgG seroconverted  
 170 PCR positive only 
 9 IgM/IgG seroconverted (ELISA) 
 8 IgM seroconverted only & 1 IgG seroconverted 
only (ELISA) 
 
Dengue probable in 72 patients 
 11 IgM and IgG seropositive in paired samples 
(ELISA) 
 1 IgM seropositive in paired samples (ELISA) 
 44 IgM positive in single serum (ELISA) 
 15 positive on NS1 on RDT in single serum 
 1 positive on IgM of RDT (IgG sero-positive in paired 
samples) 
Completed Visit 2 (Collection of 
the convalescent sample and 
clinical data on CRF) 
Completed Visit 1 only 
282 patients  231 patients 
 
Declined to 
participate: 
70 patients  
Agreed to participate: 
514 patients enrolled and completed visit 1 (acute 
blood sample collection and data collection on CRF) 
 
- CPGH: 259; Tudor: 196; Ganjoni:59 
513 patients were tested with dengue RDT at enrollment 
 
Consent 
withdrawal: 
1 patient 
* positive on RDT 
and/or IgM/IgG 
ELISA, as well as a 
small no. of negative 
samples 
Figure 2 A chart of patient flow in the passive fever surveillance at the study facilities 
Notes: The chart shows the flow of patients from screening, enrollment to study 
participation, with determination of laboratory-based status of dengue infection, as well as 
how the analysis sample was reached.  
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Figure 3. Monthly distribution of the enrolled febrile patients and patients by dengue status 
as well as serotype distribution. 
 
 
 
Multytipic infections 
June 2016 - 1 DENV II and III  
Oct. 2016 - 1 DENV I and II  
Nov. 2016 - 4 DENV I and II 
      - 1 DENV I and III 
      - 1 DENV II and III 
 
Dec. 2016 - 1 DENV I and II  
Jan. 2017 - 1 DENV I, II, and III  
Mar. 2017 - 3 DENV II and IV 
 
Apr. 2017 - 1 DENV I and II 
- 1DENV II and III 
- 7 DENV II and IV 
May 2017 – 10 DENV II and IV 
 
Figure 3 Monthly distribution of the enrolled febrile patients by dengue-positivity as 
well as serotype distribution 
Notes: The figure has two parts: the upper part shows monthly distribution of dengue-
positive and non-dengue cases among the enrolled patients; and the lower part shows 
distribution of serotypes identified (numbers shown in the bars) by month.   
Chapter 5. Clinical and epidemiologic characteristics 
associated with dengue during and outside the 2016 
outbreak identified in health facility-based surveillance in 
Ouagadougou, Burkina Faso 
 
  
J Lim PhD Thesis 119
T"T}Ffrru{}N$fiI'{{}t}t*/"
HY$tSr.{S
stn\()pl{Rt
IvT$I}I{:INE
Lcndwr* $nhms)$ *f $'lyg'i*rtx & Trnpin*lN'd,h$ne
t{npwwl $trM. LCIndsn \sd'*'}"F ?HT
T: +{4 {$}g$ 739$S{S
F:+aa{S}t$79$SqS'sS
www;*shtm*ac"uk
RESEARCH PAPER COVER SHEET
please note that a cover sheet must be completed @h research paper included within a thesis.
SECTION A - Student D€taG
Student lD Number LSH1 405874 Title Ms.
First Name(s) Jacqueline Kyungah
Surname/Family Name LIM
Thesis Title Undocumented burden of dengue in Africa
Primary Supervisor Prof. Neal Alexander
lf the Research Paper has previously been published please complete Section B, if not please move
to Section C.
SECTION B - Paper alreadv published
Where was the work published?
When was the work published?
lf the work was published prior to
registration for your research degree,
give a brief rationale for its inclusion
Have you retained the copyright for the
work?*
Choose an
ifem"
Was the work subject
to academic peer
review?
Choose att item"
*lf yes, please attach evidence of retention. lf no, or if the work is being included in its published format,
please attach evidence of permission from the copyright holder (publisher or other author) to include this
work.
SECTION C - Prepared for publication. but not vet published
Where is the work intended to be
published? The Journal of Infectious Diseases
Please list the paper's authors in the
intended authorship order:
Jacqueline K. Lim, Yaro Seydou, Mabel Carabali, Ahmed
Barro, Desire Dahourou, Kang Sung Lee, Teguewende
Nikiema, Suk Namkung, Jung Seok Lee, Mee Young Shin,
Emmanuel Bonnet, Therese Kagone, Losseni Kaba, Tansy
Edwards, Paul-Andr6 Som 6, Jae Seung Yang, Neal
Alexander, In-Kyu Yoon, Valdry Ridd.
lmproving health worldwide www.lshtm.ac.uk
J Lim PhD Thesis 120
For multi-authored work, give full details of
your role in the research included in the
paper and in the preparation of the paper.
(Attach a further sheet if necessary)
I am first author. I led the study design and co-
developed the protocol with Dr. Mabel Carabali. Some
site-specific details were added in collaboration with the
key investigators (Y Seydou and V Ridde, as the PI and
co-investigator, and M Carabali). I oversaw the ethical
approval process, supported study set-up, monitored
data collection, performed literature review, performed
data cleaning, and conducted statistical analysis
including generating SAS code for analysis and all the
figures, except for Fig. I (by Emmanuel Bonnet, one of
co-authors). I wrote the first draft of the manuscript. I,
as the first author, led the process of manuscript
preparation, revision, and submission. M. Carabali also
supported ata and sample collection. Yaro Seydou and
Val6ry Ridde, as the PI and co-investigator, were
responsible for study set-up and execution in
Ouagadougou. Ahmed Barro, Desire Dahourou, Kang
Sung Lee, Teguewende Nikiema, Suk Namkung, Jung
Seok Lee, Losseni Kaba, and Paul-Andr6 Somd
provided support in setting up the study at the sites, in
sample and data collection, and data management and
analysis. Mee Young Shin, Therese Kagone, and Jae
Seung Yang performed laboratory work. Emmanuel
Bonnet provided support in data cleaning. Neal
Alexander and In-Kyu Yoon provided oversight and
guidance on the overall study design, project execution,
and specific methodologieS, €.9. epidemiology,
statistical, and virology and other laboratory methods.
Neal Alexander and Tansy Edwards oversaw statistical
analysis, and contributed to manuscript preparation.
Stage of publication Submitted
SECTION D - Multi-authored work
SEGTION E
Student Signature
Date
Supervisor Signature
t+ Ttl/q 2,o1
I mproving health worldwide Page 2 of 2 www,lshtm.ac.uk
23 June 2019
J Lim PhD Thesis 121
122 
J Lim PhD Thesis 
Target journal: JID 
Title: Clinical and epidemiologic characteristics associated with dengue during and outside 
the 2016 outbreak identified in health facility-based surveillance in Ouagadougou, Burkina 
Faso 
Short title: Dengue outbreak in 2016 in Burkina Faso   
 
Jacqueline K. Lim1 2*, Yaro Seydou3,, Mabel Carabali1 4, Ahmed Barro5, Desire Dahourou3 6, 
Kang Sung Lee1, Teguewende Nikiema3, Suk Namkung1, Jung-Seok Lee1, Mee Young 
Shin1, Emmanuel Bonnet7, Therese Kagone3, Losseni Kaba8, Tansy Edwards 2, Paul-André 
Somé5, Jae Seung Yang1, Neal Alexander 2, In-Kyu Yoon1, Valéry Ridde7 9 
 
Author affiliation  
1International Vaccine Institute, Seoul, Korea, Republic of; 2Faculty of Epidemiology and 
Population Health, London School of Hygiene and Tropical Medicine; 3Centre MURAZ, 
Bobo-Dioulasso, Burkina Faso; 4McGill University, Montreal, Quebec Canada; 5Action-
Gouvernance-Integration-Renforcement (AGIR), Program Equité, Ouagadougou, Burkina 
Faso; 6Institut de Recherché en Sciences de la Santé, Ouagadougou, Burkina Faso; 
7Institute for Research on Sustainable Development (IRD), CEPED, Université de Paris, 
ERL INSERM SAGESUD; 8Centre National de Transfusion Sanguine, Ouagadougou, 
Burkina Faso; 9University of Montreal Public Health Research Institute (IRSPUM), Montreal, 
Canada 
 
*Corresponding author 
Jacqueline K. Lim1 2* 
Research Scientist 
Global Dengue and Aedes-transmitted Diseases Consortium (GDAC) 
International Vaccine Institute (IVI) 
SNU Research Park, Gwankak-ro 1 
Gwanak-gu, Seoul, Korea 151-191 
T: +82-2-881-1340 (Dir) / +82-2-872-2801 (ext. 340) 
Email: kalim@ivi.int 
 
28 pages (not counting figures)  
123 
J Lim PhD Thesis 
Word count of the text: 3652 (not counting the Abstract and tables) 
Word count of the abstract: 161 
Figures and tables: 5 figures and 4 tables  
 
Abbreviations: AGIR, Action-Gouvernance-Integration-Renforcement; CI, Confidence 
Interval; CSPS, Centre de Santé et de Promotion Sociale (Health and Social Promotion 
Center); °C, Celsius degrees; CRF, Case Report Form;  DENV, Dengue Virus;  DF, 
Dengue Fever; DHF, Dengue Hemorrhagic Fever; DSS, Dengue Shock Syndrome; DVI, 
Dengue Vaccine Initiative; ELISA, Enzyme-Linked Immunosorbent Assay; ICF, Informed 
Consent Form; IgM/IgG, Immunoglobulin type M and type G; IRB, Institutional Review 
Board; IRD, Institute for Research on Sustainable Development; IVI, International Vaccine 
Institute; LRTI, lower Respiratory Tract Illness; MoH, Ministry of Health; NPV, Negative 
Predictive Value; PPV, Positive Predictive Value; RDT, Rapid Diagnostic Test; RT-PCR, 
Reverse Transcriptase-Polymerase Chain Reaction; URI, Upper Respiratory Illness; WBC, 
White Blood Cell; YF, Yellow fever  
    
124 
J Lim PhD Thesis 
Conflict of interest statement: I certify that the authors do not have any relevant financial 
relationships or potential conflicts of interest to disclose regarding the material discussed in 
this manuscript. 
 
Financial disclosure: This study was supported by funding from the Bill and Melinda Gates 
Foundation (grant #: OPP 1053432), as well as from the governments of Sweden, India, 
and the Republic of Korea. This research project was part of the “Community research 
studies and interventions for health equity in Burkina Faso” program funded by the 
Canadian Institutes of Health Research (ROH-115213). 
NA and TE were supported by award MR/R010161/1, which is jointly funded by the UK 
Medical Research Council (MRC) and the UK Department for International Development 
(DFID) under the MRC/DFID Concordat agreement and is also part of the EDCTP2 
programme supported by the European Union.  
The funders had no role in study design, data collection and analysis, decision to publish, or 
preparation of the manuscript.  
 
Contributor’s statement: All persons designated as authors have participated sufficiently in 
the work to take public responsibility for appropriate portions of the content. And all the 
authors contributed in some or all areas of acquisition of funding, conception of the study, 
collection of data, analysis and interpretation of data, drafting the article, article revision, 
scientific support, and final approval of the version to be published. The authors meet the 
criteria for authorship and qualify for authorship of this manuscript. 
125 
J Lim PhD Thesis 
Abstract 
Background: In Africa, the magnitude of dengue transmission is largely unknown. 
Methods: To better understand dengue epidemiology and clinical characteristics in Burkina 
Faso, a fever surveillance study was conducted among patients aged 1-55 years, who 
presented with non-malarial febrile illness at five primary healthcare facilities in 
Ouagadougou, Burkina Faso from December 2014 to February 2017, encompassing a 3-
month dengue outbreak in 2016.  
Results: Among 2929 patients tested with dengue RDT, RT-PCR, and IgM/IgG ELISA, 740 
(25%) were dengue–positive; 55% and 14% were dengue-positive during outbreak and 
non-outbreak periods, respectively. DENV2 predominated during the outbreak, whereas 
DENV3 predominated before the outbreak. Only 25% of dengue-positive cases were 
clinically diagnosed with suspected dengue. Dengue-positive cases were 11 times more 
likely than non-dengue cases to require observation for ≤3 days (versus routine outpatient 
care).  
Conclusion: Dengue is an important pathogen in Burkina Faso, accounting for a substantial 
proportion of non-malarial fevers both during and outside outbreak, but is only infrequently 
suspected by clinicians. 
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Author summary: 
There is not much evidence on dengue in Africa, relative to the Asia-Pacific and Latin 
American regions. To estimate the proportion of dengue among patients with fever, and to 
identify clinical features of dengue during outbreak and non-outbreak periods, we studied 
2929 patients with non-malarial fever, aged 1-55 years, who attended five primary 
healthcare centers in Ouagadougou, Burkina Faso. Patients were tested with a rapid test 
for dengue, and further tests were carried out on paired blood samples taken 10-21 days 
apart. Overall, a quarter of non-malarial febrile episodes identified between December 2014 
and February 2017 were dengue-positive. Dengue-positive cases were 11 times more likely 
than non-dengue cases to require observation for ≤3 days. During the study period in 2016, 
there was a dengue outbreak where more than half of non-malarial febrile patients were 
identified to be dengue-positive. DENV2 was the main serotype in circulation during the 
outbreak, whereas DENV3 was the main serotype before the outbreak. There was a low 
level of clinical suspicion of dengue even during the 2016 outbreak, broader use of RDTs 
and more epidemiologic data would help to improve dengue case detection and 
surveillance in Burkina Faso.  
 
Keywords: Dengue, surveillance, outbreak, Burkina Faso, Africa 
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Introduction 
Dengue Fever (DF) is a mosquito-borne disease caused by four related but 
antigenically distinct dengue viruses (DENVs, serotypes 1–4). Approximately 50 to 100 
million cases of DF and 500,000 severe dengue cases requiring hospitalization reportedly 
occur annually worldwide (1-3).  
The Aedes mosquito vectors of DENV are widely distributed in Africa, and dengue 
cases have been reported in 34 African countries (4-6). However, data are limited to 
retrospective testing of existing samples or outbreak investigations from a few countries (5, 
7-9). Several studies have identified DENV as a common cause of febrile illness in Africa, 
but there is a continued challenge to distinguish dengue from other causes of febrile illness 
given limited diagnostic capabilities (10-12). 
In Burkina Faso, several outbreaks have been reported since 1925 (5, 13, 14), 
including an outbreak declared in November 2013 by the Burkina Faso Ministry of Health 
(MoH) (11, 15). Between 5 August and 12 November 2016, the Burkina Faso MoH 
conducted an outbreak investigation as part of emergency response in collaboration with 
WHO and 1266 suspected dengue cases were identified by the MoH, with 1061 cases 
positive by dengue RDT, and 15 deaths from all 12 districts of Ouagadougou (16, 17). Most 
recently, an even larger outbreak occurred in September 2017, with 9029 suspected 
dengue cases, 5773 dengue RDT-positive cases, and 18 deaths throughout the country 
(18). These repeated outbreaks suggest a considerable dengue burden in Burkina Faso. 
Most African countries lack mandatory reporting or national surveillance systems for 
dengue (19). Burkina Faso added dengue to its routine national surveillance system for 
potential epidemic diseases in 2016. Also, the MoH conducts outbreak investigations at 
several sentinel health centers (11). 
To better understand the dengue problem in Burkina Faso (11), a passive facility-
based fever surveillance study was conducted in Ouagadougou, from 2014-2017. During 
the study period, the 2016 dengue outbreak occurred, allowing for: 1) characterization of 
dengue epidemiology and; 2) comparison of clinical features during and outside the 
outbreak.  
 
Methods 
Study area and population 
The study area was selected based on the existence of previous outbreaks and 
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case reports, past seroprevalence and modelling studies, as well as the availability of 
research infrastructure (4, 20, 21). Ouagadougou is the capital city of Burkina Faso in West 
Africa with most of its population residing in urban settings (22). The hot season occurs in 
March-May with temperatures reaching 43 °C, followed by the rainy season in May-
September. Health services in Ouagadougou are provided by three university hospitals, five 
district hospitals, and 60 primary healthcare centers (CSPS, Centres de Santé et de 
Promotion Sociale), as well as private clinics (23).   
The current study was implemented in five CSPSs (Pazani, CSPS22, CSPS25, 
Juvenat Fille, Zongo), serving a catchment population of 110,000 residents (Fig. 1). The 
population in Ouagadougou is stable with an annual transmigration rate of 4.1% and >80% 
with home ownership (24).  
 
Study design 
The passive facility-based fever surveillance study enrolled outpatients and 
observation patients (for ≤3 days), as previously described (20), between December 2014 
and February 2017 (27 months). Patients presenting with fever (body temperature ≥ 37.5º C) 
or history of (self-reported) fever for ≤7 days were tested for malaria using RDT 
(SD BIOLINE Malaria kit, Standard Diagnostics, Yongin-Si, Korea) as part of routine 
practice. Patients were eligible for study enrolment if they were malaria RDT-negative 
without localizing signs (i.e., no localized infection or known/confirmed non-dengue 
etiology), aged 1-55 years, resident of the catchment area covered by the study CSPSs, 
and provided informed consent, plus assent for individuals aged 8-17 years. 
Malaria RDT-negative patients were tested using dengue RDTs. During the 
enrollment visit, an acute blood sample (7-10 ml) was collected (Fig. 2). Then, a study 
physician/nurse conducted interviews and physical exams, and a surveillance case report 
form was completed capturing symptom history, medical history, treatment and laboratory 
results (20). A convalescent blood sample was collected at the facility between 10-14 days 
after the initial visit, or if not possible within this timeframe, the patient was followed up at 
home within 21 days. 
 
Laboratory Testing Algorithm  
As described previously (20), acute samples were tested at enrollment at the CSPS 
using a commercial RDT for dengue NS1 and IgM/IgG (Dengue Duo® , Standard 
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Diagnostics, Yongin-Si, Korea). The acute and convalescent sera were subsequently tested 
at the Centre Muraz laboratory using dengue IgM/IgG ELISA (SD Dengue IgM & IgG 
Capture ELISA® , Standard Diagnostics, Yongin-Si, Korea). Furthermore, RT-PCR was 
performed at IVI on acute sera from patients who had (25): (i) NS1 or IgM positive by RDT 
in the acute sample; and/or (ii) sero-conversion between acute and convalescent samples 
by IgM and IgG capture ELISA. RT-PCR was also performed on a limited number of 
randomly selected acute sera that were: (iii) sero-positive in both acute and convalescent 
samples by IgM and IgG capture ELISA; or (iv) IgG positive by RDT in the acute sample; or 
(v) negative by RDT and ELISA on all samples.  
Dengue infection status was categorized based on interpretation of laboratory 
results, following WHO diagnostic criteria (26). Sero-conversion by dengue IgM and/or IgG 
between acute and convalescent samples and/or virus detection by RT-PCR in the acute 
sample were considered to be laboratory-confirmed dengue. Positive IgM by ELISA in a 
single acute sample or paired acute/convalescent samples, or NS1 and/or IgM positive by 
RDT were considered as probable dengue (26). Confirmed and probable dengue cases 
were combined into a dengue-positive group for this analysis. Patients with negative RT-
PCR and negative paired acute/convalescent IgM ELISA were classified as non-dengue. 
 
Statistical analysis 
There were 2 components in the analysis. First, a descriptive summary of clinical 
and laboratory characteristics is presented for dengue-positive and non-dengue cases. 
Elevated body temperature, as a dichotomous variable, was defined as body temperature 
≥38.5°C, the 75th percentile of the body temperature measured at enrollment. Clinical 
diagnosis (i.e., made by clinician prior to laboratory confirmation) was grouped as 
suspected dengue, undifferentiated fever, and other illness. Our surveillance covered the 
entire outbreak from September to November 2016. Cases were also designated as 
outbreak or non-outbreak depending on date of occurrence, with outbreak cases 
considered as those occurring between September and November 2016, defined to be 
consistent with the outbreak period declared by Burkina Faso MoH/WHO (16, 17). Yellow 
fever (YF) vaccination history was dichotomized between those who reported having been 
vaccinated versus those who did not remember or reported no vaccination. Categorical 
pair-wise comparisons were made across dengue infection status using χ2 or Fisher’s exact 
tests with significance level of 0.05. Continuous variables were compared using Student’s t-
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test or ANOVA. 
Secondly, based on our a priori hypothesis that clinical presentation associated with 
dengue-positivity would be different between the outbreak and non-outbreak periods, 
logistic regression was used to build a multivariable model of clinical indicators associated 
with dengue-positive vs. non-dengue cases, to separately fit the outbreak and non-outbreak 
periods. The models contained age and gender as a priori confounders, possibly 
associated with exposure to Aedes vectors, and with some clinical features (27). A 
backward stepwise process was used to select a final multivariable model for each 
outbreak status, with a significance level of 0.2 for entry and 0.1 for retention. Further 
variables investigated included: demographic and clinical variables such as YF vaccination 
history, requirement for observation, fever duration prior to enrollment, temperature at 
presentation, and clinical signs/symptoms. Some signs and symptoms were used only in 
the descriptive and univariate analyses, due to data sparsity. Clinical diagnosis of 
suspected dengue was considered to be closely related to dengue-positivity and was not 
included.  
Finally, a single set of variables was obtained as the union of the sets of variables 
from regression modelling in the outbreak and non-outbreak periods. Variables found to be 
significant in only one period were applied to both periods, producing a single list of 
variables. These variables were fitted to both outbreak and non-outbreak periods to give 
comparable results between them.  
As part of sensitivity analysis, a descriptive summary of clinical and laboratory 
characteristics using three categories for dengue infection status — confirmed, probable, 
and non-dengue — is presented in supplementary S2 table. Between dengue-confirmed 
and non-dengue groups, univariate logistic analyses were conducted for during and outside 
the outbreak (S3 and S4 tables). All analyses were performed using SAS®  version 9.4 
(SAS Institute, Cary, North Carolina).  
 
Ethical considerations 
The study protocol received ethical approvals from the Institutional Review Boards 
(IRBs) of IVI, the London School of Hygiene and Tropical Medicine, the National Ethical 
Committee for Health Research of Burkina Faso, and the Ethics Committee of the Centre 
Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal.  
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Results  
Analysis was performed on 2929 out of 3012 enrolled patients with complete clinical 
and laboratory data; 83 withdrew consent or had incomplete laboratory data to determine 
dengue infection status (Fig 3). Although similar in terms of age, gender, requirement for 
observation, and days of illness before enrollment, these 83 patients were significantly 
different from the analysis sample in terms of residential neighborhood — the majority from 
Zongo (40%) and Pazani (28%) — and being mostly from non-outbreak periods (87%). In 
terms of missing data, only the patients requiring observation had information on the 
complete blood count (CBC) test and the results from CBC were not included in the 
analysis.  
 
Clinical characteristics between dengue-positive and non-dengue cases 
Table 1 describes demographic and clinical characteristics of dengue-positive vs. 
non-dengue cases. Of 2929 analyzed patients, 2189 (74.7%) were non-dengue and 740 
(25.3%) were dengue-positive. Of the 740 dengue-positive patients, 540 were laboratory-
confirmed and 200 were probable dengue. Of the dengue-positive cases, 42% (n=317) 
were confirmed by PCR and the remainder by paired ELISA (Fig. 3). A small peak in 
dengue-positive cases was observed in October-December 2015. A much larger peak 
occurred in August-December 2016 (Fig. 4). Both peaks occurred at the end or after the 
May-September rainy season. Of 777 fever cases from the outbreak, 55.1% (n=428) were 
dengue-positive, with DENV2 predominating. Of 2152 non-outbreak fever cases, 14.5% 
(n=312) were dengue-positive, mostly with DENV3 and a few DENV1. 
 
Table 1. Demographic and clinical characteristics of dengue-positive and non-dengue cases 
in the facility-based fever surveillance established in Ouagadougou, Burkina Faso, between 
December 2014 and February 2017 
Characteristics Dengue-
positive 
 (n=740) 
Non-dengue 
(n=2189) 
Total 
(n=2929) 
p-value 
Age group (years)    <.001 
1-4 37 (5.0) 275 (12.6) 312 (10.7)  
5-9 43 (5.8) 149 (6.8) 192 (6.6)  
10-14 45 (6.1) 129 (5.9) 174 (5.9)  
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15-19 85 (11.5) 231 (10.6) 316 (10.8)  
20-24 110 (14.9) 366 (16.7) 476 (16.3)  
25-29 134 (18.1) 375 (17.1) 509 (17.4)  
30-34 94 (12.7) 269 (12.3) 363 (12.4)  
35-39 71 (9.6) 155 (7.1) 226 (7.7)  
40-44 57 (7.7) 111 (5.1) 168 (5.7)  
45-49 33 (4.5) 67 (3.1) 100 (3.4)  
50-55 31 (4.2) 62 (2.8) 93 (3.2)  
Female 465 (62.8) 1563 (71.4) 2028 (69.2) <.001 
CSPS    <.001 
Pazani 113 (15.3) 400 (18.3) 513 (17.5)  
Zongo 91 (12.3) 592 (27.0) 683 (23.3)  
CSPS22 65 (8.8) 240 (11.0) 305 (10.4)  
CSPS25 266 (36.0) 502 (22.9) 768 (26.2)  
   Juvenat Fille 205 (27.7) 446 (20.4) 651 (22.2)  
Under observation ≤3 
days/OPD 
135 
(18.2)/605 
(81.8) 
45 (2.1)/2144 
(97.9) 
180 
(6.2)/2749 
(93.9) 
<.001 
Mean days, fever duration 
prior to visit (SD) 
2.92 (1.21) 2.61 (1.22) 2.69 (1.23) <.001 
Fever duration prior to 
visit 
   <.001 
   1-2 days 301 (40.7) 1153 (52.7) 1454 (49.6)  
   3 days 238 (32.2) 634 (29.0) 872 (29.8)  
   4-7 days 201 (27.2) 400 (18.4) 603 (20.6)  
Mean temperature at 
enrollment (SD) 
38.29 (0.77) 38.03 (0.78) 38.09 (0.78) <.001 
Temperature at enrollment     <.001 
   Below 38.5°c 478 (64.6) 1681 (76.8) 2159 (73.7)  
   ≥ 38.5°c 262 (35.4) 508 (23.2) 770 (26.3)  
Mean days, fever 
duration, entire illness 
(SD) 
4.72 (2.52) 4.04 (2.46) 4.21 (2.49) <.001 
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Prev. dengue infection 14 (1.9) 2 (0.1) 16 (0.6) <.001 
YF vaccination    <.001 
   Received 122 (16.5) 824 (37.6) 946 (32.3)  
   Not received 618 (83.5) 1365 (62.4) 1983 (67.7)  
Clinical diagnosis     
   Suspected dengue 187 (25.3) 12 (0.6) 199 (6.8) <.001 
   Undifferentiated fever 529 (71.5) 1987 (90.8) 2516 (85.9)  
   Other illness 24 (3.2) 190 (8.7) 214 (7.3)  
     URI (% of other 
illness) 
5 (20.8)  27 (14.2) 32 (15.0)  
     Bronchitis 4 (16.7) 30 (15.8) 34 (15.9)  
     Pneumonia 6 (25.0) 21 (11.1) 27 (12.6)  
     Viral syndrome 3 (12.5) 11 (5.8) 14 (6.5)  
     Diarrheal illness 2 (8.3) 28 (14.7) 30 (14.0)  
     Influenza 1 (4.2) 4 (2.1) 5 (2.3)  
     Others 3 (12.5) 69 (36.3) 72 (33.6)  
Signs and symptoms 
(presence) 
    
     Rash 95 (12.8) 163 (7.5) 258 (8.8) <.001 
     Fatigue 603 (81.5) 1526 (69.7) 2129 (72.7) <.001 
     Headache   708 (95.7) 1899 (86.8) 2607 (89.0) <.001 
     Retro-orbital pain 131 (17.7) 107 (4.9) 238 (8.1) <.001 
     Neck pain 13 (1.8) 47 (2.2) 60 (2.1) 0.517 
     Ear pain 2 (0.3) 10 (0.5) 12 (0.4) 0.741 
     Nasal congestion 20 (2.7) 105 (4.8) 125 (4.3) 0.015 
     Rhinorrhea 30 (4.1) 132 (6.0) 162 (5.5) 0.042 
     Sore Throat  11 (1.5) 64 (2.9) 75 (2.6) 0.032 
     Cough 91 (12.3) 354 (16.2) 445 (15.2) 0.011 
     Sputum production   4 (0.5) 30 (1.4) 34 (1.2) 0.075 
     Nausea & vomiting 270 (36.5) 635 (29.0) 905 (30.9) <.001 
     Diarrhea  23 (3.1) 128 (5.9) 151 (5.2) 0.004 
     Constipation 12 (1.6) 85 (3.9) 97 (3.3) 0.003 
     Abdominal pain 271 (36.6) 639 (29.2) 910 (31.1) <.001 
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     Nose bleeding 7 (1.0) 10 (0.5) 17 (0.6) 0.130 
     Gum bleeding 5 (0.7) 2 (0.1) 7 (0.2) 0.013 
     Loss of appetite 331 (44.7) 739 (33.8) 1070 (36.5) <.001 
     Capillary refill >2 sec 8 (1.1) 19 (0.9) 27 (0.9) 0.600 
     Myalgia   319 (43.1) 560 (25.6) 879 (30.0) <.001 
     Arthralgia   426 (57.6) 953 (43.5) 1379 (47.1) <.001 
 
Overall, dengue-positive cases were older than non-dengue cases (Table 1). Among 
dengue-positive cases, those after the 2016 outbreak were younger than those before or 
during the outbreak (about 75% <30 years old, compared to before and during the outbreak 
with about 50% <30 years) (Fig. 5); the age difference before, during and after the outbreak 
was statistically significant (ANOVA, p-value<.001).  
There were 180 patients requiring observation at the CSPS. Patients later 
determined to be dengue-positive were more likely, on presentation, to require observation: 
18% of dengue-positive cases versus 2% of non-dengue cases (Table 1). A small but 
significant difference was observed in average time between fever onset and enrollment for 
dengue-positive versus non-dengue cases (2.9 days vs. 2.6 days, p <.001). Likewise, the 
entire duration of fever illness on average was significantly longer for dengue-positive cases 
(mean 4.7 versus 4.0 days, among the 2926 patients with such data, p <.001). Dengue-
positive cases were half as likely to self-report that they had been vaccinated for YF (17%, 
versus 38% for non-dengue cases, p <.001).  
Of 2929 available RDT results, 11% (316/2929) and 4% (129/2929) were positive for 
NS1 and IgM, on the RDT kit, respectively (Fig. 1). There were 38 patients with positive 
results for both NS1 and IgM on the RDT. During the outbreak period, 86% (271/316) were 
NS-1 positive and 40% (52/129) were IgM positive (28 showing positive on both NS1 and 
IgM).   
Only 25% of dengue-positive cases were clinically diagnosed with suspected 
dengue, prior to lab-confirmation, and more than 90% of non-dengue cases were clinically 
diagnosed with undifferentiated fever. During the outbreak, 31.3% (131/428) of dengue-
positive cases were diagnosed with suspected dengue, while 17.0% (53/312) were 
diagnosed with suspected dengue during non-outbreak periods.  
 
Clinical features associated with dengue during and outside the 2016 outbreak 
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Demographic and clinical associations with dengue-positivity are shown in Table 2 for the 
outbreak and in Table 3 for non-outbreak periods. During the outbreak, independently 
associated symptoms were: rash, retro-orbital pain, cough, headache, nausea/vomiting, 
and loss of appetite. During non-outbreak periods, retro-orbital pain, headache, 
nausea/vomiting, and constipation were independently associated. In addition to the 
symptoms, the multivariable model selected requirement for observation and lack of YF 
vaccination to be associated with dengue-positivity in both outbreak and non-outbreak 
periods. Age in non-outbreak periods and, gender, elevated temperature at enrollment, and 
fever duration prior to enrollment in the outbreak period were also selected. Age and gender 
were a priori confounders and were significantly associated with dengue. Enrolled CSPS 
may be a proxy for otherwise any unexplained variation across centers, but was not 
selected for either of the outbreak or non-outbreak periods. In the absence of observation of 
variation with respect to dengue-positivity, it was not entered in the models.  
 
 
Table 2. Univariate logistic analyses showing significant indicators and their odds ratios of 
dengue-positivity during the outbreak period, from the facility-based fever surveillance 
established in Ouagadougou, Burkina Faso, between December 2014 and February 2017 
Characteristics During outbreak (n= 777) 
Total 
N 
N (%) 
dengue-
positive 
(n=428) 
N (%)  
Non- 
dengue 
(n=349) 
Univariate analysis 
Dengue-positive vs. non-
dengue  
OR  95% CI  p-
Value  
Age group (years)      0.195 
   1-14 129 63 (48.8) 66 (51.2) Ref -  
   15-24 213 121 (56.8) 92 (43.2) 1.38 0.89-2.14  
   25-34 242 128 (52.9) 114 (47.1) 1.18 0.77-1.80  
   35-55 193 116 (60.1) 77 (39.9) 1.58 1.01-2.47  
Gender*      0.004 
   Male 293 181 (61.8) 112 (38.2) Ref -  
   Female  484 247 (51.0) 237 (49.0) 0.65 0.48-0.87  
Under observation** (ref. 128 110 (85.9) 18 (14.1) 6.36 3.77-10.71 <.001 
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Statistical significance of the frequencies: *p-value<0.05 **p-value<.001 
†based on self-report 
 
OPD) 
Fever duration prior to 
visit* 
     0.007 
   1-2 days 330 168 (50.9) 162 (49.1) Ref -  
   3 days 244 129 (52.9) 115 (47.1) 1.08 0.78–1.51  
   4-7 days 203 131 (64.5) 72 (35.5) 1.75 1.23-2.51  
Temperature at 
enrollment*   
     0.009 
   Below 38.5°c 468 240 (51.3) 228 (48.7) Ref -  
   ≥ 38.5°c 309 188 (60.8) 121 (39.2) 1.48 1.10-1.98  
No YF vaccination†* (ref. 
received vaccination)  
630 363 (57.6) 267 (42.4) 1.72 1.19-2.46 0.004 
Presence of signs and 
symptoms (ref. absence) 
      
     Rash* 84 60 (71.4) 24 (28.6) 2.21 1.34–3.63 0.002 
     Fatigue* 620 353 (56.9) 267 (43.1) 1.45 1.02-2.05 0.040 
     Retro-orbital pain** 104 92 (88.5) 12 (11.5) 7.69 4.14-14.30 <.001 
     Headache* 749 420 (56.1) 329 (43.9) 3.19 1.39-7.33 0.006 
     Nasal congestion* 21 5 (23.8) 16 (76.2) 0.25 0.09-0.68 0.007 
     Rhinorrhea* 28 7 (25.0) 21 (75.0) 0.26 0.11-0.62 0.002 
     Neck pain 11 6 (54.6) 5 (45.5) 0.98 0.30-3.23 0.971 
     Sore throat 11 4 (36.4) 7 (63.6) 0.46 0.13-1.59 0.220 
     Cough** 81 28 (34.6) 53 (65.4) 0.39 0.24-0.63 <.001 
     Nausea & vomiting 285 154 (54.0) 131 (46.0) 0.94 0.70-1.25 0.655 
     Diarrhea 21 8 (38.1) 13 (61.9) 0.49 0.20-1.20 0.120 
     Abdominal pain 263 153 (58.2) 110 (41.8) 1.21 0.90-1.63 0.216 
     Loss of appetite 383 217 (56.7) 166 (43.3) 1.13 0.85-1.50 0.385 
     Myalgia** 366 227 (62.0) 139 (38.0) 1.71 1.28-2.27 <.001 
     Arthralgia 521 295 (56.6) 226 (43.4) 1.21 0.89-1.63 0.219 
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Table 3. Univariate logistic analyses showing significant indicators and their odds ratios of 
dengue-positivity during non-outbreak periods, from the facility-based fever surveillance 
established in Ouagadougou, Burkina Faso, between December 2014 and February 2017 
Characteristics During non-outbreak (n=2152) 
Tota
l N 
N (%) 
dengue-
positive 
(n=312) 
N (%)  
Non- 
dengue 
(n=1840) 
Univariate analysis 
Dengue-positive vs. non-
dengue  
OR  95% CI  p-
Value  
Age group (years)*      0.003 
   1-14 549 62 (11.3) 487 (88.7) Ref -  
   15-24 579 74 (12.8) 505 (87.2) 1.15 0.80-1.65  
   25-34 630 100 (15.9) 530 (84.1) 1.48 1.06-2.08  
   35-55 394 76 (19.3) 318 (80.7) 1.88 1.31-2.70  
Gender       
   Male 608 94 (15.5) 514 (84.5) Ref -  
   Female  154
4 
218 (14.1) 1326 
(85.9) 
0.90 0.69-1.17 0.426 
Under observation** (ref. 
OPD) 
52 25 (48.1) 27 (51.9) 5.85 3.35-10.22 <.001 
Fever duration prior to 
visit* 
     0.001 
   1-2 days 112
4 
133 (11.8) 991 (88.2) Ref -  
   3 days 628 109 (17.4) 519 (82.6) 1.57 1.19-2.06  
   4-7 days 400 70 (17.5) 330 (82.5) 1.58 1.15-2.17  
Temperature at enrollment       0.285 
   Below 38.5°c 169
1 
238 (14.1) 1453 
(85.9) 
Ref -  
   ≥ 38.5°c 461 74 (16.1) 387 (84.0) 1.17 0.88-1.55  
No YF vaccination†** (ref. 
received vaccination)  
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225 (18.9) 1098 
(81.2) 
3.02 2.24-4.09 <.001 
Presence of signs and       
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Statistical significance of the frequencies: *p-value<0.05 **p-value<.001 
†based on self-report 
 
Table 4 shows the final set of variables. During both outbreak and non-outbreak 
periods, dengue-positive patients had increased odds of presenting with rash [outbreak: 2.6 
(95%CI=1.5-4.6); non-outbreak: 1.5 (95%CI=1.0-2.4)] and retro-orbital pain [outbreak: 7.4 
(95%CI= 3.7-14.7); non-outbreak: 1.4 (95%CI=1.01-1.8)].  
  
symptoms (ref. absence) 
     Rash* 174 35 (20.1) 139 (79.9) 1.55 1.05-2.29 0.029 
     Fatigue** 150
9 
250 (16.6) 1259 
(83.4) 
1.86 1.39-2.50 <.001 
     Retro-orbital pain** 134 39 (29.1) 95 (70.9) 2.62 1.77-3.89 <.001 
     Headache** 185
8 
288 (15.5) 1570 
(84.5) 
2.06 1.33-3.19 0.001 
     Nasal congestion 104 15 (14.4) 89 (85.6) 0.99 0.57-1.74 0.982 
     Rhinorrhea 134 23 (17.2) 111 (82.8) 1.24 0.78-1.98 0.366 
     Neck pain 49 7 (14.3) 42 (85.7) 0.98 0.44-2.21 0.966 
     Sore throat 64 7 (10.9) 57 (89.1) 0.72 0.33-1.59 0.414 
     Cough 364 63 (17.3) 301 (82.7) 1.29 0.96-1.75 0.096 
     Nausea & vomiting** 620 116 (18.7) 504 (81.3) 1.57 1.22-2.02 <.001 
     Diarrhea  130 15 (11.5) 115 (88.5) 0.76 0.44-1.32 0.325 
     Abdominal pain* 647 118 (18.2) 529 (81.8) 1.51 1.17-1.94 0.001 
     Loss of appetite 687 114 (16.6) 573 (83.4) 1.27 0.99-1.64 0.059 
     Myalgia* 513 92 (29.5) 421 (82.1) 1.41 1.08-1.84 0.012 
     Arthralgia   858 131 (15.3) 727 (84.7) 1.11 0.87-1.41 0.409 
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Table 4. Multivariate logistic analysis showing significant indicators and their odds ratios of dengue-positivity by outbreak or non-
outbreak periods, in the facility-based fever surveillance established in Ouagadougou, Burkina Faso, between December 2014 and 
February 2017 
Characteristics Multivariate analysis 
During outbreak (n=777)  
ref. non-dengue (n=349) 
During non-outbreak (n=2152)  
ref. non-dengue (n=1840) 
Dengue-positive 
(n=428) 
p-Value Dengue-positive 
(n=312) 
p-
Value 
aOR  95% CI  aOR  95% CI  
Female (ref. Male) 0.63 0.45-0.89 0.008 0.98 0.73-1.30 0.869 
Age (years)   0.612   0.041 
   1-14 Ref   Ref   
   15-24 1.23 0.73-2.06  1.18 0.80-1.75  
   25-34 0.99 0.59-1.64  1.45 0.98-2.14  
   35-55 1.24 0.73-2.09  1.74 1.16-2.62  
Under observation ≤3 days (ref. OPD) 6.01 3.33-10.84 <.001 4.32 2.33-8.02 <.001 
No YF vaccination* (ref. received vaccination)   1.73 1.12-2.68 0.013 2.42 1.76-3.32 <.001 
Temperature at enrollment   0.015   0.752 
   Below 38.5°c Ref   Ref   
   ≥ 38.5°c 1.54 1.09-2.17  1.05 0.77-1.44  
Fever duration prior to visit   0.081   0.087 
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*based on self-report; aOR = adjusted odds ratio
   1-2 days Ref   Ref   
   3 days 0.93 0.62-1.41  1.40 1.04-1.89  
   4-7 days 1.53 0.97-2.43  1.25 0.87-1.80  
Presence of signs and symptoms (ref. absence)        
   Rash 2.59 1.46-4.59 0.001 1.54 1.00-2.37 0.049 
   Retro-orbital pain 7.37 3.69-14.71 <.001 1.42 0.90-2.25 0.134 
   Nausea & vomiting 0.75 0.52-1.08 0.117 1.36 1.01-1.82 0.042 
   Cough 0.36 0.21-0.63 <.001 1.21 0.87-1.69 0.248 
   Loss of appetite 0.46 0.30-0.71 <.001 0.93 0.69-1.27 0.659 
   Headache 2.28 0.93–5.62 0.072 1.43 0.90-2.29 0.130 
   Constipation 1.08 0.23-4.97 0.926 0.52 0.24-1.10 0,087 
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Discussion  
Recent reports of dengue outbreaks in Burkina Faso suggest substantial dengue 
transmission in this region. However, existing evidence on epidemiological characterization 
of dengue in Burkina Faso was limited in scope prior to this study. The current study 
collected population-based epidemiologic data in Ouagadougou during a 27-month period 
from 2014-2017, including all three months of the 2016 dengue outbreak. Our data 
demonstrated that dengue is an important cause of febrile illnesses, accounting for one-
quarter of non-malarial febrile illness in patients seeking care at CSPSs in the study. This 
proportion was very high (55%) during the outbreak itself, but even outside the outbreak, a 
considerable proportion (15%) of non-malarial febrile episodes was dengue-positive. Since 
then, Ouagadougou has experienced another, larger, dengue outbreak in 2017 (16, 18). 
Recent outbreaks and the current study indicate that dengue transmission is likely to be 
underestimated and underdiagnosed in Burkina Faso (16, 18).  
 
Differences between outbreak and non-outbreak periods 
The predominant DENV serotype identified from PCR-positive outbreak cases in the 
study was DENV2. This was consistent to the results of MoH/WHO investigation of the 
2016 outbreak where DENV2 was the predominant serotype (16, 17). DENV2 was also the 
dominant serotype detected in outbreaks in Burkina Faso in 1982 and 1983-1986 (9, 28). 
The study found DENV3 to be predominant during the non-outbreak period preceding the 
2016 outbreak. DENV3 was the dominant serotype in the 2013 outbreak in Burkina Faso 
(29). A change in predominant DENV serotype may have fueled the outbreak in 2016. 
Although the current study did not determine DENV strain, DENV2 strains reported from ill 
French travelers returning from Burkina Faso in November 2016 were nearly identical to a 
DENV2 strain detected in Burkina Faso in 1983. This suggests that the 2016 outbreak may 
have been due to an endemic strain of DENV2 circulating in Burkina Faso for 30 years, 
perhaps maintained partly through a sylvatic cycle (30). More detailed phylogenetic analysis 
of DENVs from the current study is planned. 
Only a quarter of dengue-positive cases received a clinical diagnosis of suspected 
dengue in this study, with this proportion being only slightly higher during the 2016 outbreak 
(31% of dengue cases were suspected clinically) compared to outside the outbreak (17%). 
In the routine care system, clinicians in the CSPS refer to a guideline issued by the Burkina 
Faso MoH (31), primarily based on the 2009 WHO dengue guidelines. The dengue RDTs 
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were made available at the CSPSs in the study, but the results of dengue RDT might not 
have contributed to the clinical assessment, if the results were not made available in time 
(dependent on patient volume and clinician availability). Dengue RDTs are typically 
unavailable for routine use in Africa; and many non-malaria febrile etiologies, including 
dengue, are likely to be under-diagnosed (12, 32). Clinicians in Burkina Faso may need to 
consider dengue more frequently as a clinical diagnosis, with or without point-of-care 
assays. 
Our multivariable analysis showed differing patterns of signs and symptoms 
associated with dengue-positivity during the outbreak period compared to non-outbreak 
periods. Rash was associated with dengue-positivity during both outbreak and non-
outbreak periods. Rash is a common sign for dengue and listed in dengue classification in 
both 1997 and 2009 WHO dengue guidelines (3, 33, 34). However, retro-orbital pain 
showed increased odds of dengue-positivity only during the outbreak. Retro-orbital pain, 
also listed in the 2009 WHO case definition, is another common sign associated with 
dengue-positivity (3, 33, 34). Also, it was suggested that ocular symptoms, including retro-
orbital pain, in dengue patients may possibly indicate thrombocytopenic state with 
increased likelihood of hemorrhage (35). In our data, dengue-positive patients with retro-
orbital pain were 5.8 times (95% C.I: 3.5 – 9.6, p<.001) more likely to require observation 
than dengue-positive patients without retro-orbital pain during the outbreak. During non-
outbreak, it also showed a similar pattern with statistical significance, but with a wide 
confidence interval. Therefore, further information is needed for validation. While 
hemorrhagic signs were not commonly reported in our data, requiring observation may 
indicate severity of dengue illness and retro-orbital pain being associated with dengue-
positive cases in the outbreak, but not outside the outbreak, may indicate likely severity of 
dengue illness during the outbreak.  
 
Epidemiologic characteristics of dengue in Ouagadougou 
Our data showed a high proportion of individuals 15-40 years of age among 
dengue-positive cases in the outbreak period (a mean age of 26.8 years in dengue-positive 
patients). This was also found in the outbreak investigation by the Burkina Faso MoH with 
WHO where 70% of affected people were 25 years and older, with a mean age of 30 years 
(16). It suggests that those in the labor force may be impacted, leading to significant 
economic and social burden (36).  
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In our data, the adjusted model showed that female sex was associated with 
decreased odds of dengue-positivity (OR=0.65, 95 C.I= 0.48-0.87) in the outbreak period. 
This finding was consistent to a finding of another study conducted in Burkina Faso in 2016 
where only 23% of cases were female (17) as well as other previous data reporting excess 
of reported male dengue cases among older adolescents and adults (27, 37). However, 
such pattern was to the contrary to the finding of the investigation conducted by MoH of the 
2016 outbreak. In the MoH investigation, women were more affected than men (16). There 
may have been differences in terms of gender ratio and demographic profile in the studied 
populations in previous reports. Thus, more assessment of gender differences for dengue 
incidence would be necessary to study biological or gender-related association for the risk 
of dengue in Africa (27).  
Adjusted for age and gender, our model found higher odds that dengue-positive 
cases required observation, compared to non-dengue, during both outbreak (6.0 times) and 
non-outbreak (4.3 times) periods. Given the substantial proportion of dengue-positive cases 
among non-malarial febrile illnesses, this suggests that dengue may account for greater 
utilization of healthcare resources in CSPSs than other etiologies, during both outbreak and 
non-outbreak periods. As in many other parts of Africa, these primary healthcare centers 
have limited resources, such as beds (38), and could be especially overextended during 
outbreaks. Since the study only enrolled patients at CSPSs, the burden on the healthcare 
system due to dengue inpatients is unclear. 
Self-reported YF vaccination was associated with increased odds of dengue-
positivity, suggesting predisposition of YF vaccinated individuals to develop symptomatic 
dengue (39). However, self-reporting may be unreliable due to recall bias, and the study 
could not confirm YF vaccination using patient records. 
 
Study limitations and strengths 
Dengue transmission can vary substantially over time and space. Hence, the 
generalizability of the current study is limited by enrollment from the five selected CSPSs in 
the capital during the 27-month study period. We would have missed those community 
residents with relevant symptoms seeking care elsewhere than study centers, including 
private providers. In addition, patients with severe illness would have not been enrolled 
since they would likely have sought care directly at inpatient facilities; and subclinical and 
mild DENV infections would also not have been detected. 
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The study surveillance excluded patients with malaria RDT positive results, 
localizing signs or known/confirmed diagnosis with other diseases, possibly omitting co-
infections of dengue with another pathogen. In particular, given the prevalence of malaria in 
this region, dengue and malaria co-infection may require further investigation. Nevertheless, 
the available information on co-infections suggests they are uncommon (9, 40-43).  
Performance of malaria RDTs, in terms of sensitivity, would depend on local 
conditions, especially the level of malaria transmission shown to be variable from reported 
incidence in Ouagadougou (44, 45). There could have been misclassification among non-
malarial patients (i.e. false negative results on malaria RDT included in the study being 
differently classified between dengue-positive and non-dengue groups). Also, this could 
vary by the level of dengue transmission (i.e. during and outside of the outbreak), leading to 
differential misclassification. 
Our findings were based on outpatients and patients requiring observation, and 
clinical characteristics may be different for hospitalized patients and individuals with 
subclinical infections. Also, such findings may depend on other co-circulating pathogens 
endemic in the area, however our study did not confirm etiologies of non-dengue cases. 
Therefore, further information on the etiologies of non-dengue febrile cases may be needed 
to verify which signs are useful in distinguishing non-dengue from dengue illnesses (46).  
In our analysis, laboratory-confirmed and probable dengue cases were combined 
into the dengue-positive group. There may be some limitations with probable dengue being 
not as certain as lab-confirmed dengue. However, we performed analysis using 3 
categories of dengue infection status (lab-confirmed-; probable-; and non-dengue) as part 
of sensitivity analysis and this yielded similar results (see S2-S4 tables). 
 
Conclusion 
Dengue is an important cause of non-malarial fever in Burkina Faso, both during 
and outside of outbreaks, despite being infrequently suspected by clinicians. Despite the 
many possible etiologies of febrile illness in this region, limited surveillance and diagnostic 
capacity will continue to pose challenges to dengue prevention and control. Additional 
longitudinal studies to better characterize dengue epidemiology and clinical presentation, 
including in inpatients and for subclinical/mild cases, along with encouraged use of dengue 
RDTs, would help to inform strategies to approach dengue countermeasures in this region.  
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Fig. 1 A map of the study area in Ouagadougou  
 
A map of the study area in Ouagadougou - The map shows the approximate location of the 
selected facilities of 5 CSPSs (Pazani, CSPS22, CSPS25, Juvenat Fille, Zongo), serving a 
catchment population of 110,000 residents of Ouagadougou, Burkina Faso. 
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Fig. 2 A chart of patient flow in passive fever surveillance  
  
A chart of patient flow in passive fever surveillance- The chart shows the study flow when a 
febrile patient presents at the CSPS. 
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Fig. 3 Flow chart of patient enrollment and lab testing of the samples 
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The chart shows the flow of patients from screening, enrollment to study participation, with 
the samples undergoing multiple stages of lab testing for determination of laboratory-based 
status of dengue infection, as well as how the analysis sample was reached. 
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Fig. 4. Monthly distribution of febrile enrollees, dengue-positive and non-dengue cases & 
monthly distribution of dengue serotypes* in PCR-positive cases 
 
*number of identified serotypes shown in the bars 
 
The figure has two parts: the upper part shows monthly distribution of dengue-positive and 
non-dengue cases among the enrolled patients; and the lower part shows distribution of 
serotypes identified (numbers shown in the bars) by month  
  
Outbreak in Sept.-Nov. 2016 
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Figure 5. Age distribution of dengue-positive cases before, during, and after the 2016 
outbreak  
 
The figure shows age distribution of dengue-positive cases, compared to non-dengue 
cases, before, during, and after the 2016 outbreak  
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Abstract 
Background: There is limited information on dengue burden in Burkina Faso. To 
understand the dynamic of dengue virus, we conducted repeated serological surveys 
and estimated seroprevalence and force of infection in Ouagadougou, Burkina Faso.   
 
Methods: Four consecutive age-stratified serological surveys, with an interval of six 
months covering the rainy period, were conducted among the same individuals aged 
between 1-55 years residing in Ouagadougou. To reflect the age distribution of the 
general population of the district, 80% of the serosurvey samples were from individuals 
< 35 years-of-age and 20% from adults between 35 and 55 years of age. The 
enrollment bleed (S1) took place in June 2015, and enrolled subjects were followed in 
subsequent serosurveys in Dec. 2015 (S2), May 2016 (S3), and in March 2017 (S4). 
The last two serosurveys covered the 2016 outbreak between September and 
November. All samples were tested with commercial Panbio Dengue IgG indirect ELISA. 
Lab results and basic demographic and clinical data were analyzed to determine 
antibody prevalence, and to calculate force of infection (FoI), the rate at which 
susceptible individuals become infected, based on sero-conversion between pre-and 
post-transmission paired sera. The sero-conversion rate up to the enrollment 
serosurvey was estimated by binomial regression, taking age as the duration of 
exposure, and assuming that this FoI had been constant over age and calendar time. 
Then, FoIs between consecutive surveys were estimated, with rate ratios for potential 
characteristics in association, including age, also being assessed.   
 
Results: Among 2897 at enrollment, 66.3% were IgG positive. At S2, 67.2% were IgG 
positive among 2387 subjects followed up. At S3, 2215 were followed up and 67.2% 
were IgG positive. At S4, 67.9% were IgG positive among 1681 subjects followed up. 
Based on initial seroprevalence, a previous FoI of 5.95% per year was estimated, 
assumed to be constant over age and calendar time. Of 1269 subjects who stayed in all 
4 serosurveys, 438 were IgG-negative at enrollment, with 107 sero-converting over the 
subsequent study period of almost two years. The annualized FoI was 14% over the 
rainy season in 2015; 10% over the non-rainy season of 2016; and 20% during the 
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outbreak in 2016. In those intervals covering the non-outbreak times, older age and self-
reported pre-existing conditions were associated with increased rate of sero-conversion. 
For the interval covering the 2016 outbreak, rates were similar across age.  
 
Conclusion: Overall, we observed a high level of seroprevalence and also high FoIs. 
The randomly sampled population-based follow-up design provides stronger evidence 
on DENV transmission in the studied community than previously available data on the 
seroprevalence and incidence of dengue in Burkina Faso. However, the results are 
subject to limitations of losses to follow-up, and possible cross-reaction of the IgG 
ELISA with other flaviviruses. The results could be used to facilitate informed decision-
making on implementation of control and preventive measures for dengue, such as 
vaccine introduction. Nonetheless, additional evaluation across the region would be 
necessary to assess the generalizability of our findings.  
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Introduction 
Dengue Fever (DF) is a mosquito-borne disease caused by four related but 
antigenically distinct dengue viruses (DENVs, serotypes 1–4). There has been a 
dramatic increase in the burden of dengue globally and DF with dengue hemorrhagic 
fever (DHF) are considered major causes of mortality and morbidity in tropical and sub-
tropical countries (1, 2). About 50 to 100 million cases of DF are reported to occur 
annually worldwide, with 500,000 severe dengue cases requiring hospitalization and 
20,000 deaths annually (3-6).  
Aedes mosquitoes and dengue cases were documented as early as 1823 in 
Africa and Ae. aegypti and Ae. albopictus are widely distributed in the continent (7-9). 
Amarasinghe et al. indicated that dengue cases have been reported in 34 countries in 
Africa (10). Previously, dengue was not recognized as an important etiology of non-
malarial febrile episode in Africa, but there are reports of repeated outbreaks and more 
studies demonstrate dengue to be a common viral infection (11-13). However, most of 
the data are from a few countries and studies are often not representative or population-
based, often limited to retrospective testing using existing samples or reports from 
outbreak investigations (10, 12, 14).  
There have been multiple outbreaks of DENV in Burkina Faso, the first being 
reported in 1925 (10). There was an outbreak declared by the Ministry of Health of 
Burkina Faso in November 2013, and, more recently, in 2016 and 2017 (15-18). The 
outbreak in 2016, between August and November, reported 1061 dengue RDT positive 
cases and 15 deaths from Ouagadougou (17, 19). The outbreak in September 2017 
was larger, with 9029 suspected dengue cases, 5773 dengue RDT-positive cases, and 
18 deaths throughout the country (18). These repeated outbreaks suggest a 
considerable dengue burden in Burkina Faso.  
Despite information from outbreaks, there are not many data available on dengue 
virus burden in Burkina Faso and Africa, in terms of seroprevalance and force of 
infection (FoI), the rate at which susceptible individuals become infected (20, 21). In 
terms of seroprevalence, there was a study based on testing 683 samples from 
pregnant women and blood donors with a mean age of 25 years, using IgG ELISA, and 
the estimated prevalence was 26.3% in rural settings and 36.5% in urban settings in 
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2003-2004 (22). While this is not a representative sample of the general population, it 
showed similar estimates to seroprevalence estimated in Nigeria, where a study 
estimated the prevalence of flavivirus infections among 1,816 children and adults in 
urban and rural areas during the early 1970s using virus-specific hemagglutination 
inhibition and neutralization testing (23). The prevalence was 45% for DENV-2 infection 
and higher in urban (48%) than in rural areas (37%) (23).  
To better understand the ongoing DENV transmission in Burkina Faso, in terms 
of seroprevalence and FoI, measured by IgG sero-conversion, we conducted four 
serological surveys in the same individuals residing in the capital, Ouagadougou, from 
2015-2017, in collaboration among Centre MURAZ, University of Montreal, the French 
Research Institute for sustainable Development (IRD), Action-Gouvernance-Integration-
Renforcement (AGIR), and Dengue Vaccine Initiative (DVI). The study served two 
objectives. First, seroprevalence of dengue virus was measured at enrollment. Secondly, 
we estimated age-specific annual FoI, measured by sero-conversion. Lastly, the 
outbreak occurring from September to November, 2016, between serosurveys 3 and 4, 
allowed identification of demographic and clinical characteristics associated with DENV 
sero-conversion in the outbreak and non-outbreak periods.   
 
Methods 
 
Study area and population 
 
Selection of the study area was based on previous outbreaks and case reports 
as well as seroprevalence studies in the literature, modelling studies and the availability 
of research infrastructure (7, 24, 25). Ouagadougou is the capital city of Burkina Faso in 
West Africa. The 2016 population was 2.6 million, almost 95% residing in urban settings 
(26, 27). The rainy season is from May-October, with a mean temperature of 28 °C 
(82 °F). The maximum temperature during the hot season (March-May) can reach 43 °C 
(109 °F).  
The serosurveys were conducted on residents in a defined catchment population 
of 100,000 residents of Ouagadougou (Fig. 1). The resident population in Ouagadougou 
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is very stable with a rate of transmigration of 4.1% per year, and more than 80% of the 
inhabitants with home ownership (28).  
 
Study design 
 
Four serosurveys were conducted approximately six months apart covering the 
rainy season. The age-stratified sample of approximately 3000 residents between 1 and 
55 years of age reflected age distribution of the general population of the district (24), 
with 80% of the serosurvey sample under 35 years-of-age and the remainder aged from 
35-55 years. Pre-and post-transmission paired sera were tested with a commercial 
Panbio®  Dengue IgG Indirect ELISA (Abbott Diagnostics, United States).  
The serological survey enrollment was performed at the household-level. There 
were 12 districts and 52 sectors in Ouagadougou. For randomization, sectors were 
randomly selected using previously collected census data. In the selected sectors, 
households in the chosen sectors were pre-selected, also, randomly. In the selected 
households, all the eligible household members were offered enrollment. When 
members of the selected house declined, the study team invited the residents of the 
neighboring household for the enrollment, to reach the needed sample size. The 
serosurvey was briefly described to the head of the household. Once the eligible 
member(s) of the family was identified and study participation is agreed, then informed 
consent and assent were sought. The consent documents were transported to and 
stored at AGIR/ Centre Muraz.  
Trained phlebotomists performed a blood draw of 3 -5 ml in subjects 1-7 years-
of-age and 5-10ml in subjects 8 years and older with aseptic measures using 
disposable needles and syringes. After blood sample collection, a short interview was 
conducted and the data collection forms were completed (24). After the IgG ELISA 
results become available, the study team delivered the results and made arrangement 
for the follow-up visit. The same procedures were followed with the same family 
members for the subsequent serosurveys.  
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Subject eligibility  
Individuals who meet the following criteria were considered as eligible subjects:  
 
Inclusion Criteria  
1. Age 1- 55 years old  
2. Residents of Ouagadougou for more than six months  
3. An informed consent from (ICF) obtained from each participant.  For those aged 
between 8 and 17 years, an assent form, plus informed consent from at least one 
parent or legal guardian.  
 
Exclusion Criteria  
1. Individuals with plans to move out of the catchment area during the study period, 
October 2014- September 2017) 
2. Individuals who are willing to provide only a single blood sample (i.e. at only one 
survey)  
 
Laboratory Testing Algorithm  
 
Samples collected were first transported to the Centre National de Transfusion 
Sanguine (CNTS), Ouagadougou, Burkina Faso where blood samples were centrifuged 
and separated into four aliquots of 0.5 – 1 ml serum in cryotubes under sterile 
conditions, labeled and stored at -70°C freezer. The samples were transported to 
Centre Muraz and stored at -70°C immediately at their arrival waiting for testing with a 
commercial IgG ELISA test (Panbio®  Dengue IgG Indirect ELISA, Abbott Diagnostics, 
United States). The laboratory testing procedure was previously described in more 
detail (24). 
The IgG ELISA was used to detect IgG antibodies to dengue antigen serotypes 
(1, 2, 3 and 4). The IgG cut-off were set to detect levels of IgG present in past dengue 
virus infections. The index value > 1.1, shown by Panbio unit > 11, indicated evidence 
of past or recent dengue infection; index value 0.9 – 1.1, indicated by Panbio unit 9 – 
11, was classified equivocal (samples require repeated testing); index value < 0.9 
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indicated by Panbio unit < 9 was considered negative. Dengue status was categorized 
by the cut-off as positive, equivocal, and negative. For this analysis, sero-conversion of 
anti-dengue IgG between the pre- and post- transmission was considered to be dengue 
infection.  
 
Statistical analysis 
 
 There are 3 components in the analysis. 
 
1. Characteristics of subjects by the status of dengue IgG at enrollment  
 
A descriptive summary of characteristics is presented by the status of dengue 
IgG ELISA at enrollment (IgG-positive and negative). Age was initially broken down to 
8-level categorical variable for descriptive purposes. Yellow fever vaccination history 
was dichotomized between those who reported having been vaccinated versus those 
who did not remember or reported no vaccination. Known previous dengue infection 
was also based on self-report and was dichotomized between those who reported 
having had dengue versus those who did not remember or reported none. Pre-existing 
condition was initially a 8-level categorical variable, and was compressed to a 
dichotomous variable (i.e., any pre-existing condition vs. none reported). Dichotomous 
variables were also created for various signs and symptoms (presence vs. absence). 
For nausea and vomiting, patients were asked whether they either had nausea and/or 
vomiting during their illness. 
Occupation was initially 11-level categorical variable, but was later compressed 
to a 3-level categorical variable: i) student; ii) housewife or retired/unemployed – to 
indicate those that stay mostly at home; and iii) others, e.g. business owners, 
public/private sector employees, farmers, service/skilled/unskilled workers, etc. Level of 
education, initially a 7-level categorical variable, was compressed to a 3-level 
categorical variable: illiterate or no official education; elementary school; and secondary 
education or more. Categorical pair-wise comparisons were made across dengue status 
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(sero-positive versus sero-negative) using χ2 or Fisher’s exact tests. Continuous 
variables were compared using Student’s t-test or ANOVA.  
DENV infection can occur with any of the 4 serotypes, and infection with one 
serotype provides long-term protection against the infecting serotype, but not to other 
three (29, 30). Therefore, individuals who already experienced prior infection of DENV 
are still susceptible to heterotypic infections (29, 30). However, the IgG ELISA test 
cannot distinguish between dengue serotypes (29). Therefore, in the analysis, infection 
refers to sero-conversion with any DENV serotype. 
Assuming a constant rate of exposure (µ) to the totality of serotypes — so that µ 
is the force of infection — the probability of a person sero-converting within the 
subsequent time t is 1-e- µt (31). If µ is assumed constant across ages and calendar time 
prior to the enrollment serosurvey, then, if person i has age Ai at that serosurvey, t can 
be replaced by Ai in the above expression.  So, if this person’s probability of being sero-
positive is denoted pi then we have (31):  
 
log (-log (1 - pi)) = log (µ) + log (Ai)  
 
Hence, if we apply binomial regression with a complementary log-log link, with 
log(midpoint of age category) as an offset, we can interpret the intercept as the 
logarithm of the FoI (31). 
 
2. Seroconversion and FoI in IgG-negative subjects who contributed to all 4 
serosurveys  
 
In the subset of subjects who contributed to all 4 serosurveys, IgG ELISA results 
among IgG-negative subjects were followed through S1 to S4 to observe changes in 
IgG status. S1-S2 covered the non-outbreak rainy season in 2015; S2-S3 covered the 
non-outbreak non-rainy season in the first half of 2016; and S3-S4 covered the 2016 
outbreak. Starting with those IgG negative at enrollment, the proportions of sero-
conversion from IgG– to IgG+ were measured over each interval.  
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FoI was also estimated over each interval, using a similar approach as before.  
The value of the repeat surveys is that the FoI no longer needs to be assumed constant 
across ages. Rather, age can be included among other risk factors in the regression, 
and sero-conversion rate ratios obtained. The logarithm of the time between samples, 
rather than the logarithm of age, is included as an offset. In the analysis based on 
paired surveys, only the paired results were considered for sero-conversion. For 
example, if a subject was IgG negative at S2, and IgG positive at S3, then this was 
considered sero-conversion between S2 and S3, even if they had been IgG positive at 
S1.  
 
3. Seroconversion rate ratios  
 
To assess how demographic and clinical characteristics are associated with 
DENV sero-conversion, and the difference in patterns in the outbreak (S3-S4) vs. the 
non-outbreak times (S1-S2 and S2-S3), a descriptive summary of demographic and 
clinical characteristics is presented among IgG-negative subjects at each preceding 
serosurvey between those who sero-converted (IgG – at the preceding serosurvey 
turning IgG+ at the subsequent serosurvey) vs. those who remained sero-negative (IgG 
– at the preceding serosurvey remaining IgG- at the subsequent serosurvey). Chi-
squared tests were used to test for differences between sero-status groups.  
Furthermore, to assess how different variables were associated with changes in 
the rate of sero-conversion, demographic and clinical information investigated were: age, 
gender, neighborhood, level of education, occupation, any known previous infection of 
dengue, and yellow fever vaccination history, as well as signs and symptoms obtained 
from subjects based on self-reports for the particular interval. Binomial regression 
models with the log time of the interval between the surveys as offset were run with a 
binary outcome of the sero-converted cases vs. those who remained sero-negative in 
each interval. Changes in the rates of sero-conversion were reported as rate ratios. All 
analyses were performed using SAS®  version 9.4 (SAS Institute, Cary, North Carolina).  
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Ethical considerations 
The study protocol received ethical approvals from the Institutional Review 
Boards (IRBs) of IVI, the London School of Hygiene and Tropical Medicine, the National 
Ethical Committee for Health Research of Burkina Faso, and the Ethics Committee of 
the Centre Hospitalier de l'Université de Montréal (CRCHUM) at University of Montreal. 
Consent forms were obtained from each participant: If the subject is between 8 to 17 
years old, an assent form from the subject and an informed consent from at least one 
parent or legal guardian were obtained. If subject is 7 years old or younger, an informed 
consent was obtained from at least one parent or legal guardian. If the subject is >17 
years old, an informed consent was obtained from the subject. 
 
Results 
 
Among 3026 enrolled subjects, 2897 subjects had complete demographic (age, 
gender, and neighborhood) data and laboratory results at enrollment; 129 had 
incomplete demographic data (Fig 1). The subjects who were enrolled at S1 and 
followed up at S4, compared to those that were lost and not followed up at S4 were 
significantly different in terms of: age distribution, younger among the ones that stayed 
at S4; and residing neighborhood, those stayed at S4 more likely to be residing in 
Juvenat Fille, Pazani, and Zongo. However, the two groups were similar in terms of 
gender and yellow fever vaccination history.  
Of 2897 subjects at enrollment (S1) in the enrollment bleed conducted in June 
2015, 66.3% (n=1920) were IgG positive and 33.7% (n=977) were IgG negative. There 
were three additional follow-up serosurveys. In the second serosurvey (S2) conducted 
in December 2015 in 2,109 subjects, 651 (30.9%) were IgG negative and 1417 were 
(67.2%) IgG positive. In the third serosurvey (S3) in May 2016 in 2,106 subjects, 672 
were (31.9%) IgG negative and 1400 were (66.5%) IgG positive. In the fourth 
serosurvey (S4) in March 2017 in 1,651 subjects, 509 were (30.8%) IgG negative and 
1121 (67.9%) were IgG positive. 
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1. Characteristics of subjects by the status of dengue IgG at enrollment  
 
The first part of the analysis was performed on 2897 subjects with complete 
clinical and laboratory data at enrollment. By IgG status at enrollment, IgG positive 
subjects were significantly older than IgG negative subjects with the mean age for IgG 
sero-positive subjects being twice that of the IgG negative subjects (Table 1). There 
were 82% (171/208) and 65% (268/410) of 1-4 and 5-9 year olds, respectively, were 
IgG negative and at risk of infection at the start of the study.  
Almost all of our subjects were Burkinabe and more female subjects were IgG 
sero-positive. With the given age difference between the groups, more of sero-negative 
subjects were student, about 46%, and higher proportions of sero-positive subjects had 
occupations, such as housewife, business owner, skilled/unskilled worker, private/public 
sector employees, etc.  
In terms of pre-existing conditions, also possibly due to age patterns, 
cardiovascular-, lung, musculoskeletal-, and gastrointestinal-related pre-existing 
conditions were more frequently found among sero-positive subjects than in sero-
negative subjects. Overall, self-report of previous dengue infection was rare and none of 
the IgG-negative individual reported having had previous dengue infection.  
The seroprevalence by dengue IgG at enrollment by age is shown in Fig. 2. The 
binomial regression based on IgG positivity by age at enrollment, assuming the force of 
infection was constant over calendar time, resulted in FoI, shown by the curve in blue, 
of 5.950% (95% C.I: 5.658-6.242) per year. With increasing IgG positivity with age, by 
age 11, it shows that about 50% of dengue IgG positivity was reached and by age 26, 
IgG positivity reached 80%.  
 
2. Seroconversion and annual FoI in IgG-negative subjects who contributed to all 4 
serosurveys 
 
The second part of the analysis is based on 438 IgG negative subjects among 
1269 who stayed in all 4 serosurveys. Cascade by IgG ELISA status throughout the 4 
serosurveys is shown in Table 2. Of the IgG negative subjects in S1, there were 33 
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(7.5%) that sero-converted by S2. Of the subjects that were IgG negative in S1 and S2, 
there were 10 (2.5%) that sero-converted by S3. Of the subjects that were IgG negative 
in S1-S2-S3, there were 64 (16.5%) that sero-converted by S4, over the 2016 outbreak.  
Using the binomial regression with the log duration of interval as denominator for 
each interval, FoI was calculated among IgG negative subjects at the preceding 
serosurvey. For the interval S1-S2, FoI was 14.03%; for the interval S2-S3, 9.90%; and 
for the interval S3-S4, 20.40% (Table 3). Age-specific annual FoIs were calculated for 5-
year age bands. For the intervals S1-S2 and S2-S3, the FoIs was higher for older ages, 
and the lowest FoI was found in children under 5 years in both intervals (Table 3). For 
the interval S3-S4, the annual FoI was also high in older ages, but high FoI was also 
found in those aged 15-19 years (33.5%) and even the lowest FoI was 11.21%, in those 
aged 30-34 years. 
 
3. Seroconversion rate ratios in intervals with and without outbreak 
 
The 3rd part of the analysis is based on each pair of surveys. For S1-S2 (analysis 
sample = 1494 subjects), among 455 subjects at risk (i.e. IgG negative at S1), 33 
subjects sero-converted and 422 stayed sero-negative. For S2-S3 (analysis sample = 
1488 subjects), among 443 subjects at risk (i.e. IgG negative at S2), 23 sero-converted 
and 420 stayed sero-negative. For S3-S4 (analysis sample= 1401 subjects), among 455 
subjects at risk (i.e. IgG negative at S3), 78 sero-converted and 377 stayed sero-
negative. Table 4 describes demographic and clinical characteristics of IgG sero-
converted, compared to those that stayed IgG negative for each interval.  
Proportions of sero-conversion were different by age and pre-existing conditions 
in S1-S2 and S2-S3 with statistical significance. Proportions of sero-conversion were 
different by presence of myalgia, for S1-S2, and arthralgia, for S2-S3 with statistical 
significance. During S3-S4 encompassing the 2016 outbreak, proportions of sero-
conversion were different by age and presence of fatigue with statistical significance.    
To assess how these variables might be associated in changes in rates of sero-
conversion, ratios of rate  sero-conversion of dengue IgG antibodies over the intervals 
were estimated from the binomial regression analysis. Over S1-S2, those 25-55 years 
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[rate ratios: 4.1 (95% C.I: 1.4-15.0)], compared to children under 5 years, those with 
self-reported pre-existing conditions [rate ratios: 2.7 (95% C.I: 1.1-5.7)], compared to 
those without any conditions, and those from Pazani, compared to those from Juvenat 
Fille [rate ratios: 3.3 (95% C.I: 1.2-12.1)], were associated with increased rate of dengue 
sero-conversion with statistical significance (Table 5).  
Over S2-S3, age of 15 and older, compared to 1-4 years, was associated with 
increased the rate of sero-conversion, with wide confidence intervals. Having self-
reported pre-existing conditions [rate ratios: 3.1 (95% C.I: 1.1-7.5)], compared to those 
without any conditions, being a housewife, retired/unemployed than being a student 
[rate ratios: 3.8 (95% C.I: 1.5-11.1)], and presence of arthralgia [rate ratios: 2.5 (95% C.I: 
1.0-5.8)], compared to absence, were associated with increased rate of dengue sero-
conversion with statistical significance. Over S3-S4, presence of fatigue [rate ratios: 1.6 
(95% C.I: 1.0-2.5)] was associated with increased rate of sero-conversion with statistical 
significance. Presence of loss of appetite in S2-S3, and nausea/vomiting in S3-S4, 
compared with absence, were associated with decreased rate of sero-conversion with 
statistical significance.  
 
 
Discussion 
 
 To our knowledge, this is the first study from Africa to present data on population-
based seroprevalence and rates of DENV sero-conversion. Also, we were able to 
longitudinally follow the same enrolled subjects in 4 repeated serosurveys at 6 month 
intervals to calculate sero-conversion empirically as well as estimate based on binomial 
regression models. 
 
1. Characteristics of subjects by the status of dengue IgG at enrollment  
 
Overall, it shows that two-thirds of the 2897 enrolled subjects already were IgG 
positive at enrollment. It was observed that seroprevalence increased with age, 
reaching 80% IgG positivity by age 26 years in the catchment area population. There 
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have been speculations of the dengue burden in Africa to be similar to that of the 
Americas, supported by a largely unrecognized burden in the region and also masked 
by other illnesses with similar symptomatic presentation (32, 33).  
The seroprevalence reported in this study were comparable to areas which are 
considered to be highly endemic: 61% in individuals 1-65 years in Colombia; 83.1% in 
individuals aged 15-19 years in Tahiti; 86.6% sero-positive in adults, 18 years and older, 
in Malaysia; and 68.7% in Salvador, Brazil (34-37). In Recife, Brazil, the seroprevalence 
measured with IgG ELISA was estimated at 74 and 91%, for areas of high and low 
socio-economic status, respectively (38). In all these studies, testing was done using 
IgG ELISA and interpretation should consider the possible cross-reactivity of IgG across 
different flaviviruses circulating. Nonetheless, hyperendemicity of dengue is well 
documented in these countries, and we would expect more intense transmission of 
DENV. However, their estimates of seroprevalence by IgG positivity were not so 
different from what we observed in Burkina Faso.  
With the assumption of the constant force of infection over calendar time used in 
the binomial regression model, FoI was estimated to be 6% per year based on sero-
positivity. The FoI of 6% is generally lower than what was reported previously from other 
known endemic regions, such as Sri Lanka at 14% (29), Colombia at 8.7% (36) and 
Recife, Brazil at 5.3 and 17.7% for urban areas of high and low socio-economic status, 
respectively (38).  However, our estimate was higher than those of Nicaragua, in the 
times of high FoIs in 1997-1998 at 480 per 1000 and 1998-1999 at 555 per 1000 (39) 
and Thailand at 0.019-0.038/year (40).  
 
2. Seroconversion and annual FoI in IgG-negative subjects who contributed to all 4 
serosurveys 
 
Based on repeat surveys following up with the same individuals, we empirically 
measured the proportion of sero-conversion. In our study, there was a subset (n=1269) 
of enrolled subjects that stayed in all 4 serosurvey serosurveys and following the IgG 
ELISA results changing over 4 surveys, it was found that 7.5% sero-converted between 
S1-S2; 2.5% that were IgG negative in S1 and S2 sero-converted by S3; and 16.5% 
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that were IgG negative in S1, S2, and S3 sero-converted by S4.  
In the non-outbreak period, for S1-S3, 43 of 437 IgG negative subjects sero-
converted (9.8%) whereas it was 17% in the outbreak period. While the durations differ, 
this shows the magnitude of DENV transmission, indicated by sero-conversion, during 
the outbreak. Also, given the IgG results throughout the 4 serosurveys, these are likely 
primary infections. The majority of the IgG negative subjects were children: 50% of IgG 
negative subjects at S1, S2, and S3 were children under 10 years. This age distribution 
of IgG negative subjects also supports that most of these sero-conversions could be 
primary infections.  
In addition to these observed proportions of sero-conversions among IgG 
negative subjects, annual FoIs were measured by the binomial regression: 14% for S1-
S2; 10% for S2-S3; and 20% per year for S3-S4. These estimates provide 
understanding on how the annual FoI could be as low as 10% if in the non-outbreak and 
no rainy season (likely to be the peak time of transmission) and can reach as high as 20% 
in a large outbreak setting, as the one declared in 2016. Unlike the observed 
proportions of likely primary infections, these show the annual rates of infection, 
measured by sero-conversion due to DENV, which may include both first infection as 
well as subsequent heterotypic infection, which will not be distinguished by IgG ELISA. 
Also, the highest FoI was found during the interval of the outbreak, but what is 
noteworthy was a substantial level of FoI even during those non-outbreak periods. In 
terms of repeat surveys, there is limited information available. Nonetheless, these are 
comparable to what had been reported from Colombia at 8.7% (36), but our estimates 
are higher than those of Nicaragua (39).  
In calculation of the age-specific FoIs, given that seroprevalence increases with 
age, there was a small number of IgG negative subjects in older age groups and this led 
to few of these remaining IgG negative subjects sero-converting over the interval, 
leading to a high FoI. The age groups with number of sero-negative subjects < 5 are 45 
years and older, among whom close to 90% of subjects were already sero-positive. 
Disregarding these age groups, for intervals of the non-outbreak times, at S1-S2 and 
S2-S3, higher rates were found among adults above 30 years, at rates ranging between 
29 to 47% per year. Overall, FoI increased with age in the intervals of the non-outbreak 
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times. For the interval with the outbreak, FoI was similar across age, with rates ranging 
between 13 to 34% per year.  
Consistent with the findings from the facility-based surveillance, which was 
conducted in the same catchment area during the same period, adults were more at risk 
for dengue in Burkina Faso. However, during the outbreak, it was both adults and 
children at similar risk for dengue in Burkina Faso. It could possibly be due to the 
serotype change from DENV 3 before to DENV 2 during the outbreak, but this has not 
been confirmed with the serosurvey samples. Further analyses using neutralization 
assay on the samples from the current study is planned.  
 
3. Seroconversion rate ratios in intervals with and without outbreak  
 
The 3rd part of the analysis was in the context of cases of sero-conversion in 
paired serosurveys. Various demographic and clinical variables were assessed to see if 
they are associated with changes in rates of sero-conversion. Using the binomial 
regression analysis, it was found that over S1-S2 and S2-S3, older age, compared to 
age under 5 years, and having self-reported pre-existing conditions, compared to none, 
were associated with DENV sero-conversion. Over S2-S3, presence of arthralgia, 
compared to absence, and being a housewife, retired or unemployed, compared to 
student, most likely due to older age, were associated with DENV sero-conversion. 
Over S3-S4, rate of sero-conversion was similar across age. And, presence of fatigue 
was a risk factor of sero-conversion.  
It is likely that pre-existing conditions come with age. In our data, the mean age 
of those that reported pre-existing conditions was 31.2 years whereas the mean age for 
those that reported none was 20.3 and the difference was statistically significant 
(p<.001 based on t-test). With the rate of sero-conversion increasing with age, having 
pre-existing condition also showed to be associated with rate of sero-conversion for 
both intervals S1-S2 and S2-S3, but not in S3-S4.  
In terms of symptoms, arthralgia was associated with increased rate of sero-
conversions in S2-S3, but for S3-S4 it was fatigue/weakness. Subjects were asked 
whether they experienced these symptoms in each interval, since the previous survey. 
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However, we cannot conclude that these associations are causal. Nonetheless, it is 
interesting that these are persistent signs associated with dengue infection (41, 42). 
Overall, there were not many symptoms reported during the intervals. However, these 
subjects are likely to have suffered from subclinical illness with low frequency of fever 
reported. Also, about 18% at S2, 17% at S3, and 26% at S4 reported that they visited 
health centers during the interval. Our data cannot validate whether these visits were 
associated with dengue sero-conversion and self-reports of symptoms were not verified 
during their visits.  
 
4. Considerations in interpretation and limitations  
 
 This study is subject to a number of limitations. Firstly, our results were based on 
serology using IgG ELISA. Further analyses using neutralization assay is planned, but 
in this analysis, there is no confirmatory testing applied to verify the IgG results. Due to 
serological cross-reaction with other flaviviruses, this could result in inaccurate 
seroprevalence and force of infection estimates as antibodies to other flaviviruses, as 
well as dengue, could have been detected (29, 43). The most important of other 
flaviviruses in circulation in Africa could be yellow fever virus (YFV). Also, neutralizing 
antibodies against YFV generated by YFV vaccine could result in interference with the 
specificity of DENV IgG ELISA tests (43). In our study, the subjects were explicitly 
asked whether they had been vaccinated for yellow fever after each interval, and by the 
4th bleed, among 2526 subjects, 4% (n=90) answered that they had been vaccinated. 
While this was based on self-report and there could be recall bias, it was still a low level 
of YF vaccination. This is different from what was reported as the coverage rate of 
Expanded Program on Immunization (EPI) at the end of 2007 at 85.3% (44). Also there 
have been reported outbreaks of YFV in 1998, 2003, and 2004, (44-46). When we 
investigate this using self-reported YF vaccination history as a proxy for YFV sero-
positivity, we did not find any evidence for this effect, indicating that those with YF 
vaccination were not more likely to be detected by our ELISA (i.e. there was no 
difference in sero-positivity by IgG ELISA between those that received YF vaccination 
vs. those that did not). Also, there are some data on cross-reaction between DENV and 
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YF vaccination, reporting that recent yellow fever vaccination did not affect DENV sero-
positivity (43, 47).  
 For other flaviviruses, such as West Nile virus, Burkina Faso has not reported the 
presence of WNV (48). However, for Zika virus (ZIKV), Burkina Faso had reported 
prevalence of ZIKV antibodies in human populations and was classified in 2018 as 
category 2 country where there is either evidence of virus circulation before 2015 or 
ongoing transmission that is no longer in the new or re-introduction phase, with no 
evidence of interruption (49, 50). While the extent to which ZIKV is present in Burkina 
Faso is unknown, there was a study which followed neutralizing antibodies to ZIKV and 
DENV in longitudinal serologic specimens in in patients with Zika and DENV from Latin 
America and Asia (51). The authors reported that cross reactivity was low to DENV in 
Zika patients and also low to Zika among DENV patients, indicating ZIKV and the DENV 
serocomplex to be distinct, based on the patterns of antibody cross-neutralization (51). 
Still, there might be other cross-reacting flaviviruses or arboviruses in circulation in 
Africa. And, given these viruses at unknown levels as background transmission 
affecting our measurement of sero-positivity, our results could be overestimates.  
Despite these limitations, there were previous studies with findings supportive of 
its performance in dengue diagnosis. Chungue et al. conducted a study comparing 
performance of IgG ELISA to that of haemagglutination inhibition test (HI) in detection of 
dengue antibodies using a baseline serosurvey with age-stratified samples collected 
from 327 children up to 19 years in Tahiti between April and June 1987 (34). The 
authors reported that both sensitivity and specificity, as well as agreement between two 
tests, were good (34). Tahiti is an island in French Polynesia, with circulation of 
flaviviruses, such as DENV and Zika virus (52-54), and the population would have been 
exposed to some of the flaviviruses. In addition, Inoue et al. conducted a study 
comparing dengue IgG indirect ELISA results to HI for diagnosis of secondary DENV 
infection using 187 samples from patients with known dengue secondary infection, 40 
samples of known dengue primary infection, and 44 samples from healthy volunteers 
(55). The results were also compared to JE indirect IgG ELISA to measure anti-
flavivirus IgG as DENV cross-reacts with the Japanese encephalitis virus (55). The 
authors reported that the results of DENV IgG highly correlated with those of the DENV 
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HI test and concluded that DENG IgG ELISA could be a simple, rapid, sensitive, and 
quantitative test to use in the determination of dengue secondary infection (55).  
A study conducted in Malaysia, another country with DENV hyperendemicity and 
circulation of other flavivirus, among 277 healthy adults in a rural district between April 
and May 2015 (35). The samples were tested for immunoglobulin G (IgG) using the 
same test as in our study (Panbio®  Dengue Indirect IgG ELISA) and were confirmed on 
a subset of randomly selected samples of IgG-positive sera with the plaque reduction 
neutralization test (PRNT) (35).  The authors found evidence of past infection in 75.5% 
(209/277) of participants and of these 96 samples were confirmed with the PRNT assay, 
to show that the detected antibodies were indeed specific to DENV (35). Even in a rural 
community, there was a high exposure to dengue when measured by IgG indirect 
ELISA and confirmed by PRNT. While these studies were not conducted in Africa, 
where there may be a different and unknown composition of flaviviruses in circulation, 
there are available data in support of IgG indirect ELISA to be well correlated with the 
results from more confirmatory and better validated tests, such as HI and PRNT.  
Also, our estimates are based on results of IgG ELISA, which does not 
distinguish the serotypes. Therefore, our estimates are rates of sero-conversion due to 
any serotype.  
 
Conclusion 
 
Our estimates of both seroprevalence and FoI showed to be comparable to 
results of other studies from more dengue endemic countries in the Americas. While 
repeated outbreaks indicate a considerable level of transmission of DENV in 
Ouagadougou, the extent of transmission and hyperendemicity of dengue needs to be 
further verified. Specifically, additional evaluation with confirmatory tests in the general 
population in the region would be necessary to further confirm and validate our findings. 
Burden estimates, such as the seroprevalence and the FoI, are important factors 
to be considered for evidence-based policy decisions for implementation of 
interventions for prevention and control, including introduction of vaccines. To our 
knowledge, there have been no published data on seroprevalence and FoI, even if 
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measured by sero-conversion, of dengue in Africa. Nonetheless, in absence of other 
reliable population-based data on dengue in Africa, our data provide practical evidence, 
despite limitations in interpretation of our estimates based on the IgG ELISA results, 
and could be used to support decisions and develop strategies for vaccine introduction.  
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Fig. 1 Flow chart of the subject enrollment 
 
 
 
 
 
 
129 subjects with 
incomplete* 
information 
2106 subjects at S3 
 
- 672 (31.9%) IgG negative 
- 1400 (66.5%) IgG positive 
- 34 (1.6%) IgG equivocal 
2109 subjects at S2 
 
- 651 (30.9%) IgG negative 
- 1417 (67.2%) IgG positive 
- 41 (1.9%) IgG equivocal 
2897 subjects at enrollment (S1)  
 
- 977 (33.7%) IgG negative 
- 1920 (66.3%) IgG positive 
639 
missed 
visits  
109 
incomplete
* data 
collection 
278 
incomplete* 
data 
collection 
2387 subjects in 
serosurvey 2 (S2) in 
December 2015-
January 2016 
2215 subjects 
retained in 
serosurvey 3 (S3) in 
May-June 2016 
1681 subjects 
retained in 
serosurvey 4 (S4) 
in March-April 2017 
3026 subjects  
enrolled in 
serosurvey 1 (S1) in 
June-July 2015 
172 
missed 
visits  
534 
missed 
visits  
30 
incomplete* 
data 
collection  
1651 subjects S4 
 
- 509 (30.8%) IgG negative 
- 1121 (67.9%) IgG positive 
1269 subjects in all S1-S4 
*Lab results and basic demographic information required to be considered complete  
**In the analysis based on paired surveys, only the paired results were considered for sero-conversion (i.e. if a subject was IgG negative 
at S2, and IgG positive at S3, then this was considered sero-conversion between S2 and S3, even if they had been IgG positive at S1) 
Analysis sample for S1-S2 = 1494 
subjects with complete* data for the 
paired serosurveys**  
Analysis sample for S2-S3 = 1488 
subjects with complete* data for the 
paired serosurveys**  
Analysis sample for S3-S4 = 1401 
subjects with complete* data for 
the paired serosurveys**  
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Table 1. Demographic and clinical characteristics of subjects by the dengue IgG status 
at enrollment in June-July 2015 in Ouagadougou, Burkina Faso  
Characteristics Total 
(n=2897) a 
Sero-positive at 
enrollment 
(n=1920) b 
Sero-
negative at 
enrollment 
(n=977) c 
p-value (χ2 
test)  
 
n (%) n (%) n (%) 
Mean age (SD) 22.32 
(13.92) 
27.02 (13.36) 13.08 (9.74) <.001 
Age group    <.001 
     1-4 years 208 (7.2) 37 (1.9) 171 (17.5)  
     5-9 years 410 (14.2) 142 (7.4) 268 (27.4)  
     10-14 years 384 (13.3) 189 (9.8) 195 (20.0)  
     15-19 years 379 (13.1) 243 (12.7) 136 (13.9)  
     20-29 years 694 (24.0) 560 (29.2) 134 (13.7)  
     30-39 years 410 (14.2) 357 (18.6) 53 (5.4)  
     40-49 years 264 (9.1) 249 (13.0) 15 (1.5)  
     50-55 years 148 (5.1) 143 (7.5) 5 (0.5)  
Female 1741 (60.1) 1218 (63.5) 523 (53.5) <.001 
Ethnicity    0.712 
     Burkinabé 2871 (99.6) 1906 (99.6) 965 (99.5)  
     Others  13 (0.5) 8 (0.4) 5 (0.5)  
Neighborhood    <.001 
     Sector 22 447 (18.2) 342 (20.5) 105 (13.3)  
     Sector 25 510 (20.7) 395 (23.6) 115 (14.6)  
     Juvenat fille 517 (21.0) 353 (21.1) 164 (20.8)  
     Pazani 433 (17.6) 281 (16.8) 152 (19.2)  
     Zongo 547 (22.2) 297 (17.8) 250 (31.7)  
     Nioko 8 (0.3) 4 (0.2) 4 (0.5)  
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Occupation    <.001 
     Student 1033 (35.8) 586 (30.6) 447 (46.0)  
     Housewife 885 (30.7) 666 (34.8) 219 (22.5)  
     Small business owner 163 (5.7) 130 (6.8) 33 (3.4)  
     Unskilled worker 153 (5.3) 124 (6.5) 29 (3.0)  
     Government official 92 (3.2) 77 (4.0) 15 (1.5)  
     Private sector employee 82 (2.8) 66 (3.5) 16 (1.7)  
     Merchant 55 (1.9) 46 (2.4) 9 (0.9)  
     Retired 53 (1.8) 26 (1.4) 27 (2.8)  
     Farmer 49 (1.7) 35 (1.8) 14 (1.4)  
     Skilled worker 43 (1.5) 32 (1.7) 11 (1.1)  
     Service sector worker 43 (1.5) 34 (1.8) 9 (0.9)  
Education level    <.001 
     Illiterate 887 (30.7) 596 (31.1) 291 (29.9)  
     Literate, but not 
educated 
72 (2.5) 58 (3.0) 14 (1.4)  
     1-6 years of school 803 (27,8) 455 (23.8) 348 (35.8)  
     7-10 years of school 551 (19.1) 388 (20.3) 163 (16.8)  
     11-13 years of school 274 (9.5) 200 (10.4) 74 (7.6)  
     University or higher  210 (7.5) 171 (8.9) 39 (3.0)  
     Others* 57 (2.0) 39 (2.0) 18 (1.9)  
Pre-existing conditions d     
     Cardiovascular 113 (4.0) 100 (5.3) 13 (1.4) <.001 
     Diabetes 10 (0.4) 7 (0.4) 3 (0.3) 0.817 
     Lung disease 19 (0.7) 17 (0.9) 2 (0.2) 0.034 
     Cerebrovascular 27 (0.9) 18 (0.9) 9 (0.9) 0.990 
     Musculoskeletal 101 (3.5) 82 (4.3) 19 (2.0) 0.002 
     Gastro-intestinal 193 (6.7) 148 (7.8) 45 (4.7) 0.002 
     Anemia 10 (0.4) 2 (0.1) 8 (0.80) 0.002 
     Others  108 (3.8) 79 (4.1) 29 (3.0) 0.139 
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Values are N (col. %) unless otherwise noted. 
P values based on χ2 test 
*religious and other informal education  
a Total subjects enrolled at S1 
b Dengue positive on IgG indirect ELISA among the enrolled subjects at S1 
c Dengue negative on IgG indirect ELISA among the enrolled subjects at S1 
d Pre-existing conditions are based on self-report by the subjects 
 
 
  
Self-reported previous 
dengue  
  
 
 
     Yes 13 (0.5) 13 (0.7) 0 <.001 
     No 2421 (84.7) 1635 (86.0) 786 (82.1)  
     Unknown 426 (14.9) 254 (13.4) 172 (18.0)  
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Figure 2. Seroprevalence by dengue IgG by age at enrollment, showing the FoI per year 
 
The figure shows observed seroprevalence at enrollment measured by IgG ELISA (in 
red) and fitted seroprevalence using FoI (in blue). The FoI per year was 0.0595 (95% 
CI: 0.05658 – 0.06242), estimated by binomial regression, with the assumption of 
constant risk across ages and calendar time prior to the enrollment serosurvey, and a 
complementary log-log link, with log(mid-point of age) as an offset. The intercept is 
interpreted as the logarithm of the FoI.  
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Table2 Cascade of ELISA results among 1269 subjects who stayed in all 4 serosurveys 
ELISA result 
N (% of subjects with identified IgG status at the preceding serosurvey) 
(n=1269) 
S1 S2 S3 S4 
Negative 
(NEG) 
438 
(34.5%) 
NEG 398 
(90.9%) 
NEG 387 
(97.2%) 
NEG 323 
(83.5%) 
POS 64 
(16.5%) 
 
POS 10 
(2.5%) 
NEG 8 (80.0%) 
POS 2 (20.0%) 
Equivocal 1 (0.3%)   
POS 33 
(7.5%) 
NEG 6 
(18.2%) 
NEG 5 (83.3%) 
POS 1 (16.7%) 
POS 25 
(75.8%) 
NEG 2 (8.0%) 
POS 23 
(92.0%) 
Equivocal 2 (6.1%)   
Equivocal 
 
7 (1.6%)     
Positive 
(POS) 
831 
(65.5%) 
NEG 22 
(2.7%) 
NEG 11 
(50.0%) 
NEG 11 
(100%) 
POS 0 
POS 8 
(36.4%) 
NEG 2 (25.0%) 
POS 6 (75.0%) 
Equivocal 3 
(13.6%) 
  
POS 797 
(95.9%) 
NEG 6 (0.8%) NEG 0  
POS 6 
(100.0%)  
POS 788 
(98.9%) 
NEG 15 (1.9%) 
POS 773 
(98.1%) 
Equivocal 3 (0.4%)   
Equivocal 12 
(1.4%) 
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Table 3. Number and rates of sero-conversion by age group between surveys  
Age 
group 
(year
s) 
enrolle
es with 
all 4 ser
osurvey
s 
(n=126
9) 
S1-S2 (between June-July 2015 and 
December 2015-January 2016) 
S2-S3 (between December 2015-January 
2016 and May-June 2016) 
S3-S4 (between May-June 2016 and March-
April 2017), covering the outbreak in 2016 
Sero-
negati
ve at 
S1 
Ser
o-co
nver
ted  
% ser
o-con
verte
d  
Mean d
uration 
of expo
sure 
(years) 
Age-
specific 
annual 
FoI  
(95% C.I) 
Sero-
negati
ve at 
S2 
Ser
o-co
nver
ted  
% s
ero-
con
vert
ed  
Mean d
uration 
of expo
sure
(years)  
Age-
specific 
annual 
FoI 
(95% C.I) 
sero
-ne
gati
ve a
t S3 
Sero
-con
verte
d  
% se
ro-co
nvert
ed 
Mean 
duratio
n of ex
posure 
(years) 
Age-
specific 
annual FoI 
(95% C.I) 
1-4 95 72 3 4.17 0.513 0.080 (-
0.007-
0.166) 
69 1 1.45 0.427 0.034 (-0.
031-0.09
8) 
68 13 19.12 0.859 0.219 (0.11
4-0.324) 
5-9 218 142 7 4.93 0.518 0.093 
(0.027-
0.159) 
140 3 2.14 0.439 0.048 (-0.
005-0.10
1) 
136 15 11.03 0.827 0.132 (0.0
70-0.194) 
10-14 193 93 6 6.45 0.514 0.122 
(0.031-
0.213) 
89 2 2.25 0.435 0.051 (-0.
018-0.1
20) 
91 16 17.58 0.840 0.206 (0.11
6-0.296) 
15-19 145 53 5 9.43 0.521 0.173 
(0.035-
0.311) 
50 5 10.0
0 
0.446 0.211 (0.
047-0.37
4) 
48 14 29.17 0.845 0.335 (0.19
2-0.478) 
20-24 124 28 2 7.14 0.552 0.126 (-
0.037-
0.289) 
25 1 4.00 0.416 0.093 (-0.
081-0.26
8) 
25 4 16.00 0.839 0.188 (0.02
2-0.353) 
25-29 139 19 3 15.79 0.546 0.270 
(0.010-
0.531) 
18 1 5.56 0.423 0.126 (-0.
105 – 0.3
58) 
18 5 27.78 0.839 0.321 (0.0
90-0.553) 
30-34 81 12 2 16.67 0.535 0.289 (-
0.048-
0.625) 
11 2 18.1
8 
0.439 0.367 (-0.
035-0.76
9) 
10 1 10.00 0.887 0.112 (-0.0
95-0.319) 
35-39 74 9 2 22.22 0.512 0.388 (-
0.030-
0.805) 
9 0 - - - 9 2 22.22 0.838 0.259 (0.0
50-0.568) 
40-44 69 7 2 28.57 0.527 0.472 
(0.002-
0.941) 
5 0 - - - 5 0 - - - 
45-49 59 2 0 - - - 3 2 66.6
7 
0.445 0.915 (0.
611-1.2
20) 
1 0 - - - 
50-55 72 1 1 100.0
0 
0.564 -** 1 1 100.
00 
0.427 -** 2 1 50.00 0.871 0.549 (-0.1
69-1.267) 
Total 1269 438 33 7.53 0.528 0.140*  
(0.096-0.
185) 
420 18 4.29 0.433 0.099* 
(0.056-0.
142) 
413 71 17.19 0.857 0.204* 
(0.162-0.24
6) 
*when constant risk of infection is assumed; **omitted due to small numbers   
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Table 4. Demographic and clinical characteristics by the status of IgG sero-conversion  
 
 Seroconverted vs. IgG negative  
between S1-S2 
Seroconverted vs.  IgG negative  
between S2-S3 
Seroconverted vs. IgG negative  
between S3-S4 
Characteristics Total 
N 
(n=4
55) 
IgG 
sero-
converte
d  
(n=33) 
a
 
Stayed 
IgG-
negative 
(n=422) 
b
 
p-
Value 
Total 
N 
(N=4
43) 
IgG sero-
converted  
(n=23) 
a
 
Stayed 
IgG-
negative 
(n=420) 
b
 
p-
Value 
Total 
N 
(N=4
55) 
IgG sero-
converted  
(n=78) 
a
 
 
Stayed 
IgG-
negative 
(n=377) 
b
 
p-
Value 
Age group    0.003    0.002    0.037 
   1-4 77 4 (5.2) 73 (94.8)  74 1 (1.4) 73 (98.7)  78 13 (16.7) 65 (83.3)  
   5-10 138 5 (3.6) 133 (96.4)  138 3 (2.2) 135 (97.8)  146 16 (11.0) 130 (89.0)  
   10-14 97 5 (5.2) 92 (94.9)  95 4 (4.2) 91 (95.8)  97 16 (16.5) 81 (83.5)  
   15-24 91 9 (9.9) 82 (90.1)  85 7 (8.2) 78 (91.8)  85 23 (27.1) 62 (72.9)  
   25-55 52 10 (19.2) 42 (80.8)  51 8 (15.7) 43 (84.3)  49 10 (20.4) 39 (79.6)  
Female 236 21 (8.9) 215 (91.1) 0.160 227 15 (6.6) 212 (93.4) 0.169 237 42 (17.7) 195 (82.3) 0.733 
Neighborhood    0.097    0.118    0.072 
    Juvenat fille 103 5 (4.9) 98 (95.2)  100 3 (3.0) 97 (97.0)  94 24 (25.5) 70 (74.5)  
    Nioko 4 0 4 (100.0)  4 0 4 (100.0)  2 0 2 (100.0)  
    Pazani 73 11 (15.1) 62 (84.9)  63 0 63 (100.0)  68 12 (17.7) 56 (82.4)  
    Zongo 118 6 (5.1) 112 (94.9)  121 10 (8.3) 111 (91.7)  157 17 (10.8) 140 (89.2)  
    Sector 22 61 3 (4.9) 58 (95.1)  62 3 (4.8) 59 (95.2)  57 12 (21.1) 45 (79.0)  
    Sector 25 96 8 (8.3) 88 (91.7)  93 7 (7.5) 86 (92.5)  77 13 (16.9) 64 (83.1)  
Pre-existing 
conditions
d
   
   0.014    0.013    0.458 
   No/unknown 404 25 (6.2) 379 (93.8)  396 17 (4.3) 379 (95.7)  402 67 (16.7) 335 (83.3)  
   Yes 51 8 (15.7) 43 (84.3)  47 6 (12.8) 41 (87.2)  53 11 (20.8) 42 (79.3)  
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Occupation    0.930    0.016    0.180 
   Student 221 15 (6.8) 206 (93.2)  212 6 (2.8) 206 (97.2)  232 34 (14.7) 198 (85.3)  
   Housewife or 
retired/unemployed 
106 8 (7.6) 98 (92.5)  106 11 (10.4) 95 (89.6)  105 24 (22.9) 81 (77.1)  
   Others (business 
owner, employees, 
workers, etc.) 
128 10 (7.8) 118 (92.2)  125 6 (4.8) 119 (95.2)  118 20 (17.0) 98 (83.1)  
Level of education    0.921    0.170    0.159 
   Illiterate or no 
official schooling 
138 9 (6.5) 129 (93.5)  139 11 (7.9) 128 (92.1)  136 23 (16.9) 113 (83.1)  
   Elementary school 169 13 (7.7) 156 (92.3)  161 5 (3.1) 156 (96.9)  182 25 (13.7) 157 (86.3)  
   Secondary school 
or more 
148 11 (7.4) 137 (92.6)  143 7 (4.9) 136 (95.1)  137 30 (21.9) 107 (78.1)  
Self-reported YF 
vaccination  
   0.371    0.469    0.535 
   No/unknown 445 33 (7.4) 412 (92.6)  429 23 (5.4) 406 (94.6)  427 72 (16.9) 355 (83.1)  
   Yes 10 0 10 (100.0)  14 0 14 (100.0)  28 6 (21.4) 22 (78.6)  
Previous dengue
 e
    -    0.052    0.865 
   No/unknown 455 33 (7.3) 422 (92.8)  442 22 (5.0) 420 (95.0)  450 77 (17.1) 373 (82.9)  
   Reported yes 0 0 0  1 1 (100.0) 0  5 1 (20.0) 4 (80.0)  
Signs and symptoms 
f
 (presence)  
            
    Fever 192 15 (7.8) 177 (92.2) 0.694 111 5 (4.5) 106 (95.5) 0.706 218 41 (18.8) 177 (81.2) 0.366 
    Fatigue/weakness 126 9 (7.1) 117 (92.9) 0.955 108 6 (5.6) 102 (94.4) 0.845 158 35 (22.2) 123 (77.9) 0.039 
    Retro-orbital pain 34 4 (11.8) 30 (88.2) 0.295 26 2 (7.7) 24 (92.3) 0.637 16 1 (6.3) 15 (93.8) 0.239 
    Headache 248 22 (8.9) 226 (91.1) 0.145 230 9 (3.9) 221 (96.1) 0.207 292 51 (17.5) 241 (82.5) 0.807 
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P values based on χ2 test 
a Subjects who sero-converted from IgG negative at the preceding serosurvey to IgG positive at the subsequent 
serosurvey on IgG indirect ELISA for DENV 
b Subjects whose sero-status stayed IgG negative at the preceding serosurvey and the subsequent serosurvey on IgG 
indirect ELISA for DENV 
d Pre-existing conditions are based on self-report by the subjects 
e Previous infections of DENV are based on self-report by the subjects 
f Presence of signs and symptoms based on the subject’s self-report during the interval between serosurveys  
 
  
    Rash 23 0 23 (100.0) 0.397 29 2 (6.9) 27 (93.1) 0.656 18 4 (22.2) 14 (77.8) 0.560 
    Eye pain 39 5 (12.8) 34 (87.2) 0.161 20 3 (15.0) 17 (85.0) 0.078 28 5 (17.9) 23 (82.1) 0.918 
    Arthralgia 81 8 (9.9) 73 (90.1) 0.315 79 8 (10.1) 71 (89.9) 0.029 81 14 (17.3) 67 (82.7) 0.970 
    Myalgia 57 8 (14.0) 49 (86.0) 0.035 60 3 (5.0) 57 (95.0) 0.943 65 15 (23.1) 50 (76.9) 0.170 
    Constipation 16 0 16 (100.0) 0.619 16 2 (12.5) 14 (87.5) 0.199 46 5 (10.9) 41 (89.1) 0.234 
    Diarrhea 52 6 (11.5) 46 (88.5) 0.206 57 1 (1.8) 56 (98.3) 0.338 40 3 (7.5) 37 (92.5) 0.090 
    Nausea/vomiting 111 11 (9.9) 100 (90.1) 0.215 117 4 (3.4) 113 (96.6) 0.466 102 11 (10.8) 91 (89.2) 0.053 
    Abdominal pain 123 10 (8.1) 113 (91.9) 0.661 155 7 (4.5) 148 (95.5) 0.638 180 25 (13.9) 155 (86.1) 0.136 
    Loss of appetite 128 13 (10.2) 115 (89.8) 0.135 179 5 (2.8) 174 (97.2) 0.061 114 23 (20.2) 91 (79.8) 0.321 
    Neck pain 18 2 (11.1) 16 (88.9) 0.381 17 3 (17.7) 14 (82.4) 0.052 14 1 (7.1) 13 (92.9) 0.481 
    Sore throat 30 3 (10.0) 27 (90.0) 0.470 28 2 (7.1) 26 (92.9) 0.649 21 3 (14.3) 18 (85.7) 0.722 
    Nasal congestion 73 4 (5.5) 69 (94.5) 0.630 58 1 (1.7) 57 (98.3) 0.339 74 9 (12.2) 65 (87.8) 0.214 
    Cough 72 6 (8.3) 66 (91.7) 0.700 71 1 (1.4) 70 (98.6) 0.149 115 19 (16.5) 96 (83.5) 0.838 
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Table 5. Binomial regression showing ratio of rates of sero-conversion, among residents in Ouagadougou, Burkina 
Faso  
Characteristics Univariable binomial regression 
Sero-converted (n=33) vs. IgG 
negative (n=422) 
between S1-S2 
Univariable binomial regression 
Sero-converted (n=23) vs.  IgG 
negative (n=420) 
between S2-S3 
Univariable binomial regression 
Sero-converted (n=78) vs. IgG 
negative (n=377) 
between S3-S4 
Rate of 
sero-
conversi
on  
95% CI  p-
Value 
Rate of 
sero-
conversi
on  
95% CI  p-
Value 
Rate of 
sero-
conversi
on  
95% CI  p-Value 
Age group   0.006   0.002   0.038 
   1-4 Ref   Ref* 
 
  Ref -  
   5-10 0.70 0.19-2.84  0.65 0.31-1.37  
   10-14 1.00 0.27-4.05  2.25 0.53-9.52  1.00 0.48-2.12  
   15-24 1.99 0.65-7.35  4.55 1.37-17.38  1.77 0.91-3.60  
   25-55 4.11 1.37-14.99  9.13 2.87-34.20  1.29 0.55-2.94  
Female 1.67 0.84-3.51 0.155 1.83 0.80-4.55 0.166 1.10 0.70-1.72 0.686 
Neighborhood   0.153   0.668   0.133 
    Juvenat fille Ref   Ref   Ref   
    Nioko -   -   0 -  
    Pazani 3.27 1.19-12.08  -   0.66 0.32-1.30  
    Zongo 1.09 0.33-3.79  2.95 0.90-13.16  0.41 0.21-0.75  
    Sector 22 1.02 0.21-4.15  1.64 0.30-8.84  0.81 0.39-1.59  
    Sector 25 1.82 0.61-6.02  2.67 0.74-12.40  0.66 0.32-1.27  
Self-reported pre-
existing conditions  
  0.016   0.017   0.433 
   No/unknown Ref   Ref   Ref   
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   Yes 2.67 1.13-5.67  3.11 1.12-7.48  1.29 0.64-2.34  
Occupation   0.935   0.025   0.177 
   Student Ref   Ref   Ref   
   Housewife or 
retired/unemployed 1.11 0.45-2.56  3.81 1.45-11.05  1.64 0.96-2.75  
   Others (business 
owner, employees, 
workers, etc.) 1.15 0.50-2.54  1.70 0.53-5.45  1.16 0.66-2.01  
Level of education   0.917   0.191   0.164 
   Illiterate or no official 
schooling 
Ref   Ref   Ref   
   Elementary school 1.19 0.52-2.89  0.39 0.12-1.06  0.80 0.45-1.42  
   Secondary school or 
more 1.15 0.48-2.85  0.61 0.23-1.55  1.33 0.78-2.32  
Self-reported YF 
vaccination  
        0.560 
   No/unknown Ref   Ref   Ref   
   Yes -   -   1.28 0.50-2.72  
Self-reported previous 
dengue 
 
    <.001   0.897 
   No/unknown Ref   Ref   Ref   
   Reported yes -   -   1.14 0.07-5.17  
Signs and symptoms 
(presence)  
         
    Fever 1.15 0.57-2.28 0.690 0.80 0.26-2.01 0.659 1.25 0.80-1.96 0.319 
    Fatigue/weakness 0.98 0.43-2.04 0.963 1.08 0.39-2.60 0.871 1.61 1.02-2.51 0.037 
    Retro-orbital pain 1.75 0.52-4.44 0.296 1.54 0.25-5.26 0.559 0.33 0.02-1.49 0.272 
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*age groups 1-4 and 5-9 were merged due to data scarcity in sero-converted subjects
    Headache 1.69 0.84-3.62 0.155 0.56 0.23-1.28 0.177 1.07 0.67-1.72 0.791 
    Rash -   1.34 0.21-4.56 0.694 1.36 0.41-3.28 0.553 
    Eye pain 1.98 0.67-4.70 0.160 3.27 0.77-9.56 0.056 1.06 0.37-2.37 0.906 
    Arthralgia 1.50 0.63-3.18 0.321 2.52 1.02-5.81 0.035 1.04 0.56-1.80 0.888 
    Myalgia 2.33 0.98-4.95 0.037 0.94 0.22-2.74 0.919 1.53 0.84-2.61 0.140 
    Diarrhea 1.75 0.65-3.95 0.217 0.29 0.02-1.40 0.231 0.39 0.10-1.04 0.109 
    Nausea/vomiting 1.56 0.73-3.15 0.228 0.57 0.16-1.50 0.300 0.55 0.27-0.99 0.065 
    Abdominal pain 1.17 0.53-2.38 0.686 0.78 0.30-1.84 0.591 0.70 0.43-1.11 0.140 
    Loss of appetite 1.67 0.81-3.33 0.149 0.39 0.13-0.98 0.062 1.28 0.77-2.06 0.318 
    Neck pain 1.58 0.26-5.22 0.531 3.99 0.94-11.65 0.026 0.39 0.02-1.76 0.349 
    Sore throat 1.46 0.35-4.09 0.535 1.41 0.23-4.81 0.642 0.82 0.20-2.21 0.743 
    Nasal congestion 0.70 0.21-1.79 0.508 0.29 0.02-1.38 0.227 0.65 0.30-1.23 0.218 
    Cough 1.19 0.45-2.71 0.695 0.23 0.01-1.08 0.146 0.95 0.55-1.56 0.832 
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7. Discussion, conclusions and future directions 
 
 Dengue is a major public health problem in tropical and sub-tropical countries and its 
transmission continues to expand globally (1, 2). Especially in Africa, the magnitude of 
dengue transmission is largely unknown. In Africa, there are some data obtained from 
outbreak investigations and also from retrospective testing of previously collected samples. 
However, there are not many data on the population-based estimates of burden of dengue in 
the region. Challenges to accurate burden assessment include limitation in terms of 
diagnostic capacity and surveillance systems to detect and monitor dengue incidence. In 
addition, many co-existing causes of fever illness with similar symptomatic presentations in 
Africa further complicate accurate assessment of dengue burden (3). Therefore, the principal 
aim of this thesis was to address knowledge gaps on dengue burden in Africa, in terms of the 
proportion of dengue fever among non-malarial febrile episodes, with the focus of outbreak 
periods, compared to non-outbreak period, as well as seroprevalence and annual rate of 
DENV infection, based on field studies conducted in Burkina Faso and Kenya. Further 
discussion is included here based upon chapters 4, 5, and 6 of this PhD thesis, by comparing 
findings from Ouagadougou and Mombasa in the times of outbreak versus non-outbreak as 
well as interpreting the results from the surveillance and seroprevalence studies conducted 
in Ouagadougou. 
 
7.1 Summary of the thesis 
 Data presented in this thesis support that there is a considerable level of transmission 
and burden of dengue in Burkina Faso and Kenya. However, given variability of dengue 
epidemiology over time and by region, more prospective longitudinal studies with further 
laboratory analyses would be necessary to confirm the conclusions presented in this thesis. 
In such resource-limited environments in Africa, consideration of preventive and control 
interventions, such as dengue vaccines, may be premature, especially considering the 
current status of vaccine development. However, should dengue become a better-recognized 
major public health problem in Africa, as it is in the Americas and Southeast Asia, these data 
will facilitate evidence-based decision making for implementation of interventions for dengue 
prevention and control, including vaccine introduction.  
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7.2 Burden of Dengue fever at health facilities  
Results from the facility-based passive fever surveillance studies in Chapters 4 and 5 
suggest that dengue may be an important cause of fever, other than malaria, in Africa. In the 
surveillance, a quarter of non-malarial febrile patients who sought care at 5 healthcare 
centers in Ouagadougou, Burkina Faso, were found to be dengue-positive. In Kenya, more 
than half of non-malarial febrile patients who sought care at 3 health facilities Mombasa were 
found to be dengue-positive. The majority of the dengue-positive cases had lab-confirmed 
dengue infections based on paired ELISA and/or PCR, both in Kenya and Burkina Faso. 
Given the considerable transmission of dengue, these data confirm that dengue is endemic 
in both Kenya and Burkina Faso.  
In both sites, the occurrence of outbreaks during the study enabled us to compare 
various demographic and clinical indicators of dengue during and outside the outbreak. 
Proportions of dengue-positive cases among non-malarial episodes were higher in the time 
of outbreak in both sites, compared to the non-outbreak periods. These support that dengue 
takes a major cause of AFI after ruling out malaria, especially in dengue outbreaks, but also 
in non-outbreak times. 
There are limited data on comprehensive identification of etiologies of AFI in Africa (4, 
5). However, the estimates in chapters 4 in both outbreak and non-outbreak in Kenya were 
higher, compared to existing data in literature on the proportion of dengue as a cause for AFI 
after ruling out malaria in Africa (6, 7). For Burkina Faso, the reported estimates were 
comparable to existing data (4, 8). 
Also, the proportion was much higher in Mombasa, than in Ouagadougou, despite the 
larger outbreak taking place during the study period in Ouagadougou compared to the one in 
Mombasa. As described in chapters 4 and 5, there were 5 health centers where subjects 
were enrolled in Ouagadougou, covering a larger catchment area population of 100,000 
residents, compared to Mombasa where subjects were enrolled at 3 facilities, of different 
healthcare provider levels, covering a smaller catchment area population of 70,000 residents. 
Also, recruitment performed much better in Ouagadougou, throughout a longer study period 
of 27 months, compared to Mombasa, where recruitment was interrupted with clinicians’ 
strike and high turnover of staff, during a shorter study period of 15 months. These differences 
led to a smaller number of enrolled subjects in Mombasa, than in Burkina Faso. Without 
enrollment interruptions and a longer study period, a larger size of enrolled subjects could 
have resulted in more comparable estimates of proportion of dengue-positivity in Mombasa.  
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In terms of age, the majority of dengue-positive cases in Kenya were adults between 
20-34 years of age. The age group with the highest proportion dengue-positive cases was 
20-24 years, followed by 25-34, and 15-19 years. Similarly in Burkina Faso, the majority of 
dengue-positive cases were older children and adults between 15-35 years of age. The age 
group with the highest proportion dengue-positive cases was 25-29 years, followed by 20-24, 
and 35-39 years. What was noteworthy was in both Kenya and Burkina Faso, dengue was 
not a disease of children. The data supporting that dengue in Africa was more frequent in 
teenagers and older adults, than in children, were consistent to reports of recent literature on 
increased mode of age for dengue (9-11). 
Outpatient dengue is known to account for the greatest burden of disease, both 
epidemiologically and economically and, although different levels of facilities were covered in 
the surveillance studies, both surveillance sites included outpatient as well as hospitalized 
(under observation) departments (12, 13). Difference between two sites was the numbers of 
patients requiring hospitalization or observation (i.e. staying in the facility up to 3 days) based 
on clinical judgement. Six percent of subjects required observation in Ouagadougou and 
there were increased odds of requiring observation that the dengue-confirmed patients were 
almost 11 times more likely, compared to non-dengue patients, to require observation at 
CSPSs. However, in Mombasa, only 2 subjects required hospitalization and both were 
dengue-positive. With only 2 subjects hospitalized and no DHF or complications reported, it 
can be concluded that most of the dengue-positive cases in the study in Kenya were mild. Of 
these two, one had a complete record of admission: no complication was reported, and they 
spent two days in hospital before discharge.  
Clinical responses depend on several factors (14), including age, and exposure to 
heterotypic virus. There is also evidence from Cuba that expression of certain genes is 
associated with severity (15). For example, in Kenya, although the current study did not seek 
to record race or ethnicity, 95% of Kenyans self-identify with an ethnic group associated with 
the Nilo-Sharan (Nilotic), Cushitic or Bantu language families (16, 17). Bantu ethnic groups 
are likely to be genetically closer to the West African ancestors of most Afro-Cubans (15). 
Since there is a large genetic variation between Africans (18), either the same or other genes 
may be responsible for the lower risk of dengue in black Africans found in Tanzania (19). In 
any case, such genetic factors, associated with race, may help explain our findings of dengue 
as mild disease in native residents of Mombasa.  
In Burkina Faso, three quarters of patients requiring observation were dengue-positive 
patients. However, there was no DHF reported and, among patients with medical record 
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during observation, there was only 1 case of complication, which was reported to be nose 
bleeding. While it may be speculated that dengue illness, in general, was more severe in 
Burkina Faso, than in Kenya. However, the data collected were insufficient to verify this and 
one detail to note is that the CSPSs in Ouagadougou were basic health facilities whereas, in 
Mombasa, three different levels of healthcare were included in the surveillance with one of 
them being a provincial level referral hospital. Decision for hospitalization and observation is 
made by clinicians and there may be differences in criteria for clinical judgement in two sites. 
Overall, the data collected did not include any information on severity and requiring 
hospitalization and observation could be an indicator of severity of dengue illness. Diseases 
severity may be associated with secondary dengue infection, but the study was unable to 
collect complete IgM/IgG lab results based on paired sera to determine this (20). Given that 
we used commercial kits, without quantitative results, the data were unable to calculate IgG/ 
IgM ratio to differentiate the secondary dengue from primary dengue cases (20).  
 
7.2.1 Clinical diagnosis and its accuracy 
In the context of clinical diagnosis of dengue, prior to lab confirmation, 63% of dengue-
positive cases were diagnosed with suspected dengue in Kenya. This was higher over the 
outbreak, but, it was lower than half of dengue-positive cases diagnosed with suspected 
dengue during the non-outbreak period. In Burkina Faso, the performance of clinical 
diagnosis was very low. Despite repeated outbreaks and consequently higher awareness of 
dengue in general, clinicians in Burkina Faso did not appear to consider dengue frequently 
as a clinical diagnosis, and only a quarter of dengue-positive cases were diagnosed with 
suspected dengue overall.  
One possible reason could be from the inherent differences in the study set-up. In 
Ouagadougou, the surveillance was launched in 5 basic health centers. However, in Kenya, 
the three facilities where the surveillance was launched covered low to high levels of 
healthcare providers, from basic health center to provincial level referral hospital. Clinicians 
in Kenya could have been more trained with higher awareness of dengue than the staff in 
CSPS, often nurses and rarely clinicians, in Burkina Faso. Availability of clinicians in addition 
to nurses as well as possibly heightened awareness in the study in Kenya could have led to 
the higher likelihood to clinically suspect dengue than in Burkina Faso.  
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7.2.1.1 Recommendations in terms of clinical diagnosis 
Febrile patients in Africa are commonly diagnosed and given presumptive treatment 
for malaria, although they are often lab-confirmed with other infections (21-23). Especially in 
resource-limited settings, it is challenging to identify any or all of the infecting pathogens (24). 
The lack of study of dengue in Africa may have contributed to the low rate of clinical diagnosis 
of suspected dengue among the patients in the current surveillance study. Given the high 
proportion of dengue-positive cases among non-malarial febrile episodes, the data in this 
thesis suggest that clinicians in Kenya and Burkina Faso should consider dengue more 
frequently as a clinical diagnosis, with or without point-of-care assays.  
Furthermore, another suggestion would be to train healthcare professionals, especially 
in terms of using clinical algorithms for dengue case identification (25). It could be the 
adoption of the 1997 and/or 2009 WHO dengue case classification criteria for routine 
reference and use (26). Considering the unknown and possible difference in terms of clinical 
presentation of dengue in Africa, there may be a need to make necessary modifications to 
the existing case classifications based on data generated from Africa to make it applicable 
and sensitive for practical use in the clinical settings in the region. In any case, more 
systematic use of a clinical algorithm for the clinicians to better identify dengue cases would 
be recommended.  
 
7.2.2 Use of RDTs for diagnosis of dengue in clinical setting 
RDTs were provided as part of the study in both sites. At enrollment, all subjects were 
tested with dengue RDT. Clinical diagnosis of suspect dengue was made prior to lab-
confirmation (ELISA and/or PCR-based) of dengue and, as for RDT results, there may have 
been cases where the RDT results were not available at the time of clinical diagnosis. This 
was often the case in high volume of patients and blood collection is done in the lab, rather 
than by clinicians/nurses in the examination room. So, clinical diagnosis could have been 
made in the absence of knowledge of the dengue RDT results. Work from chapter four of this 
thesis reported that less than half of the enrolled febrile patients in Kenya had positive results 
for NS1 and/or IgM on dengue RDT. In Burkina Faso, only one in every 7 enrolled patients 
had positive results for NS1 and/or IgM on the RDT kit.  
The laboratory algorithm in the surveillance was such that RDT results were used as 
a screening tool for further testing with RT-PCR of samples showing positive results on 
dengue RDT and/or IgM/IgG ELISA. Positive result on any side of the RDT kit (NS1, IgM, and 
IgG) prompted the sample to undergo additional testing with RT-PCR. Thus, the data were 
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limited to document accuracy in terms of sensitivity and specificity of dengue RDTs, as 
determination of dengue-confirmation was based on results from PCR testing for which RDT 
results influenced the selection of samples. Overall, much lower detection rates of RDTs were 
observed than the advertised performance, in terms of sensitivity and specificity, of the 
commercial RDT kit (27-30). 
 
7.2.2.1 Recommendations in terms of surveillance 
After the 2016 outbreak, dengue was included in the routine national surveillance 
system for potential epidemic diseases in Burkina Faso. Also, the MoH conducts outbreak 
investigations at several sentinel health centers (31). Especially during the outbreak in 2017, 
a laboratory-based arbovirus sentinel surveillance was implemented in November 2017, 
which was built on existing routine surveillance with enhancement of sample testing, 
improvements in case reporting as well as in data management (32). There have been 
outbreaks of dengue-like illness in several locations in Africa, but Burkina Faso is one of the 
few where dengue is included in the national reporting system. Despite efforts put into 
implementation of an improved surveillance system, there were some shortcomings, such as 
limited data management and delays due to procedural requirements (32). In Kenya, there is 
no ongoing surveillance of dengue, but the Division of Disease Surveillance and Response 
within the Ministry of Health conducts arbovirus outbreak investigations. In order to 
understand the burden and extent of transmission in the region, case reporting is critical. 
Active surveillance would be ideal to understand the true population-based incidence and 
severity of dengue. However, considering resource limitations, health facility-based 
surveillance would be a good start to detect cases and monitor epidemics.  
In addition, there are other Aedes vector-transmitted diseases, such as Yellow fever, 
West Nile, chikungunya and Zika, and there is continued absence of data on the distribution 
of these diseases and patterns of transmission of these arboviruses (33). Often, the 
frequently non-specific clinical presentation makes it difficult to distinguish one from other 
infectious diseases present in Africa. Also, concurrent infections are usually unrecognized 
and the extent of co-infections is largely unknown. Therefore, if the resource constraint were 
not a limiting factor, it would be ideal to establish arboviral disease surveillance, equipped 
with diagnostic assays for multiple pathogens, including dengue. If so, such surveillance 
should include case detection using the multiplex rapid diagnostic test for simultaneous 
detection (commonly trioplex with dengue, Zika, and chikungunya) with confirmation based 
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on multiplex PCR. Currently, there are efforts to develop point-of-care tests using nucleic acid 
amplification technologies for improved performance to test for multiple pathogens (34). 
In addition to the surveillance of dengue cases in humans, despite financial and 
infrastructure-wise challenges, it would be more informative to implement an integrated 
human and vector surveillance (35). As these are vector-borne diseases, entomological 
surveillance also helps to monitor the risks of arbovirus epidemics (36, 37). There is no 
comprehensive data on xenomonitoring of Aedes vectors in Africa, but a study was conducted 
in Brazil to monitor prevalence of infected mosquitoes and to understand the burden of adult 
and larval/pupae of Aedes mosquitoes with DENV (37). The study reported co-circulation of 
three of the four DENV serotypes and such finding demonstrates the possibility of co-infection 
cases by more than one serotype as well as with Yellow fever, chikungunya and Zika viruses 
(37). 
Early detection of cases through these surveillance systems will allow timely onset of 
control interventions and dissemination of outbreak alerts. Especially for dengue, monitoring 
of cases should be equipped with virus serotyping on a subset of samples, so that such 
surveillance could provide and possibly prevent severe disease caused by transmission of 
multiple DENV serotypes. 
 
7.2.3 Diagnostic options for dengue diagnosis 
As described in chapter 3, the patients enrolled in the surveillance studies who were 
febrile, or with a history of fever in the past 7 days, were first tested for malaria using RDT as 
part of routine practice. Malaria RDT-negative patients were enrolled in the study and tested 
with dengue RDTs. An acute sample of blood was taken at enrollment at the first visit, and 
the second blood sample was collected within 21 days of the first visit. All the acute and 
convalescent samples were tested using IgM/IgG ELISA. The results from IgM/IgG ELISA 
and RDT were used for selecting samples that would undergo further testing by RT-PCR.  
As described in chapter 2 of this thesis, a single method often does not provide a 
definitive conclusion for dengue diagnosis. There are multiple testing options, based on 
serologic, molecular, and virus antigen detection as well as combination of these methods 
(38-40). For serologic testing, such as ELISA, paired samples are needed to monitor change 
in the antibody level to reach a conclusion. Even so, it may require further analyses by PRNT 
testing, due to cross-reaction with other flaviviruses. PRNT and molecular methods, such as 
RT-PCR, while providing more confirmatory results of dengue diagnosis, require some 
infrastructure, such as equipment set-up and some technical expertise/training. These factors 
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contribute to challenges in the laboratory aspect, of accurate assessment of dengue burden 
in Africa.  
Given these complexities, in the studies covered in chapters 4 and 5, paired samples 
were collected and laboratory confirmation for dengue infection was performed according to 
WHO diagnostic criteria (41). Sero-conversion of anti-dengue IgM and IgG between the acute 
and convalescent phases and/or RT-PCR positive in the acute serum specimen was 
considered to be confirmed dengue. A positive IgM serology in single serum and/or positive 
on NS1 or IgM of RDT in single acute serum were considered probable dengue infection (41). 
Samples with negative results on RT-PCR and sero-negative results on paired IgM and IgG 
ELISA results were classified as non-dengue. Also, a positive IgG serology in single serum, 
with negative results from all other tests, could have been non-recent infection, and was 
classified as non-dengue.  
Such multi-layered testing for diagnosis is ideal, but may only be feasible in a research 
study setting. For clinical diagnosis, tests that are easy to perform with quick turnaround for 
results would be more adoptable in resource-limited environments in Africa.  
 
7.2.3.1 Recommendations in terms of dengue diagnosis 
While there are various new promising technologies being developed for dengue 
diagnosis, it will take time and resources for these to be made available in Africa (34). Hence, 
one way to overcome this problem might be to make the best use of the existing and already 
established networks. One possible option might be through the African Field Epidemiology 
Network (AFENET)(42). AFENET supports laboratory capacity development in the Africa 
region and its scope includes training of laboratory staff, laboratory equipment calibration, 
and provision of pre-packaged laboratory kits (42). Also, the countries without comprehensive 
diagnostic capacities should collaborate with international partners and agencies, such as 
Institut Pasteur or CDC. For example, the Institut Pasteur network includes Senegal, 
Madagascar, Cameroon, etc. and the CDC global health network includes Kenya, Ghana, 
South Africa, etc. They are already working in partnership with the governments of selected 
countries in Africa to build sustainable in-country public health capacity and laboratories of 
these agencies may serve as regional reference laboratories to perform testing of samples 
obtained from nearby countries. Based on such collaborative relationships, more data could 
be generated and countries could work together in preparation against epidemics as well as 
policy developments for necessary vector control efforts. 
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7.2.4 Advantages and benefits in using dengue RDTs  
In the context of limited information on dengue in Africa, one of the challenges in 
accurate assessment of dengue burden is diagnostics. Dengue RDTs could be a 
convenient option for acute dengue diagnosis especially in resource-limited settings. 
However, as described in chapter two, data in the current literature were limited to 
demonstrate any economic impact of using RDTs in dengue diagnosis in clinical setting.  
The data described in chapters four and five reported that lower than expected levels 
of accuracy were observed for the dengue RDTs in Burkina Faso and Kenya. However, 
RDTs, with results generated within 15 minutes, can be simple and user-friendly tools for 
dengue diagnosis. Despite their compromised sensitivity and specificity, there are benefits 
of using dengue RDTs (27). Especially as point-of-care tool, these may help to avoid 
unnecessary treatments leading to cost savings. With this as a hypothesis, the literature 
review, as reported in chapter 2, was conducted with two search terms, “dengue” and “cost 
or economic” to explore evidence of benefit of dengue RDTs, specifically with respect to its 
cost aspect. Two articles were found to describe on the cost aspect of dengue RDT use. 
Interestingly, these reached opposite conclusions on the cost-effectiveness of dengue 
RDTs. While one of the two studies reported satisfactory performance of IgM-based Panbio 
RDT, concluding that it would be cost-effective in endemic setting (43, 44), the other, based 
on modeling analysis with assumed parameters, reported that a dengue RDT would not be 
advantageous in terms of cost and effectiveness compared to current practice of antibiotics 
prescription for AFI (45). Given the lack of evidence, the review concluded that, in spite of 
growing use and need of dengue RDTs in research and clinical settings, data were limited 
to demonstrate an economic impact.  
While there was no evidence based on empirical data in the existing literature 
supporting cost savings associated with dengue RDT use, it is an area that needs to be 
explored and clearly documented. In the studies described in chapters 4 and 5, although 
not reported in the thesis, there were dengue-positive patients prescribed with antibiotics in 
both Kenya and Burkina Faso. In Kenya, 56% of dengue-positive, compared to 67% of non-
dengue cases, and in Burkina Faso, 61% of dengue-positive, compared to 69% of non-
dengue cases, were prescribed with antibiotics. Even though prescription was made prior to 
lab-confirmation and even in possible absence of RDT results, these are still high 
proportions of patients with viral infection given antibiotics treatment. With more targeted 
210 
J Lim PhD Thesis 
treatment prescription, i.e. no antibiotics given to dengue RDT positive patients, there may 
be cost savings to the patients from avoided antibiotics treatment. 
 
7.2.4.1 Recommendations in terms of dengue RDT use 
Dengue diagnostics can be complex and may require multiple testing for accurate 
confirmation. In Africa, it will be challenging and resource-limited to set-up laboratories with 
more comprehensive diagnostic capacities. Despite the low detection rates of RDTs 
observed in the field setting, considering the benefits of dengue RDTs, it would be advised 
to make dengue RDTs available for more routine use in the clinical setting (46). However, 
routine use of dengue RDTs among non-malarial fever patients year round may be too 
resource-consuming, especially considering other pathogens also commonly circulating in 
the region. Although not in Africa, it has been documented that dengue case numbers rise 
during the time of rainy season (47, 48). If it is too much of resource consumption to make 
dengue RDTs available year round, then a more targeted use limited to around the time of 
the known rainy season will help to monitor dengue cases and capture possible epidemics.  
In addition to a recommendation of more limited use covering the rainy season 
targeting dengue transmission, it is advised to use dengue RDTs in addition to malaria 
RDTs, as the febrile patients are routinely tested with the malaria tests. This will prevent 
possible influence of performance of malaria RDT on detection of dengue cases.  
 
7.3 Burden of Dengue at the community level in Ouagadougou 
To date, there is no information on dengue burden estimates, especially in terms of 
population-based seroprevalence and FOI, in Africa. In the same catchment area as the 
passive fever surveillance in Ouagadougou, there were 4 repeated serosurveys at 6 month 
intervals following up with the same individuals. As described in chapter 6, the study’s aims 
were to estimate overall prevalence and sero-conversion rates in Ouagadougou and gain 
understanding on DENV transmission in the community.  
In terms of DENV transmission in the community, with subclinical and inapparent 
dengue, a high level of seroprevalence and high force of infection (FoI), based on IgG 
seroconversion, were observed in the studied population in Ouagadougou. Benefiting from 
the repeat surveys following up with the same individuals, FoI reached 20% per year, during 
the interval covering the 2016 outbreak. IgG ELISA was used for diagnosis in the 
serosurveys and results should be interpreted with caution resulting from using serologic 
test with the possible cross-reaction across flaviviruses.  
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7.3.1 Sero prevalence 
Two thirds of the subjects were shown to be IgG positive at enrollment. 
Seroprevalence increased with age, reaching 80% by age 26 years. While this was 
measured empirically by IgG positivity, this was comparable to existing data, based on IgG 
ELISA results, from other endemic countries, such as Colombia, Tahiti, and Brazil (49-52).  
 
7.3.2 FoI measured by seroconversion 
The binomial regression, based on IgG positivity by age at enrollment (S1) assuming 
the force of infection was constant over calendar time and across age groups, led to an 
estimate of the force of infection of 6% per year, as reported in chapter 6. While this was 
calculated based on IgG positivity by age at enrollment, this was comparable to findings 
from Colombia and high SES areas of Brazil, but lower than findings from Sri Lanka and low 
SES areas of Brazil and higher than estimates from Nicaragua (9, 51, 53, 54).  
Again assuming the constant risk of infection across age, but with the mean duration 
of interval as denominator, rates of infection ranged between 10-20% per year. Given the 
highest annual rate of infection measured over the interval covering the 2016 outbreak, it 
was about twice of FoI in outbreak compared to non-outbreak period. Furthermore, age-
specific annual rates of infection were reported. For non-outbreak intervals, the rates were 
higher in adults, older than 30 years, than in children. However, for the interval covering the 
outbreak, the rates were found to be even across age. This was similar to the age patterns 
reported for the clinical disease identified in the surveillance reported in chapter 4. In the 
surveillance, which took place during the same study period in the catchment area 
population, it was found that the odds of dengue-positivity were greater for adults in non-
outbreak period, but there was no difference across age observed in the outbreak period. 
While there is a major difference that these were clinically ill cases of dengue infections 
whereas the serosurveys captured transmission in healthy individuals in the community, the 
age patterns observed in two studies were consistently indicating that age group affected 
most by dengue, at the healthcare facilities and in the community, was adults in non-
outbreak periods.   
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7.3.3 The Serologic assay used for diagnosis 
The serosurveys were based on 4 sets of blood samples collected at 6 month 
intervals in the same individuals. Only Panbio IgG ELISA results were available and without 
confirmatory results from other tests, such as PRNT, to estimate the prevalence and rate of 
infection, measured by seroconversion. In the absence of a gold standard diagnostic, taking 
advantage of the study feature of repeated surveys before and after the outbreak with a 
large sample size of about 1,700 subjects, overall and age-specific annual rates of 
infections were calculated based on seroconverted individuals with the mean duration of 
interval.  
There were concerns of cross-reaction with other flaviviruses. However, as described 
in chapter 6, there have been previous studies supporting performance dengue IgG indirect 
ELISA (i.e. the detected antibodies were indeed specific to DENV (49, 50, 55). Also, in 
terms of other co-circulating flaviviruses cross-reacting with DENV, Burkina Faso has not 
reported the presence of WNV (56). For Zika virus (ZIKV), Burkina Faso had reported 
prevalence of ZIKV antibodies in human populations (57, 58). However, possible cross-
reaction between DENV and ZIKV has been assessed in a study where neutralizing 
antibodies to ZIKV and DENV were longitudinally followed in patients with Zika and DENV 
from Latin America and Asia and  reported low cross reactivity between DENV and Zika 
viruses (59). Still, there might be other cross-reacting flaviviruses or arboviruses in 
circulation in Africa and our results could be overestimates if these viruses as background 
transmission affected our measurement of sero-positivity (59). Even with this as weakness, 
as there are no other existing data on seroprevalence and rate of infection of dengue in 
Africa, what was presented in chapter 6 is thus far the only available data on intensity of 
community-based DENV transmission in Africa. 
 
7.3.3.1 Recommendations in terms of seroprevalence and vaccination 
The data generated as part of this thesis form an evidence base for decision making 
on introduction of various strategies, in terms of preventive and control measures. 
Especially, in terms of implications in the context of dengue vaccines, these data are 
relevant and much needed. Currently, several dengue vaccine candidates have been in 
development, and recently, a first dengue vaccine from Sanofi Pasteur was licensed in 
2015 in multiple countries in Asia and Latin America. However, this vaccine has variable 
efficacy and has a restricted indication in dengue-exposed subjects only from 9 years and 
above, due to increased risk of severe dengue in seronegative subjects (60, 61). More 
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specifically, WHO issued their position with respect to the use of this first dengue vaccine 
and the recommendations are: to perform pre-vaccination screening to identify persons with 
evidence of a past dengue infection; and, if such individual screening is not available, to 
consider vaccination in areas with recent documentation of seroprevalence rates higher 
than 80% by the age of 9 years (61). In our studied population in Ouagadougou, the 
seroprevalence level of 80% is reached by the age of 20 years. By the age of 9 years, the 
seroprevalence by IgG positivity was below 50%. Therefore, given the current WHO 
recommendation, dengue vaccine introduction would not be an immediate priority for public 
health action in Burkina Faso.  
Despite substantial transmission of DENV documented in both Kenya and Burkina 
Faso, there is no supporting evidence of prior immunity with 80% threshold in population 9 
years and older. It may be similar in other populations in the region, even if more outbreaks 
are being reported in Africa. In 2013, due to the uncertainties of the disease burden, 
especially in Africa, as well as unknown vaccine efficacy with the first vaccine candidate, 
dengue was one of the vaccine-preventable diseases under consideration for GAVI vaccine 
investment strategy (VIS), but was not selected after review of the data available at the 
time. Despite known complications associated with the first dengue vaccine licensed in 
2015, efforts continue to develop safe and efficacious vaccines for dengue. Until better 
options become available in terms of individual screening and/or better vaccines without 
such complications in use become available, it would be premature to consider introduction 
of dengue vaccine for a public health use in Africa. In the meanwhile, other preventive and 
control measures, such as vector control methods, may be considered. Such approaches 
may contribute to prevention and control of other arboviral diseases also transmitted by 
Aedes mosquitoes (33).  
 
7.4 Symptoms associated with dengue 
As described in chapters 4 and 5, surveillance studies captured entire or partial 
outbreaks in Burkina Faso and Kenya, respectively. This enabled analysis to assess 
differences in clinical patterns and epidemiology of dengue during the outbreak and non-
outbreak periods. Symptoms positively associated with dengue were different between 
outbreak vs. non-outbreak periods in the two study areas. This may have been due to 
circulating serotype. There was no serotype change observed in the outbreak, remaining 
predominantly DENV 2 in Mombasa. DENV 3 was the prevalent serotype outside outbreak 
in Burkina Faso and it was DENV 2 during the outbreak. For example, in the data from 
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Kenya, nausea/vomiting was associated more significantly with DENV 2 than other 
serotypes (p-value = 0.023). There were some data supporting that gastrointestinal signs 
are associated with DENV 2 (62). However, in a multicountry outpatient-based passive 
surveillance study in the Americas, individuals infected with DENV3 were reported with a 
higher prevalence of gastrointestinal manifestations, including nausea/vomiting, compared 
to individuals with other serotypes (63, 64). 
Also, arthralgia was found to be more frequently associated with dengue during non-
outbreak in Kenya. Arthralgia has been associated with DENV 2 infection, and there is no 
clear explanation of why arthralgia was associated with dengue during non-outbreak, but 
not in the outbreak period, when prevalent serotype was DENV 2 throughout (65). Overall, 
there are no conclusive data on patterns of clinical manifestation by dengue serotype in 
existing literature.  
Symptomatic presentation may vary significantly by the history and intensity of DENV 
transmission as it may be different for secondary vs. primary infection, days into illness, and 
also by viral load (62, 65). With limitation in terms of laboratory analyses, the surveillance 
data were unable to determine between primary vs. secondary infections. Also, lacking 
detailed information on virus strain, it is difficult to determine whether there were virological 
differences affecting clinical presentation, between outbreak and non-outbreak periods.  
While the surveillance data did not have indicators of dengue severity, what was 
different between dengue patients in Kenya vs. Burkina Faso was the number of patients 
hospitalized in Kenya or requiring observation for < 3 days in Burkina Faso’s basic health 
center setting. There were a total of only 2 hospitalized patients in Kenya. In Burkina Faso, 
dengue-positive patients were more likely to be requiring observation, compared to non-
dengue cases, in both outbreak and non-outbreak periods.  
 
7.5 Limitations 
One of the major limitations of this thesis is the limited generalizability of data 
collected in Mombasa and Ouagadougou throughout Kenya and Burkina Faso, respectively, 
and ultimately to Africa. Dengue epidemiology is known to be variable over time and by 
region. Nonetheless, Mombasa and Ouagadougou are major cities of these countries, and 
the demographics and level of urbanicity of these cities may influence dengue transmission. 
Given dengue being more of an urban disease, the burden of dengue in large cities, such 
as Mombasa and Ouagadougou, would presumably differ from rural parts in Africa. 
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Therefore, the data described in this thesis would be limitedly generalizable to dengue 
endemic areas in urban setting within Kenya and Burkina Faso.  
In terms of dengue prevention and control, even if safe and efficacious vaccines 
become available, the data would not be able to provide insights as to whether an 
intervention tool, such as a dengue vaccine, would be needed in rural parts of Africa, and 
separate studies would be needed to generate evidence to support such decision-making.  
An additional limitation includes the diagnostic limitation across the studies in the 
thesis. Sequencing to obtain strain information would have been ideal for the PCR-positive 
samples from the surveillance. Also, neutralization assay on a randomly selected subset of 
samples in the serosurveys would be helpful to validate the IgG positivity to be specific to 
dengue antibodies. With limited laboratory resources and timeline, such further analyses 
were not feasible. If the IgG ELISA detected other flaviviruses, the empirically measured 
estimates of seroprevalence and seroconversions might be overestimates.  
The surveillance study excluded patients with malaria RDT positive results, 
localizing signs or known/confirmed diagnosis with other diseases, possibly omitting co-
infections of dengue with another pathogen. In particular, given the prevalence of malaria in 
this region, dengue and malaria co-infection may require further investigation. Nevertheless, 
the available information on co-infections suggest they are uncommon (4, 66-69). In 
addition to malaria, co-infection of dengue and Chikungunya is known to occur in Kenya (70, 
71). Also, there was a systematic review of the literature on concurrent detection of 
chikungunya and dengue viruses and such evidence for concurrent infection of 
chikungunya and dengue viruses has been reported in Angola, Gabon, Madagascar, 
Myanmar, Tanzania, and Yemen among countries in Africa, in addition to several other 
countries in Asia (72). The article concluded that the major limitation in accurate estimation 
of burden of such co-infection is due to absence of robust lab-based diagnosis. 
Nonetheless, when this was assessed in our surveillance samples from Kenya, none of the 
samples were positive for Chikungunya virus. As the study period was only for 15 months, it 
could have been the time of no chikungunya circulation. Nonetheless, in the literature, such 
co-infection is reported to be not commonly occurring (7, 73).  
Furthermore, due to the study design where patients with malaria RDT positive 
results were excluded, performance of malaria RDTs, which is known to be affected by local 
conditions, would be a source of bias (74). Malaria incidence in Ouagadougou is reported to 
be variable and malaria RDT performance is influenced by parasite density as well as the 
level of transmission in the population (74, 75). Therefore, depending on the test 
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performance of the malaria RDT, there could have been misclassification among non-
malarial patients (i.e. false negative results on malaria RDT included in the study being 
differently classified between dengue-positive and non-dengue groups). Also, this could be 
variable between during and outside of the outbreak (with different intensity of dengue 
transmission), leading to differential misclassification. 
Also, as shown in chapters 4 and 5, the majority of the patients in the surveillance 
are outpatients and it is possible to have missed patients with severe illness and patients 
with other mild illness seeking care elsewhere. Therefore, it is possible that the results of 
chapters 4 and 5 could be influenced by healthcare-seeking behaviour. They pertain to 
those who are able to seek healthcare at public health facilities, not private clinics. In 
resource-limited environments, such as in Africa, healthcare-seeking behaviour is closely 
related to the socioeconomic status (SES) (76, 77). The association between SES and risk 
of dengue is unclear, but some studies reported differences in seroprevalence and force of 
infection of dengue in areas of high and low SES (54). As the passive fever surveillance 
studies in this thesis did not capture those seeking care at private clinics, it would miss 
those potential subjects from a particular group of socioeconomic status.  
By contrast, the serosurveys described in chapter 6 were in randomly preselected 
residents of the defined catchment area. However, over four bleeds, there was a 
considerable proportion of lost to follow-up. Though considerable effort was made to follow 
up on all initially enrolled subjects in subsequent bleeds and, despite the stability supported 
by the reported level of home ownership, of 3026 subjects initially enrolled, 1681 subjects 
remained in the study by the fourth bleed at final follow-up over a 22-month study period.  
 
7.6 Alternative strategy and future directions 
Based on lessons learnt, there can be alternative approaches to characterize the 
epidemiology of dengue in Africa. More longitudinal cohort or active surveillance studies 
would be ideal for assessment of incidence and seroprevalence. Also, this would allow for 
analysis of severity grade of dengue-positive cases and more comprehensive follow-up to 
monitor change in the immunity status as well as progression of their illness (hospitalization, 
entire duration of illness, etc.). Also, comprehensive laboratory algorithm including further 
analyses would allow more definitive assessment of the burden without influence of 
possible cross-reaction of other flaviviruses.  
Therefore, additional future investigations into the epidemiology of dengue in other 
locations in Africa, other than Ouagadougou and Mombasa would be beneficial. As dengue 
217 
J Lim PhD Thesis 
has been recognized as a major global public health problem, efforts have been made to 
develop effective tools to prevent and control dengue, such as vector control and vaccines. 
Vaccination could be a good solution to combat this problem, once a safe and efficacious 
vaccine becomes available. However, to develop strategies on how to introduce such a 
vaccine, patterns of transmission and epidemiologic characteristics need to be better 
documented. Especially for dengue, given 4 serotypes and the possibility of subsequent 
infection with a heterotypic DENV leading to a greater risk of more severe disease 
(DHF/DSS) with pre-existing immunity to 1 serotype, such burden estimates will be 
important to make decisions for vaccine introduction (78). For the currently available 
Dengvaxia® , the vaccine demonstrated higher efficacy in pre-vaccination dengue-
seropositive individuals with a higher risk of subsequent more severe dengue in dengue-
naïve individuals. The current recommendation is to give this vaccine to dengue-
seropositive individuals by performing pre-vaccination screening for past DENV 
infection(79). If this is not feasible, then vaccine should be considered in areas where the 
dengue seroprevalence is documented to be > 80% by the age of 9 years (79). Therefore, 
in addition to identifying high incidence areas, it is important to consider level of 
seroprevelance of DENV in evaluation of the necessity of a vaccine and strategies for 
vaccine introduction, once a safe and cost-effective dengue vaccine becomes available.  
Therefore, additional studies on seroprevalence and burden would help to better 
inform policy decisions regarding dengue vaccine implementation. Another direction for 
future research derived from this thesis is the need for further data on dengue RDTs, in 
terms of its clinical benefits and economic impact to the individual from cost savings at 
hospitals, furthermore in terms of possible reduction in antibiotics resistance. These RDTs 
are easy to use, fast, and relatively inexpensive. From existing literature and the data 
described in chapters 4 and 5, low sensitivity of the RDT was the concern. In absence of 
vaccine and with repeated outbreaks, prompt identification of cases and incidence 
monitoring are critical to reduce morbidity and transmission due to DENV in Africa. As 
helpful tools for dengue diagnosis especially in resource-limited conditions, more readily 
use of RDTs should be promoted supported by evidence.  
 
7.7 Conclusions 
 Data from reported outbreaks in different parts of Africa support a considerable level 
of transmission of dengue virus in Africa. Nonetheless, accurate information on dengue 
burden in Africa based on population-based studies was limited. The principal aim of this 
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thesis was to address the knowledge gap on the magnitude of the dengue problem and 
generate improved data on dengue epidemiology in Burkina Faso and Kenya. This thesis 
assessed burden from the symptomatic side of dengue among patients seeking for care at 
study facilities in the passive health facility-based surveillance in Burkina Faso and Kenya. 
Work from this thesis has confirmed that dengue fever is an important cause of non-malarial 
acute febrile illness in study sites. Capturing outbreaks in both sites, the data provided 
differences in clinical presentation and outcomes of dengue patients between outbreak and 
non-outbreak periods. Also, the data suggest that clinicians in Burkina Faso and Kenya 
should consider dengue more frequently as a clinical diagnosis, with or without point-of-care 
assays. Additionally, transmission of varying intensity has been quantified in other regions, 
and the findings, based on the repeated serological surveys, seroprevalence at baseline 
and rates of infection, measured by sero-conversion, are within the range of those places 
where transmission is high enough to be considered a problem.  
Work from this thesis addressed the knowledge gap on the magnitude of the dengue 
problem in Ouagadougou and Mombasa, in the context of dengue-positive cases among 
non-malarial febrile episodes as well as community-based seroprevalence and FoI. In 
conclusion, data generated in the studies of the thesis would be able to facilitate informed 
decision-making on implementation of control and preventive measures for dengue in the 
region, including vaccine introduction in the future. However, given the currently available 
information on dengue burden in Africa and the status of dengue vaccine development, 
including the only licensed vaccine with restrictions in public health use, consideration of 
dengue vaccine introduction may not be an urgent priority for Africa.  Nonetheless, the data 
in this thesis will likely serve as a basis for future research to further define the burden of 
dengue in Africa.  
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Supplementary File (Tables 1, 2A, and 2B)  
Data extraction from descriptive studies on economic/clinical benefit of dengue RDT use 
Table 1. Basic information and introduction of the articles 
Basic information Introduction 
Authors Year of 
publication 
Journal Title Context/ study question (relevant to the review question) 
Mitra, 
Shubhanker; 
Choudhari, 
Rajat; Nori, 
Harshita; et 
al. & 
A meeting 
abstract by 
Mitra, S.; 
Choudhari, 
R.; Nori, H.; et 
al.(1, 2) 
2016 JOURNAL OF 
VECTOR BORNE 
DISEASES  
 
&  
 
INTERNATIONAL 
JOURNAL OF 
INFECTIOUS Meeting 
Abstract (2014) 
Comparative evaluation of validity and cost-
benefit analysis of rapid diagnostic test (RDT) 
kits in diagnosis of dengue infection using 
composite reference criteria: A cross-
sectional study from south India  
 
Performance and cost-effectiveness of 
immunochromatography 
based rapid diagnostic test (RDT) kits in 
diagnosis of dengue infection in resource 
limited set up 
To determine the sensitivity, specificity and predictive value of 
four commercially available RDTs [Panbio Dengue Duo 
cassette, 
Standard Diagnostics (SD) Bioline Dengue Duo, J. Mitra 
Dengue Day-1 test and Reckon Dengue IgG/IgM] against 
composite reference criteria (CRC), and compare the cost of 
the tests 
Lubell, Yoel; 
Althaus, 
Thomas; 
Blacksell, 
Stuart D.; et 
al.(3) 
2016 PLOS ONE    Modelling the impact and cost-effectiveness 
of biomarker tests as compared with 
pathogen-specific diagnostics in the 
management of undifferentiated fever in 
remote tropical settings 
To assess the ability of dengue and scrub typhus rapid tests to 
improve antibiotic targeting in primary care, as compared with 
testing for elevated C-Reactive Protein (CRP), a biomarker of 
host inflammation 
To determine the likely cost-effectiveness of the approaches be 
as compared with current practice in community care of febrile 
patients in the rural tropics 
1. Mitra S, Choudhari R, Nori H, al. e. Comparative evaluation of validity and cost-benefit analysis of rapid diagnostic test (RDT) kits in diagnosis of dengue infection 
using composite reference criteria: A cross-sectional study from south India. Journal of vector borne diseases. 2016;53(1):30-6. 
2. Mitra S, Choudhari R, Nori H. Performance and cost-effectiveness of immunochromatography based rapid diagnostic test (RDT) kits in diagnosis of dengue infection 
in resource limited set up. International journal of infectious diseases. 2014;21(Meeting Abstract: 64.018   ):450. 
3. Lubell Y, Althaus T, Blacksell SD, Paris DH, Mayxay M, Pan-Ngum W, et al. Modelling the impact and cost-effectiveness of biomarker tests as compared with 
pathogen-specific diagnostics in the management of undifferentiated fever in remote tropical settings. PLoS One.  March 30, 2016;11(3):e0152420. 
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Table 2A. Data extracted from the articles 
Article 
numbe
r 
Authors Methods 
Target 
population 
Population 
size 
Age location Study design Cost being 
evaluated 
Comparators  Time 
horizon 
Health 
outcome 
# cases 
1 Mitra et al. 
(including 
the 
meeting 
abstract) 
Patients 
who sought 
care for AFI 
at the study 
hospital in 
Vellore, 
India 
(using 
stored blood 
samples) 
281 patients 
with 
community 
acquired 
acute 
febrile 
illness  
>18 
years 
Christian 
Medical 
College 
(CMC), 
Vellore, 
India 
prospective 
cross-
sectional 
observational 
study 
The cost per 
test (as per 
manufacturer’s 
quoted price 
in India) 
used the 
composite 
reference criteria 
(CRC) for 
diagnosis 
of dengue-related 
illness to compare 
the performance 
of the four RDTs 
from 4 
manufacturers 
(Panbio, SD, 
J.Mitra and 
Reckon) 
Septemb
er 2012-
February 
2013 
 
Dengue 
infections 
against other 
cases of 
proven 
alternative 
diagnosis 
132 
cases of 
dengue 
(149 
controls)  
2 Lubell et 
al. 
Outpatients 
who sought 
care with 
fever 
  
1083 
outpatients 
(among 
1938 febrile 
patients 
recruited) 
5-49 
years 
 
three 
provincial 
hospitals 
in the 
provinces 
of 
Salavan, 
Luang 
Namtha, 
and Xieng 
Khouang 
in rural 
Laos 
Cost-
effectiveness 
modelling 
based on data 
from a 
hospital-
based 
prospective 
fever study 
 
cost 
effectiveness 
of different 
testing 
approaches, 
including a 
dengue RDT 
the ability of 
dengue and scrub 
typhus rapid tests 
to inform antibiotic 
treatment, 
as compared with 
testing for 
elevated C-
Reactive Protein 
(CRP) 
(based on 
data 
collected) 
May, 
2008- 
Decembe
r, 2010 
A 
viral/bacterial 
infection 
(Influenza, 
leptospirosis, 
scrub typhus, 
dengue, etc.) 
 
156 
dengue 
cases 
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Article 
No. 
Methods 
Effectiveness Prefer
ence 
based 
(meas
ureme
nt 
/valuat
ion) 
Estimated 
costs 
(resources) 
Curren
cy 
(price 
date/co
nversio
n) 
Model choice Methods 
Sensitivity & specificity Singl
e 
study 
or 
synth
esis-
base
d? 
Note. 
1 Manuf
acture
r  
 
Comparison of the performance of dengue RDTs 
IgM assay NS1 assay 
Sensitivity 
(%) (95% 
CI) 
Specificity 
(%) (95% 
CI) 
Sensitivity 
(%) (95% 
CI) 
Specificity 
(%) (95% 
CI) 
Panbi
o 
97.7 (93.5–
99.5) 
87.8 (81.5–
92.5) 
NA NA 
SD 
Biolin
e  
 
64.3 (55.4–
72.6) 
96.6 (92.2–
98.9) 
20.9 (14.3–
28.9) 
97.3 (93.2–
99.2) 
Reck
on  
 
13.9 (8.6–
21.2) 
99.3 (96.2–
99.9) 
18.6 (12.3–
26.4) 
96.6 (92.2–
98.9) 
J. 
Mitra  
 
36.4 (28.1–
45.4) 
68.7 (60.6–
76.1) 
27.1 (19.7–
35.7) 
92.5 (87.0–
96.2) 
 
Singl
e 
study 
Comparison 
of sensitivity, 
specificity 
and 
predictive 
values of 
four 
commercial 
RDTs was 
done   
against 
CRC 
measu
rement 
Cost of the 
study (no 
costs for the 
RDT kits -2 
manufacturer
s [J. Mitra 
and Reckon] 
provided 
test kits for 
testing free 
of cost and 
other two 
tests were 
part of the 
routine 
testing in the 
study 
hospital) 
US$ Four commercially 
available and most 
commonly 
used RDTs were 
selected for the 
study, from the 
following 
manufacturers: 
Panbio®(Dengue 
Duo cassette), 
Standard 
Diagnostics Bioline 
(Dengue Duo), J. 
Mitra (Dengue 
Day-1 test), and 
Reckon 
Diagnostics 
(Dengue IgG/ 
IgM) 
Measuring the 
performance 
of the four 
commercially 
available and 
widely 
used RDTs and 
comparing 
sensitivities and 
specificities 
against CRC  
 
2 They assumed a sensitivity and specificity of 95% for a 
dengue RDT when performed on presentation and for 
Scrub typhus IgM RDTs (based on beta distribution). 
Authors have also assumed the same baseline accuracy 
with no cross reactivity with other rickettsial infections.  
Synth
esis-
based 
- valuati
on 
Data 
obtained 
from a 
previously 
conducted 
fever study; 
cost of 
resources for 
the 
modelling 
efforts 
 
US$ Cost-effectiveness 
assessment of the 
tests in primary 
care setting  
Economic 
evaluation of 
diagnostics 
using a decision 
tree model and 
calculating the 
number of 
DALYs averted 
for each strategy 
using as inputs 
probability of an 
antibiotic being 
effective for the 
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bacterial 
pathogens, as 
well as the 
estimated 
excess duration 
of illness and 
mortality in 
patients that did 
not receive an 
effective 
antibiotic.  
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Table 2B. Data extracted from the articles 
Article 
No. 
Results Discussion 
Parameters Incremental 
costs and 
outcomes 
(cost-
effectiveness) 
Uncertainty Heterogeneity 
 
Study findings Limitations Generalizab
ility 
Funding 
source 
1 Performance 
(accuracy value) of 
the RDT kits for 
diagnosis of acute 
dengue febrile illness 
(sensitivity, 
specificity, PPV and 
NPV) and different 
costs of the kits 
  
 
The cost per test 
for Panbio, SD, 
Reckon and J. 
Mitra is US$ 
6.90, 4.27, 3.29 
and 3.61 
- seroprevalenc
e of IgG 
positivity 
measured in 
the 
population 
using Panbio 
IgG RDT was 
lower (49.3%), 
compared to a 
previously 
measured 
93% in a 
household 
based 
survey 
In dengue outbreak, 
Panbio IgM capture 
RDT alone could be a 
reliable and easily 
available test for use 
in resource-limited 
setting; other 3 RDTs 
of NS1 assay may not 
be reliable for the 
diagnosis of acute 
dengue infection with 
low sensitivity. The 
cost per test for 
Panbio, SD, Reckon 
and J. Mitra is US$ 
6.90, 4.27, 3.29 and 
3.61 respectively. 
Comparison of the 
sensitivity, specificity 
and predictive values of four 
commercial RDTs was made 
against 
CRC, which may not be the 
gold standard of dengue 
confirmation; comparison 
could not be done with 
standard 
ELISA based NS1 or IgM 
capture assay; further 
verification of the lab results 
(due to possible cross-
reactivity with other 
flaviviruses) was not done 
due to resource constraints  
Generalizabl
e in similar 
settings – 
where 
dengue 
prevalence 
as high as 
Vellore, 
India   
 
NA 
2 Sensitivity and 
specificity of dengue 
and scrub typhus 
tests; Mortality rate for 
bacterial infections in 
the absence of an 
effective antibiotic; 
Years of life lost per 
death; Cost of RDTs; 
Cost of a course of 
antibiotics; Probability 
of treatment in 
patients with 
a negative dengue or 
scrub typhus test 
(38% and uniform 
distribution used) 
 
Median 
incremental cost 
(CrI) $1.5 (0.5; 
3.2)  
Median DALYs 
averted (CrI) -
0.006 (-0.301; 
0.089) for a 
dengue RDT.  
Dengue RDT is 
dominated by 
current practice, 
with a higher 
cost and fewer 
numbers of 
DALYs averted. 
A 
probabilistic 
Sensitivity 
analysis 
was done 
with 
relevant 
distributions
, to address 
uncertainty 
in most 
parameters. 
From the 
cost 
effectivenes
s 
acceptability 
curve, it 
was shown 
Variable utility 
and accuracy 
of tests, 
subject to 
seasonal and 
spatial 
heterogeneity, 
whether used 
alone or in 
combination  
 
Heterogeneity 
in fever 
etiology  
 
Variability in 
terms of the 
incidence of 
different 
Use of dengue RDTs 
would lead to a 
reduction in antibiotics 
prescription for viral 
infections, whereas 
use of scrub typhus 
RDTs led to a larger 
proportion of bacterial 
infections receiving 
antibiotics. The CRP 
test performed better 
than the two tests 
above in terms of 
reduction in antibiotic 
prescription for both 
viral and bacterial 
infections. The model 
showed that the 
dengue test offers 
These simulations use data 
from a fever study in which 
enrollees did not have an 
identifiable pathogen or had 
multiple pathogens as the 
cause of illness. For patients 
with no identifiable cause, 
implication of the findings is 
not clear. For patients with 
multiple pathogens, a 
positive test result for a 
specific viral pathogen could 
mistakenly suggest that no 
antibiotic is required, when a 
treatable bacterial infection 
is also present. There is a 
need for further clinical 
studies about these 
approaches. Another 
In cases 
without an 
identified 
pathogen, 
CRP tests 
may be an 
effective tool 
(albeit 
imperfect) to 
guide 
antibiotic 
prescription. 
Overall, the 
model 
outputs will 
have limited 
generalizabil
ity to the 
broader 
The fever 
study where 
the aetiology 
data 
originated 
was funded 
by the WHO 
WPRO; the 
Australian 
Agency for 
International 
Development
, the Ministry 
of Foreign 
Affairs of 
Japan, and 
the USAID; 
the 
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Main assumptions and 
inputs:  
the differences in 
resources use are 
only those related to 
the diagnostics and 
treatments; other 
capital and labour 
overheads are similar 
in all strategies; for the 
costs of tests, a 
gamma distribution 
was applied with a 
mean of $1.5; the cost 
of a course of 
antibiotic is estimated 
at a mean of $0.5; all 
self-limiting viral 
infections and treated 
bacterial infection are 
associated with a 
week of ill health with 
a disability weight of 
0.053; bacterial 
infections that do not 
receive an appropriate 
treatment are 
associated with a 
further week of illness 
and a 1% mortality 
rate; each of these 
deaths is associated 
with a mean loss of 45 
life-years (one way 
sensitivity analysis 
between 20-60); the 
willingness to pay 
threshold was set at 
$1400 
that Dengue 
RDT is 
associated 
being cost 
effective 
<50% at 
any value of 
willingness-
to-pay 
 
infections, and 
baseline 
antibiotic 
prescription 
practices 
little or no advantage 
over current practice 
(-0.006 median 
DALYs averted). The 
scrub typhus averted 
an average 0.031 
DALYs and the CRP 
test averted 0.017 
DALYs per febrile 
episode.  
These estimates 
suggest that either the 
scrub typhus or CRP 
testing is likely to be 
cost-effective, given 
uncertainty in many 
model parameters. 
limitation is that it did not 
account for the longer-term 
societal health and economic 
costs associated with 
antibiotic consumption and 
resistance. It would be 
necessary to incorporate 
these aspects into economic 
evaluation for more 
comprehensive assessments 
of the costs and benefits 
involved.  
population 
of febrile 
patients.  
Foundation 
for 
Innovative 
New 
Diagnostics 
(the UK 
Department 
for 
International 
Development
), National 
Center for 
Immunization 
and 
Respiratory 
Diseases, 
US CDC; 
and the 
Wellcome 
Trust 
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Appendix D. Chapter 4 S1 STROBE checklist 
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 STROBE Statement: Clinical and epidemiologic characteristics associated with dengue fever before and during the 2017 outbreak in 
Mombasa, Kenya 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract (Page 1, title; 3, 
para 1) 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found (Page 3, para 2-3) 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported (Page 5 para 2-3) 
Objectives 3 State specific objectives, including any prespecified hypotheses (Page 6 para 1) 
Methods 
Study design 4 Present key elements of study design early in the paper (Page 8 para 1-2) 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-
up, and data collection (Page 7 para 1-3; page 8 para 2) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. 
Describe methods of follow-up  
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment 
and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of 
participants (Page 9 para 2) 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable (Page 10 para 1;  Page 11 para 2; page 12 para 2) 
Data sources/ 
measurement 
8  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group (Page 
10 para 1;  page 11 para 2-3; page 12 para 2-3) 
Bias 9 Describe any efforts to address potential sources of bias (Page 12 para 3; page 24 para 2) 
Study size 10 Explain how the study size was arrived at (Figure 2 on page 37) 
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 Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
groupings were chosen and why (Page 11 para 1-2; page 12 para 2-3) 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (Page 11 para 2; 
page 12 page 2-3) 
(b) Describe any methods used to examine subgroups and interactions (Page 11 para 2 - subgroups) 
(c) Explain how missing data were addressed (Page 13 para 3; page 24 para 2) 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed  
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
(Not applicable) 
(e) Describe any sensitivity analyses (none) 
 
Results 
Participants 13 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed (Figure 2 on page 37) 
(b) Give reasons for non-participation at each (Figure 2 on page 37) 
(c) Consider use of a flow diagram (Figure 2 on page 37) 
Descriptive 
data 
14 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders (Page 13 para 3; Table 1 page 14) 
(b) Indicate number of participants with missing data for each variable of interest  (Table 1, footnote on page 16) 
(c) Cohort study—Summarise follow-up time (eg, average and total amount)  (Not applicable) 
Outcome data 15 Cohort study—Report numbers of outcome events or summary measures over time  
Case-control study—Report numbers in each exposure category, or summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures (Page 13 para 3, Table 1 on 
page 14) 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included (Page 19 para 
1; Page 21 para 1; tables 2, 3A/B, and 4 on pages 18-22)  
(b) Report category boundaries when continuous variables were categorized (Page 11, para 1-2; specified in the 
tables) 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (Not 
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 applicable) 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (Not applicable) 
Discussion 
Key results 18 Summarise key results with reference to study objectives (Page 22 para 1; page 23 para 1; page 26 para 1, 3) 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias (Page 29 para 1) 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence (Page 23 para 2-3; Page 24 para 1; Page 25 para 1-2; Page 26 
para 1; Page 27 para 1-2; Page 28 para 1-3) 
Generalisability 21 Discuss the generalisability (external validity) of the study results (Page 29 para 1) 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study 
on which the present article is based (Financial disclosure on pages 30-31) 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in 
cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published 
examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites 
of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 
http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
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Appendix E. Chapter 4 S2 Table S1: Data by 3-level 
dengue-confirmation status 
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Table S1. Demographic and clinical characteristics by dengue confirmation status (confirmed-, probable dengue, 
non-dengue) among febrile enrollees of the health facility-based fever surveillance in Mombasa, Kenya in 2016-
2017  
 
Characteristics Dengue-
confirmed 
 (n=223) 
Dengue-
probable 
(n=72) 
Non-dengue 
(n=187) 
Total 
(n=482) 
p-value 
Place of enrollment     0.215 
 CPGH 97 (43.50) 42 (58.33) 94 (50.27) 233 (48.34)  
 Tudor 100 (44.84) 23 (31.94) 70 (37.43) 193 (40.04)  
 Ganjoni 26 (11.66) 7 (9.72) 23 (12.30) 56 (11.62)  
Mean age (SD) 23.04 (8.28) 24.29 (11.71) 23.14 (13.46) 23.27 (11.05) 0.694 
Age group (years)     <.001 
1-4 4 (1.79) 4 (5.56) 31 (16.58) 39 (8.09)  
5-9 6 (2.69) 4 (5.56) 6 (3.21) 16 (3.32)  
10-14 11 (4.93) 2 (2.78) 6 (3.21) 19 (3.94)  
15-19 38 (17.04) 7 (9.72) 21 (11.23) 66 (13.69)  
20-24 95 (42.60) 29 (40.28) 39 (20.86) 163 (33.82)  
25-34 48 (21.52) 13 (18.06) 44 (23.53) 105 (21.78)  
35-44 17 (7.62) 7 (9.72) 28 (14.97) 52 (10.79)  
45-55 4 (1.79) 6 (8.33) 12 (6.42) 22 (4.56)  
Female 87 (39.01) 30 (41.67) 90 (48.13) 207 (42.95) 0.173 
IPD/OPD 1 (0.45)/222 
(99.55) 
1 (1.39)/71 
(98.61) 
0/187 (100.0) 2 (0.41)/480 
(99.59) 
0.296 
Fever duration prior to visit 
(SD) 
2.96 (1.86) 2.97 (2.12) 2.84 (1.79) 2.91 (1.87) 0.806 
Fever duration, entire illness 
(SD)* 
7.04 (3.78) 6.28 (3.61)  4.91 (2.76) 6.17 (3.55) <.001 
Temperature at 
presentation (SD) 
37.87 (0.67) 37.81 (0.63) 37.71 (0.73) 37.80 (0.69) 0.064 
Temperature at 
presentation  
    0.031 
   Below 38.0°c 132 (59.19) 47 (65.28) 134 (71.66) 313 (64.94)  
   ≥ 38.0°c 91 (40.81) 25 (34.72) 53 (28.34) 169 (35.06)  
Prev. dengue infection 2 (0.90) 1 (1.39) 3 (1.60) 6 (1.24) 0.426 
YF vaccination 115 (51.57) 31 (43.06) 77 (41.18) 223 (46.27) 0.092 
Clinical diagnosis      
   Suspected dengue 156 (69.96) 30 (41.67) 18 (9.63) 204 (42.32) <.001 
   Undifferentiated fever 44 (19.73) 32 (44.44) 121 (64.71) 197 (40.87)  
   Non-dengue  23 (10.31) 10 (13.89) 48 (25.67) 81 (16.80)  
     URI (% of non-dengue) 13 (56.52) 5 (50.00) 27 (56.25) 45 (55.56)  
     Malaria 1 (4.35) 0 3 (6.25) 4 (4.94)  
     UTI 2 (8.70) 0 2 (4.17) 4 (4.94)  
     Pneumonia 0 0 3 (6.25) 3 (3.70)  
     Diarrheal illness 1 (4.35) 0 1 (2.08) 2 (2.47)  
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     Others 6 (26.09) 5 (50.00) 12 (25.00) 23 (28.40)  
Signs and symptoms 
(presence) 
     
     Rash 27 (12.11) 7 (9.72) 10 (5.35) 44 (9.13) 0.060 
     Fatigue/weakness 205 (91.93) 64 (88.89) 156 (83.42) 425 (88.17) 0.029 
     Headache   215 (96.41) 67 (93.06) 155 (82.89) 437 (90.66) <.001 
     Retro-orbital pain 133 (59.64) 33 (45.83) 69 (36.90) 235 (48.76) <.001 
     Neck pain 70 (31.39) 20 (27.78) 43 (22.99) 133 (27.59) 0.166 
     Ear pain 19 (8.52) 4 (5.56) 10 (5.35) 33 (6.85) 0.401 
     Breathing difficulty 1 (0.45) 0 5 (2.67) 6 (1.24) 0.131 
     Nasal congestion 10 (4.48) 5 (6.94) 26 (13.90) 41 (8.51) 0.003 
     Rhinorrhea 18 (8.07) 9 (12.50) 37 (19.79) 64 (13.28) 0.002 
     Sore Throat  12 (5.38) 5 (6.94) 22 (11.76) 39 (8.09) 0.057 
     Cough 35 (15.70) 11 (15.28) 48 (25.67) 94 (19.50) 0.025 
     Sputum production   6 (2.69) 3 (4.17) 15 (8.02) 24 (4.98) 0.044 
     Nausea & vomiting 120 (53.81) 31 (43.06) 75 (40.11) 226 (46.89) 0.017 
     Diarrhea  25 (11.21) 6 (8.33) 25 (13.37) 56 (11.62) 0.509 
     Constipation 10 (4.48) 3 (4.17) 9 (4.81) 22 (4.56) 0.972 
     Abdominal pain 81 (36.32) 20 (27.78) 55 (29.41) 156 (32.37) 0.220 
     Nose bleeding 6 (2.69) 2 (2.78) 0 8 (1.66) 0.041 
     Gum bleeding 9 (4.04) 1 (1.39) 0 10 (2.07) 0.008 
     Flushed face 3 (1.35) 3 (4.17) 5 (2.67) 11 (2.28) 0.287 
     Loss of appetite 155 (69.51) 40 (55.56) 93 (49.73) 288 (59.75) <.001 
     Myalgia   169 (75.78) 52 (72.22) 114 (60.96) 335 (69.50) 0.004 
     Arthralgia   171 (76.68) 51 (70.83) 104 (55.61) 326 (67.63) <.001 
*only among those that reported the end of fever illness (n=309; 156 dengue-confirmed, 43 dengue-probable, and 
110 non-dengue cases) 
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S1. STROBE Statement: Clinical and epidemiologic characteristics associated with dengue during and outside the 2016 outbreak 
identified in health-facility-based surveillance in Ouagadougou, Burkina Faso  
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract (Page 1) 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found (Page 4) 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported (Page 6, para 2-5) 
Objectives 3 State specific objectives, including any prespecified hypotheses (Page 6, para 5) 
Methods 
Study design 4 Present key elements of study design early in the paper (Page 7 para 3, page 8 para 1-2, Figure 2) 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-
up, and data collection (Page 7 para 1-2, Figure 1, 3) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. 
Describe methods of follow-up  
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment 
and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of 
participants (Page 7 para 3) 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable (Page 8 para 2-3, Page 9 para 1) 
Data sources/ 
measurement 
8  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group (Page 
9 para 1, page 10 para 1) 
Bias 9 Describe any efforts to address potential sources of bias (page 25 para 2, page 26 para 2) 
Study size 10 Explain how the study size was arrived at (Figure 3) 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
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groupings were chosen and why (Page 8 para 3, page 9 para 1) 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (Page 9 para 2, 
Page 10 para 1-2) 
(b) Describe any methods used to examine subgroups and interactions (Page 10 para 2, 4) 
(c) Explain how missing data were addressed (Page 10 para 4) 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed  
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
(Not applicable) 
(e) Describe any sensitivity analyses (Page 10 para 2- analysis just between dengue-confirmed and 
non-dengue groups, reported in tables S2-S4) 
 
Results 
Participants 13 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed (figure 3) 
(b) Give reasons for non-participation at each (figure 3) 
(c) Consider use of a flow diagram (figures 3) 
Descriptive 
data 
14 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders (Page 10 para 1, Page 11, Table 1) 
(b) Indicate number of participants with missing data for each variable of interest  (Page 10 para 4, explained on 
Fig 3 to have reached a sample size with complete information from variables used)  
(c) Cohort study—Summarise follow-up time (eg, average and total amount)  (Not applicable) 
Outcome data 15 Cohort study—Report numbers of outcome events or summary measures over time  
Case-control study—Report numbers in each exposure category, or summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures (Tables 1, 2, 3) 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included (Tables 2, 3, 
and 4) 
(b) Report category boundaries when continuous variables were categorized (Page 9 para 1, in methods) 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (Not 
applicable) 
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Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses (Table S2-S4) 
Discussion 
Key results 18 Summarise key results with reference to study objectives (Page 20 para 1) 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias (Page 22 para 3, page 23 para 1-4) 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence (Page 20 para 2-3, Page 21 para 1-2, page 22 para 1-2) 
Generalisability 21 Discuss the generalisability (external validity) of the study results (Page 22 para 3) 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study 
on which the present article is based (Page 3) 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in 
cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published 
examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites 
of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 
http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
Appendix G. Chapter 5 Supporting information 
Demographic and clinical characteristics of patients by 
dengue infection status in the fever surveillance in 
Ouagadougou, Burkina Faso 
- S2 Table: Demographic and clinical characteristics of patients by 
dengue infection status from the health facility-based fever 
surveillance established in Ouagadougou, Burkina Faso  
- S3 Table: Univariate logistic regression analyses showing 
significant indicators and their odds ratios between dengue-
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the health facility-based fever surveillance 
- S4 Table: Univariate logistic regression analyses showing 
significant indicators and their odds ratios between dengue-
confirmed and non-dengue cases during the period of non-
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S2. Table. Demographic and clinical characteristics of patients by dengue confirmation status from 
the health facility-based fever surveillance established in Ouagadougou, Burkina Faso  
Characteristics Dengue-
confirmed 
 (n=540) 
Dengue-
probable 
(n=200) 
Non-dengue 
(n=2189) 
Total 
(n=2929) 
p-value 
Age group (years)     <.001 
1-4 25 (4.6) 12 (6.0) 275 (12.6) 312 (10.7)  
5-9 26 (4.8) 17 (8.5) 149 (6.8) 192 (6.6)  
10-14 28 (5.2) 17 (8.5) 129 (5.9) 174 (5.9)  
15-19 70 (13.0) 15 (7.5) 231 (10.6) 316 (10.8)  
20-24 85 (15.7) 25 (12.5) 366 (16.7) 476 (16.3)  
25-29 97 (18.0) 37 (18.5) 375 (17.1) 509 (17.4)  
30-34 70 (13.0) 24 (12.0) 269 (12.3) 363 (12.4)  
35-39 53 (9.8) 18 (9.0) 155 (7.1) 226 (7.7)  
40-44 39 (7.2) 18 (9.0) 111 (5.1) 168 (5.7)  
45-49 23 (4.3) 10 (5.0) 67 (3.1) 100 (3.4)  
50-55 24 (4.4) 7 (3.5) 62 (2.8) 93 (3.2)  
Female 333 (61.7) 132 (66.0) 1563 (71.4) 2028 (69.2) <.001 
CSPS     <.001 
Pazani 81 (15.0) 32 (16.0) 400 (18.3) 513 (17.5)  
Zongo 60 (11.1) 31 (15.5) 592 (27.0) 683 (23.3)  
CSPS 22 45 (8.3) 20 (10.0) 240 (11.0) 305 (10.4)  
CSPS25 206 (38.2) 60 (30.0) 502 (22.9) 768 (26.2)  
     Juvenat Fille 148 (27.4) 57 (28.5) 446 (20.4) 651 (22.2)  
Under observation ≤3 
days/OPD 
117 
(21.7)/423 
(78.3) 
18 (9.0)/182 
(91.0) 
45 (2.1)/2144 
(97.9) 
180 
(6.2)/2749 
(93.9) 
<.001 
Mean days, fever 
duration prior to visit 
(SD) 
2.89 
(1.20) 
3.03 (1.23) 2.61 (1.22) 2.69 (1.23) <.001 
Fever duration prior to 
visit 
    <.001 
   1-2 days 233 (43.2) 68 (34.0) 1153 (52.7) 1454 (49.6)  
   3 days 162 (30.0) 76 (38.0) 634 (29.0) 872 (29.85)  
   4-7 days 145 (26.9) 56 (28.0) 402 (18.4) 603 (20.6)  
Mean temperature at 38.34 38.14 (0.78) 38.03 (0.78) 38.09 <.001 
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enrollment (SD) (0.75) (0.78) 
Temperature at 
enrollment  
    <.001 
   Below 38.5°c 333 (61.7) 145 (72.5) 1681 (76.8) 2159 (73.7)  
   ≥ 38.5°c 207 (38.3) 55 (27.5) 508 (23.2) 770 (26.3)  
Mean days, fever 
duration, entire illness 
(SD) 
4.77 
(2.44) 
4.57 (2.71) 4.04 (2.46) 4.21 (2.49) <.001 
Prev. dengue infection 10 (1.9) 4 (2.0) 2 (0.1) 16 (0.6) <.001 
YF vaccination     <.001 
   Received 83 (15.4) 39 (19.5) 824 (37.6) 946 (32.3)  
   Not received 457 (84.6) 161 (80.5) 1365 (62.4) 1983 (67.7)  
Clinical diagnosis      
   Suspected dengue 144 (26.7) 43 (21.5) 12 (0.6) 199 (6.8) <.001 
   Undifferentiated fever 379 (70.2) 150 (75.0) 1987 (90.8) 2516 (85.9)  
   Non-dengue  17 (3.2) 7 (3.5) 190 (8.7) 214 (7.3)  
     URI (% of non-
dengue) 
3 (17.6) 2 (28.6)  27 (14.2) 32 (15.0)  
     Bronchitis 2 (11.8) 2 (28.6) 30 (15.8) 34 (15.9)  
     Pneumonia 6 (35.3) 0 21 (11.1) 27 (12.6)  
     Viral syndrome 1 (5.9) 2 (28.6) 11 (5.8) 14 (6.5)  
     Diarrheal illness 1 (5.9) 1 (14.3) 28 (14.7) 30 (14.0)  
     Influenza 1 (5.9) 0 4 (2.1) 5 (2.3)  
     Others 3 (17.6) 0 69 (36.3) 72 (33.6)  
Signs and symptoms 
(presence) 
     
     Rash 73 (13.5) 22 (11.0) 163 (7.5) 258 (8.8) <.001 
     Fatigue 446 (82.6) 157 (78.5) 1526 (69.7) 2129 (72.7) <.001 
     Headache   518 (95.9) 190 (95.0) 1899 (86.8) 2607 (89.0) <.001 
     Retro-orbital pain 103 (19.1) 28 (14.0) 107 (4.9) 238 (8.1) <.001 
     Neck pain 8 (1.5) 5 (2.5) 47 (2.2) 60 (2.1) 0.556 
     Nasal congestion 16 (3.0) 4 (2.0) 105 (4.8) 125 (4.3) 0.044 
     Rhinorrhea 21 (3.9) 9 (4.5) 132 (6.0) 162 (5.5) 0.120 
     Sore Throat  7 (1.3) 4 (2.0) 64 (2.9) 75 (2.6) 0.088 
     Cough 62 (11.5) 29 (14.5) 354 (16.2) 445 (15.2) 0.024 
     Sputum production   2 (0.4) 2 (1.0) 30 (1.4) 34 (1.2) 0.123 
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     Nausea & vomiting 190 (35.2) 80 (40.0) 635 (29.0) 905 (30.9) <.001 
     Diarrhea  14 (2.6) 9 (4.5) 128 (5.9) 151 (5.2) 0.008 
     Constipation 6 (1.1) 6 (3.0) 85 (3.9) 97 (3.3) 0.005 
     Abdominal pain 195 (36.1) 76 (38.0) 639 (29.2) 910 (31.1) <.001 
     Nose bleeding 6 (1.1) 1 (0.5) 10 (0.5) 17 (0.6) 0.198 
     Gum bleeding 4 (0.7) 1 (0.5) 2 (0.1) 7 (0.2) 0.021 
     Loss of appetite 251 (46.5) 80 (40.0) 739 (33.8) 1070 (36.5) <.001 
     Capillary refill >2 
sec 
4 (0.7) 4 (2.0) 19 (0.9) 27 (0.9) 0.218 
     Alterations to 
consciousness 
2 (0.4) 4 (2.0) 7 (0.3) 13 (0.44) 0.014 
     Myalgia   234 (43.3) 85 (42.5) 560 (25.6) 879 (30.0) <.001 
     Arthralgia   315 (58.3) 111 (55.5) 953 (43.5) 1379 (47.1) <.001 
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S3 Table. Univariate logistic regression analyses showing significant indicators and their odds 
ratios of between dengue-confirmed and non-dengue cases during the period of outbreak in the 
health facility-based fever surveillance 
Characteristics Total 
N 
N (%) 
dengue 
confirmed 
(n=357) 
N (%)  
Non- 
dengue 
(n=349) 
Univariate analysis 
Dengue-confirmed vs. no 
dengue  
OR  95% CI  p-
Value  
Age group (years)      0.095 
   1-14 129 46 (35.7) 66 (51.2) Ref -  
   15-24 213 106 (49.8) 92 (43.2) 1.65 1.04-2.64  
   25-34 242 110 (45.5) 114 (47.1) 1.38 0.88-2.19  
   35-55 193 95 (49.2) 77 (39.9) 1.77 1.09-2.87  
Female* (ref. male) 484 207 (42.8) 237 (49.0) 0.65 0.48-0.89 0.007 
Under observation** (ref. 
OPD) 
128 99 (77.3) 18 (14.1) 7.05 4.16-11.96 <.001 
Fever duration prior to visit*      0.011 
   1-2 days 330 147 (44.6) 162 (49.1) Ref -  
   3 days 244 101 (41.4) 115 (47.1) 0.97 0.68–1.37  
   4-7 days 203 109 (53.7) 72 (35.5) 1.67 1.15-2.42  
Temperature at enrollment *       0.004 
   Below 38.5°c 468 195 (41.7) 228 (48.7) Ref -  
   ≥ 38.5°c 309 162 (52.4) 121 (39.2) 1.57 1.16-2.12  
No YF vaccinationA* (ref. 
received vaccination)  
630 309 (49.1) 267 (42.4) 1.98 1.34-2.93 <.001 
Presence of signs and 
symptoms (ref. absence) 
      
     Rash* 84 48 (57.1) 24 (28.6) 2.10 1.26–3.52 0.005 
     Fatigue* 620 300 (48.4) 267 (43.1) 1.62 1.11-2.35 0.012 
     Retro-orbital pain** 104 80 (76.9) 12 (11.5) 8.11 4.33-15.19 <.001 
     Nasal congestion* 21 5 (23.8) 16 (76.2) 0.30 0.11-0.82 0.019 
     Rhinorrhea* 28 6 (21.4) 21 (75.0) 0.27 0.11-0.67 0.005 
     Cough** 81 23 (28.4) 53 (65.4) 0.39 0.23-0.64 <.001 
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Statistical significance of the frequencies: *p-value<0.05 **p-value<.001 
Abased on self-report 
  
     Nausea & vomiting 285 131 (46.0) 131 (46.0) 0.97 0.71-1.31 0.817 
     Diarrhea 21 5 (23.8) 13 (61.9) 0.37 0.13-1.04 0.060 
     Abdominal pain 263 127 (48.3) 110 (41.8) 1.20 0.88-1.64 0.255 
     Loss of appetite* 383 191 (49.9) 166 (43.3) 1.27 0.94-1.70 0.115 
     Myalgia* 366 189 (51.6) 139 (38.0) 1.70 1.26-2.29 <.001 
     Arthralgia 521 246 (47.2) 226 (43.4) 1.21 0.88-1.65 0.242 
     Headache* 749 350 (46.7) 329 (43.9) 3.04 1.27-7.28 0.013 
     Sore throat 11  3 (27.3) 7 (63.6) 0.41 0.11-1.62 0.204 
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S4 Table. Univariate logistic regression analyses showing significant indicators and their odds 
ratios between dengue-confirmed and non-dengue cases during the period of non-outbreak in 
the health facility-based fever surveillance 
Characteristics Total N N (%) 
dengue 
confirmed 
(n=183) 
N (%)  
Non- dengue 
(n=1840) 
Univariate analysis 
Dengue-confirmed vs. no 
dengue  
OR  95% CI  p-
Value  
Age group (years)*      <.001 
   1-14 549 33 (6.0) 487 (88.7) Ref -  
   15-24 579 49 (8.5) 505 (87.2) 1.43 0.91-2.27  
   25-34 630 57 (9.1) 530 (84.1) 1.59 1.02-2.48  
   35-55 394 44 (11.2) 318 (80.7) 2.04 1.27-3.28  
Female (ref. male) 1544 126 (8.2) 1326 (85.9) 0.86 0.62-1.19 0.358 
Under observation** (ref. 
OPD) 
52 18 (34.6) 27 (51.9) 7.33 3.95-13.58 <.001 
Fever duration prior to 
visit* 
     0.196 
   1-2 days 1124 86 (7.7) 991 (88.2) Ref -  
   3 days 628 61 (9.7) 519 (82.6) 1.35 0.96-1.91  
   4-7 days 400 36 (9.0) 330 (82.5) 1.26 0.84-1.89  
Temperature at 
enrollment   
     0.263 
   Below 38.5°c 1691 138 (8.2) 1453 (85.9) Ref -  
   ≥ 38.5°c 461 45 (9.8) 387 (84.0) 1.22 0.86-1.75  
No YF vaccination A** 
(ref. received 
vaccination)  
1353 148 (10.9) 1098 (81.2) 2.86 1.95-4.18 <.001 
Presence of signs and 
symptoms (ref. absence) 
      
     Rash* 174 25 (14.4) 139 (79.9) 1.94 1.23-3.06 0.005 
     Fatigue** 1509 146 (9.7) 1259 (83.4) 1.82 1.25-2.65 0.002 
     Retro-orbital pain** 134 23 (17.2) 95 (70.9) 2.64 1.63-4.28 <.001 
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Statistical significance of the frequencies: *p-value<0.05 **p-value<.001 
Abased on self-report 
 
     Nasal congestion 104 11 (10.6) 89 (85.6) 1.26 0.66-2.40 0.485 
     Rhinorrhea 134 15 (11.2) 111 (82.8) 1.39 0.79-2.44 0.249 
     Cough 364 39 (10.7) 301 (82.7) 1.39 0.95-2.02 0.088 
     Nausea & vomiting** 620 59 (9.5) 504 (81.3) 1.26 0.91-1.75 0.163 
     Diarrhea  130 9 (6.9) 115 (88.5) 0.78 0.39-1.56 0.475 
     Abdominal pain* 647 68 (10.5) 529 (81.8) 1.47 1.07-2.01 0.018 
     Loss of appetite* 687 60 (8.7) 573 (83.4) 1.08 0.78-1.49 0.647 
     Myalgia* 513 45 (8.8) 421 (82.1) 1.10 0.77-1.57 0.601 
     Arthralgia   858 69 (8.0) 727 (84.7) 0.93 0.68-1.27 0.634 
     Headache* 1858 168 (9.0) 1570 (84.5) 1.93 1.12-3.32 0.018 
     Sore throat 64 4 (6.3) 57 (89.1) 0.70 0.25-1.95 0.495 
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Appendix H. Chapter 6 STROBE checklist 
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 STROBE Statement: Dengue virus seroprevalence and force of infection estimated using repeated serosurveys in Ouagadougou, 
Burkina Faso 
 Item 
No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract (Page 1) 
(b) Provide in the abstract an informative and balanced summary of what was done and what was 
found (Page 3) 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported (Page 4, para 4-5) 
Objectives 3 State specific objectives, including any prespecified hypotheses (Page 4, para 5) 
Methods 
Study design 4 Present key elements of study design early in the paper (Page 6 para 2-3) 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-
up, and data collection (Page 6 para 1, Page 7 para 1) 
Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. 
Describe methods of follow-up  
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment 
and control selection. Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of 
participants (Page 7 para 1-2) 
(b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed 
Case-control study—For matched studies, give matching criteria and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable (Page 7 para 3, Page 8 para 1-3, Page 9 para 1-3) 
Data sources/ 
measurement 
8  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one group (Page 
8 para 1, 4, page 9 para 1-2) 
Bias 9 Describe any efforts to address potential sources of bias (Page 8 para 3, Page 10 para 1) 
Study size 10 Explain how the study size was arrived at (Figure 1) 
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which 
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 groupings were chosen and why (Page 7 para 3, page 8 para 1-2) 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding (Page 8 para 1-4, 
Page 9 para 1-3) 
(b) Describe any methods used to examine subgroups and interactions (-) 
(c) Explain how missing data were addressed (Page 10 para 1) 
(d) Cohort study—If applicable, explain how loss to follow-up was addressed  
Case-control study—If applicable, explain how matching of cases and controls was addressed 
Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy 
(Not applicable) 
(e) Describe any sensitivity analyses (none) 
 
Results 
Participants 13 (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, 
confirmed eligible, included in the study, completing follow-up, and analysed (figure 1, page 10 para 1) 
(b) Give reasons for non-participation at each (figure 1) 
(c) Consider use of a flow diagram (figure 1) 
Descriptive 
data 
14 (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and 
potential confounders (Page 10 para 2-5, Page 11 para 1-5, Page 12 para 1-2) 
(b) Indicate number of participants with missing data for each variable of interest  (page 11 para 2) 
(c) Cohort study—Summarise follow-up time (eg, average and total amount)  (Not applicable) 
Outcome data 15 Cohort study—Report numbers of outcome events or summary measures over time  
Case-control study—Report numbers in each exposure category, or summary measures of exposure 
Cross-sectional study—Report numbers of outcome events or summary measures (Tables 1, 2, 3, 4) 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% 
confidence interval). Make clear which confounders were adjusted for and why they were included (Tables 3-5) 
(b) Report category boundaries when continuous variables were categorized (Page 8 para 1, in methods) 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period (Not 
applicable) 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses  
Discussion 
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 Key results 18 Summarise key results with reference to study objectives (Page 12 para 3-4, page 13 para 2-3, page 14 para 2) 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction 
and magnitude of any potential bias (Page 15, page 16 para 1) 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results 
from similar studies, and other relevant evidence (Page 13 para 1, 4, Page 15 para 1, 4, Page 16 para 4) 
Generalisability 21 Discuss the generalisability (external validity) of the study results (Page 16 para 3) 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the original study 
on which the present article is based (Page 2) 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in 
cohort and cross-sectional studies. 
 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published 
examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites 
of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at 
http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
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Appendix I. Sample size calculation 
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Appendix I. Sample size calculation 
 
Sample size calculations for the surveillance and serosurvey were based on standard error or 
margin of error at a fixed significance level (Chow, Shao, Wang. (2008). Sample size calculations 
in clinical research (2nd edition). Taylor & Francis Group.).  
The formula for confidence interval is as below (Altman D G. (1999). Practical statistics for 
medical research. Chapman & Hall/CRC):  
x ̅ ±  z ∗ /
σ
√n
  =   x̅ ±  margin of error 
Taking the margin of error part of the formula above, we get an equation as below: 
 
margin of error = 0.25p =   z ∗ /
p(1 − p)
√n
  
where  σ = p(1-p) 
z =1.96 
p = anticipated population proportion (incidence or seroprevalence) 
 
As we wish to have the resulting estimate to fall within 25% of the true proportion with 95% 
assurance, margin of error is 0.25 x p. This gives relative precision of 75% and this is an 
acceptable level, considering the gap in evidence for dengue incidence in the study area. 
 
Rearranging it for n, the sample size for precision equals to: 
n =
{z2[p(1 − p)]}
(p x 0.25)2
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Passive facility-based fever surveillance 
 
The incidence of 0.002% per year (column D) was obtained from unpublished data from the local 
investigator on a sub groups tested for dengue within a previously conducted Malaria study. 
Unfortunately, population level age-specific incidence reported from previous literature or 
surveillance was not available and this was used across all age groups. Expansion factor of 21.3 
was applied for age under 15 years based on the reported expansion factor (275). For gradual 
reduction in the value used in adjustment, there was the expansion factor of 10 assumed for age 
between 15-39 years and no adjustment was applied for those 40 years and older (column E). 
With 95% assurance, Z-score 1.96, and relative precision of 75%, using the formula above for n, 
the sample size was calculated per age group, as shown in column J. The sample sizes for age 
groups 0 to 54 years were added to reach 105623.  
A B C D E F G H I J K 
Age 
group 
Popula
tion 
size 
% of 
the 
natio
nal 
pop 
Est. 
inciden
ce 
Expa
nsion 
Mean 
correct
ed 
inciden
ce (1-P) 
1-
Relativ
e 
precisi
on 
(margi
n of 
error) 
Precisi
on 
N 
(sampl
e size 
for age 
groups
) 
Total 
(0-55 
yrs) 
0-4 
295742
3 0.182 
0.0021
05 21.3 0.045 0.955158 0.25 
0.0112
11 1309 105623 
5-9 
242894
4 0.150 
0.0021
05 21.3 0.045 0.955158 0.25 
0.0112
11 1309  
10-14 
208413
3 0.128 
0.0021
05 21.3 0.045 0.955158 0.25 
0.0112
11 1309  
15-19 
177268
5 0.109 
0.0021
05 10 0.021 0.978947 0.25 
0.0052
63 2858  
20-24 
146007
3 0.090 
0.0021
05 10 0.021 0.978947 0.25 
0.0052
63 2858  
25-29 
122050
4 0.075 
0.0021
05 10 0.021 0.978947 0.25 
0.0052
63 2858  
30-34 
104318
0 0.064 
0.0021
05 10 0.021 0.978947 0.25 
0.0052
63 2858  
35-39 838019 0.052 
0.0021
05 10 0.021 0.978947 0.25 
0.0052
63 2858  
40-44 662548 0.041 
0.0021
05 1 0.002 0.997895 0.25 
0.0005
26 29135  
45-49 492282 0.030 
0.0021
05 1 0.002 0.997895 0.25 
0.0005
26 29135  
50-54 363812 0.022 
0.0021
05 1 0.002 0.997895 0.25 
0.0005
26 29135  
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The serosurvey  
 
Using the same formula above, the sample size for the serosurvey is calculated using the 
prevalence proportion of 30.4 % from a previous study conducted in Burkina Faso (260).  
 
A B C D E F G H I 
Age 
group 
Population 
size 
% of 
the 
national 
pop 
Est. 
prevalence (1-P) 
1-
Relative 
precision 
(margin 
of error) 
Precision 
N 
(sample 
size for 
age 
groups) 
Total 
(0-55 
yrs) 
0-4 2957423 0.182 0.3040 0.696 0.25 0.076 141 1548 
5-9 2428944 0.150 0.3040 0.696 0.25 0.076 141  
10-14 2084133 0.128 0.3040 0.696 0.25 0.076 141  
15-19 1772685 0.109 0.3040 0.696 0.25 0.076 141  
20-24 1460073 0.090 0.3040 0.696 0.25 0.076 141  
25-29 1220504 0.075 0.3040 0.696 0.25 0.076 141  
30-34 1043180 0.064 0.3040 0.696 0.25 0.076 141  
35-39 838019 0.052 0.3040 0.696 0.25 0.076 141  
40-44 662548 0.041 0.3040 0.696 0.25 0.076 141  
45-49 492282 0.030 0.3040 0.696 0.25 0.076 141  
50-54 363812 0.022 0.3040 0.696 0.25 0.076 141  
 
Taking 20% non-response rate into consideration per follow-up visits and with 3 additional follow-
up in plan after enrollment, the final sample size reached was 2477.  
 
Following the same calculation as in the surveillance, the sample size reached was 141 per age 
group and when these are added to cover 0-55 years, the total sample size for the serosurvey 
reached 1548. With lack of seroprevalence data from Burkina Faso, the same prevalence (30.4%) 
was used in calculation across age. If a higher prevalence estimate (e.g., what we may find for 
older adults, if data were available) was used, then the sample size will become smaller than 
what we have here. Therefore, we believe this is a conservative estimate (i.e. bigger sample size 
than what may be needed) for the sample size needed for the serosurvey.  
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